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Preface 
The work contained in this dissertation was conducted in the department of 
Chemical Engineering at Michigan Technological University from May 2016 to February 
2020. This dissertation was written by Dylan Gregory Turpeinen. All experiments and 
measurements discussed within this dissertation were performed by Dylan Gregory 
Turpeinen with the assistance of collaborators who are listed in the following paragraphs. 
Chapter 3 discusses the results of analyte detection using printed graphene 
biosensors. All the sheet resistivity results from printing the graphene ink onto paper and 
non-paper substrates were obtained by myself in Dr. Julie King’s laboratory. I received 
help in changing ink properties such as ink viscosity and number of printing coats by 
Clara Peterson (UG). I custom-made different graphene ink during an internship with XG 
Sciences under Dr. Hiroyuki Fukushima and Thomas Ritch. Design, fabrication, and 
testing of antibody-functionalized graphene sensors was performed by myself under the 
direction of Dr. Caryn Heldt. 3-D printing wax barriers onto the graphene paper sheets 
was performed by Matthew Weiss (UG) and Cameron Miller (UG) under my supervision. 
During development and testing of the sensors, the work was presented in poster format 
at the 2017 American Institute of Chemical Engineers (AIChE) national meeting in 
Minneapolis, MN. The work discussed in Chapter 3 will not be published as no 
significant, positive results were obtained for analyte detection.  
Chapter 4 expands upon the previously published work using gold nanoparticles 
(AuNPs) for virus detection. From Dr. Xue Mi’s AuNP/virus assay, we were able to 
detect porcine parvovirus (PPV) and bovine viral diarrhea virus (BVDV) using 
unmodified 15 nm AuNPs aggregated by mannitol. Ellie Lucier (UG) had significant 
contribution to the work discussed in Chapter 4, from running the experimental assay and 
collecting dynamic light scattering (DLS) results for my analysis. I learned how to 
synthesize and characterize various shapes and sizes of AuNPs while at the National 
University of Singapore working in Dr. James Chen Yong Kah’s lab in collaboration with 
Nural ‘Ain Azman (Ph.D. candidate) and Malvin Wei Cherng Kang (Ph.D. candidate). 
The results obtained during development of the virus detection assay was presented at the 
2019 American Chemistry Society (ACS) national meeting in oral presentation format in 
xiii 
Orlando, FL, and at the 2019 AIChE national meeting in poster format in Orlando, FL. 
The results obtained and discussed in Chapter 4 showed no improvement to limits of 
detection of PPV and BVDV than the previously tested 15 nm AuNPs, and will be 
published. 
Chapter 5 is about the design and testing of a continuous virus purification 
technique based on an aqueous two-phase system (ATPS). Using Pratik Joshi’s (Ph.D. 
candidate) batch-mode ATPS work to find an optimized ATPS for purification of PPV, I 
designed and tested the possibility of the ATPS to be ran continuously without loss in 
purification performance. Pratik trained me in forming ATPSs and how to determine the 
composition of the phases using phase diagrams he generated for the PEG/citrate system. 
With help from Erin Browne (UG), we constructed a continuous ATPS using a static in-
line mixer and tubular separator to achieve mixing and separation of the phases. Human 
immunodeficiency virus type 1 group antigen labelled with green fluorescent protein 
virus-like particles (HIV VLPs) were donated by Dr. David O’Hagan and Dr. Savita 
Nikam from Esperovax for testing the continuous purification system. The COMSOL 
Multiphysics modeling of the helical mixer was performed and analyzed by Dr. Hassan 
Masoud from the Mechanical Engineering Department at Michigan Technological 
University. Results obtained during the development of the ATPS process was presented 
in poster format at the 2019 ACS national meeting in Orlando, FL. The results contained 
in Chapter 5 are also currently in preparation for submission to the Separation and 
Purification Technology journal. 
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Abstract 
Viruses are responsible for many human diseases that lead to suffering and death. 
Acquired immunodeficiency syndrome (AIDS), influenza, and coronavirus disease 2019 
(COVID-19) have claimed the lives of millions of people. Two methods have been 
created to reduce the suffering caused by these diseases. The first is the manufacturing of 
vaccines that prevent disease and the second is the development of virus detection tests 
that lead to treatment. The work summarized in this dissertation discusses the 
development of a continuous virus purification process using an aqueous two-phase 
system for use in vaccine manufacturing. Additionally, two novel virus detection 
methods were developed using graphene biosensors and a gold nanoparticle aggregation 
assay.  
This dissertation contains results obtained from a novel continuous viral particle 
purification technique. The biomanufacturing industry would greatly benefit by switching 
from traditional batch processes to continuous processing. The reduction in costs and 
increase in productivity of continuous unit operations are driving the desire for 
continuous biomanufacturing processes. Switching to continuous processing would 
eliminate the current downstream processing challenges of viral-based biotherapeutics 
including limited yield and throughput. The method developed here was a 
chromatography-free separation technique aimed to increase throughput, purity, and yield 
of viral particles. The technique utilized an aqueous two-phase system (ATPS) to 
partition viral particles to a different phase than contaminant proteins. The ATPS 
consisted of poly(ethylene glycol) (PEG) and sodium citrate to separate viral particles 
from contaminant proteins from cell culture media. The ATPS was scaled-up from 1 g 
batch systems and run continuously for porcine parvovirus (PPV) and human 
immunodeficiency virus-like particles (HIV VLPs). Results from the purification of both 
viruses showed >70% recovery with a majority of the contaminating proteins and DNA 
being removed. This system has the potential to be further scaled-up for full-scale 
continuous biomanufacturing of vaccines.  
This dissertation also contains results from the development of two viral detection 
methods. The first detection method used a graphene ink-based paper biosensor to 
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electrochemically detect the presence of biomolecules. These graphene biosensors were 
created with the goal of being lab-on-a-chip devices for rapid detection in low-resource 
areas without the need of expensive laboratory equipment. The biosensors initially 
showed promise for portable, inexpensive, and rapid detection of proteins via electrical 
resistance changes at the sensor surface, but ultimately could not be applied to virus 
particles. The second detection test utilized osmolyte-induced gold nanoparticle 
(AuNP)/virus complex aggregation to detect whole viral particles. The AuNP aggregation 
assay was previously developed to detect two model viruses, PPV and bovine viral 
diarrhea virus (BVDV), using one size of AuNPs. The AuNP assay was capable of 
nanomolar level detection of both viruses. Optimization of this previously established 
virus detection method was performed by utilizing various sizes of AuNPs to lower the 
limit of detection (LOD). Results from using other sizes of AuNPs showed no 
improvement to the LOD. 
 
1 
1 Introduction and chapter summaries 
1.1 Introduction 
Viruses are difficult-to-detect microorganisms capable of infecting living cells 
and causing numerous communicable diseases. Communicable diseases caused by a wide 
variety of viruses claim the lives of millions of people each year around the world. Every 
year, an estimated one billion people get sick and 290,000-650,000 people die due to 
influenza [1]. Acquired immunodeficiency syndrome (AIDS) resulted in 770,000 deaths 
and 1.7 million new cases in 2018 [2]. The novel coronavirus causing coronavirus disease 
2019 (COVID-19) has already claimed the lives of 500,000 people, with 10 million cases 
worldwide [3]. These communicable viral diseases and nearly 20 others are responsible 
for extreme human suffering and death. However, with either prophylactic or early 
treatment, these harmful effects can be decreased. To have as early treatment as possible, 
rapid virus detection techniques are necessary. A non-specific virus detection method 
would be helpful in confirming the presence of any disease-causing virus without the 
need to test for individual viruses with time-consuming multiple tests. In addition to 
detecting a disease as early as possible, vaccination remains as one of the best methods of 
preventing deaths caused by infectious diseases [4]. However, the challenge of 
developing early detection tests and manufacturing large quantities of vaccines still 
exists. To help in reducing human suffering and death caused by diseases, my research 
shown in the dissertation focused on developing two novel virus detection methods and 
one vaccine manufacturing method.  
 The work contained in this dissertation explored two different methods for virus 
detection. The first method utilized graphene/cellulose biosensors to electrochemically 
detect the presence of biomolecules on the sensor surface. The graphene biosensor 
initially showed promise for portable, inexpensive, and rapid detection of proteins via 
electrical resistance changes at the sensor surface, but ultimately could not be applied to 
virus particles. The second method utilized osmolyte-induced gold nanoparticle 
(AuNP)/virus complex aggregation to detect viral particles. The AuNP aggregation assay 
was previously developed to detect two model viruses, porcine parvovirus (PPV) and 
2 
bovine viral diarrhea virus (BVDV), using one size of AuNPs. The AuNP assay was 
capable of nanomolar level detection of both viruses, which is significantly more 
sensitive than standard commercially available ELISA kits. Optimization of this 
previously established virus detection assay was attempted by utilizing various sizes of 
AuNPs to lower the limit of detection of the assay. 
This dissertation also contains results from developing a novel virus purification 
technique that has the potential to be used in large scale manufacturing of vaccines. To 
create a safe and effective vaccine, the viral product during downstream processing must 
be purified from contaminants while maintaining high titer. To aid in supplying the world 
with critical vaccines, the recovery of viral products from downstream processes must 
also be increase beyond the currently accepted 30% [5]. The developed virus purification 
method utilizes an aqueous two-phase system (ATPS) of poly(ethylene glycol) and 
sodium citrate to partition viral particles to a different phase than contaminant proteins 
with high recovery (>70%) and purity. The ATPS was scaled-up and run continuously for 
PPV and human immunodeficiency virus-like particles (HIV VLPs). This system has the 
potential to be further scaled-up for full-scale continuous biomanufacturing of vaccines. 
1.2 Chapter summaries 
Chapter 2 of this dissertation begins with a literature review of current analyte 
detection strategies and vaccine manufacturing processes. Each section discusses 
conventional methods that have their limitations, and current research aimed at breaking 
through those limitations. The graphene biosensor literature review focuses on the 
different electrochemical detection techniques, and the advantages and disadvantages of 
each technique used to detect proteins and viruses. The gold nanoparticle literature 
review focuses on how functionalized particles have been used for virus detection, and 
how attempts have been made to use more simple, non-functionalized particle systems. 
The virus purification literature review focuses on the traditional batch processes used to 
purify viruses for use in vaccines, and the development of semi-continuous processes. 
Chapter 3 discusses the graphene biosensors project aimed at designing and 
testing an inexpensive paper-based sensor for the electrochemical detection of analytes at 
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the sensor surface. The ultimate goal of the graphene biosensors was to create a point-of-
care device for the detection of a malaria biomarker, plasmodium falciparum 
topoisomerase I (pfTopI). The biosensors were created from a sheet of blended 
cellulose/graphene nanoplatelets from XG Sciences. From previous experiments 
performed and published in 2013, it was shown that an increase in the protein 
concentration present on the sensor surface caused an increase in electrical resistivity due 
to an altered electron flow path. This increase in resistivity was also found to be 
dependent on the protein’s molecular weight. In 2012, XG Sciences’ manufacturing 
process of the graphene/cellulose sheets was changed, which caused a project shift to 
flexographic printing of graphene ink onto various paper and non-paper substrates. 
Printing the graphene ink onto various substrates allowed us to tune printing parameters 
such as ink viscosity, number of coats, and ink composition to achieve conditions for 
analyte detection during testing. Due to the new biosensor creation method, protein 
detection on the surface of the graphene-ink printed biosensors needed to be confirmed 
before application to virus particle detection. XG Sciences’ standard graphene 
nanoplatelet ink was printed on common copier paper and on qualitative chromatography 
filter paper to attempt to mimic the cellulose/graphene biosensors previously created. The 
graphene ink was also printed onto highly hydrophobic poly(ethylene terephthalate) 
(PET) and various grades of Tyvek. An additional optimization strategy was altering the 
composition of the ink to various grades of graphene nanoplatelets to induce different 
resistivity changes as proteins were applied. The graphene-ink printed biosensors were 
tested for their ability to detect the presence of proteins in a buffer solution compared to 
the buffer solution alone as a control. Although numerous combinations of graphene ink 
types and printing substrates were tested, no combination led to a statistically significant 
difference in resistivity change when the target protein was applied to the sensor surface, 
compared to when protein-free solutions were applied. To enhance the electrochemical 
signal due to analyte presence, the graphene surface was functionalized with antibodies to 
specifically bind antigens to the sensor surface. Testing the functionalized graphene 
sensors resulted in the same conclusion that antigen presence could not be distinguished 
from buffer-only application. Although the number of tests performed covered a large 
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experimental area, there could exist a combination of parameters not tested which would 
lead to accurate detection of analytes. As another possible system for analyte detection, a 
gold nanoparticle virus detection assay was developed and tested in the Heldt lab. 
Chapter 4 discusses the gold nanoparticle (AuNP)-virus assay to detect two 
different viruses at the lowest concentration possible. The goal of the AuNP-virus assay 
was to find an optimal size ratio between AuNPs and virus particles to enhance 
electrostatic interactions for binding and signal enhancement using dynamic light 
scattering (DLS). With an optimal size ratio determined, the assay could be applied to 
practical applications such as rapid surface cleanliness tests for hospital rooms or 
equipment. This assay is possible due to the unique ability of osmolytes (mannitol and 
glycine) to preferentially aggregate virus particles, by decreasing the hydration layer 
around the virus while leaving proteins un-aggregated in solution. Unmodified, citrate-
capped AuNPs are electrostatically bound to the positive patches present on virus 
surfaces and aggregated in the presence of mannitol and glycine. By performing serial 
dilutions of the non-enveloped porcine parvovirus (PPV), the limit of detection was 106 
MTT50/mL [6]. To test the non-specific nature of the assay, a larger enveloped bovine 
viral diarrhea virus (BVDV) was detected to a limit of 104 MTT50/mL [6]. Both of these 
virus detection tests were performed alongside a control test of various concentrations of 
a model bovine serum albumin (BSA) protein, which showed no ability to be detected. 
This AuNP-virus assay demonstrates the ability to detect virus particles at lower 
concentrations than conventional immunodetection methods with unmodified, 
nonfunctionalized AuNPs. In an attempt to improve the limit of detection of the 
AuNP/virus assay, AuNPs of different diameters were synthesized and applied in the 
assay to find an optimal ratio of diameters between the virus particles and AuNPs. 
Chapter 5 discusses the continuous aqueous two-phase system (ATPS) used to 
purify and recover virus particles directly from crude cell lysate supernatant. An ATPS is 
a type of liquid-liquid extraction technique; which is formed by mixing two components 
above critical concentrations, where they separate into two distinct phases over time. The 
ATPS used here was a mixture of poly(ethylene glycol) (PEG) and trisodium citrate. This 
project was the developmental beginning of a continuous ATPS. The future goal of the 
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continuous ATPS will be to scale up and run the process for up to a week to purify 
various novel vaccine candidates. Batch-mode ATPS experiments performed in the Heldt 
lab showed ≥80% of virus particles can be recovered in a different phase than 
contaminant proteins [7]. Using the batch-mode results, a bench-scale continuous process 
was designed and tested for the ability to recover and purify PPV in the PEG-rich phase. 
The continuous process was optimized by designing and evaluating a mixer capable of 
mixing the viscous PEG, citrate, and virus streams to allow for proper partitioning of 
virus particles to the PEG-rich phase and proteins to the citrate-rich phase. Proper mixing 
and phase separation were confirmed for the various mixers tested by comparing batch-
mode and continuous-mode physical property measurements of the PEG-rich and citrate-
rich phases after separation to confirm proper ATPS formation. PPV and a human 
immunodeficiency gag-GFP virus-like particle (HIV gag-GFP VLP) were tested in the 
continuous ATPS for the ability to recover and purify the viral product in the PEG-rich 
phase with contaminating proteins in the citrate-rich phase. More than 70% of the viral 
product was recovered in the PEG-rich phase with high protein purity visualized with 
SDS-PAGE gels and more than 70% DNA removal. These results indicate that 
continuous ATPS could be used as a continuous downstream purification method. 
Chapter 6 concludes the dissertation with key findings from each project and 
provides future work theories for further development. 
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2 Literature review 
2.1 Analyte detection systems 
2.1.1 Current virus detection methods 
Currently, there are three main ways viruses are detected. The first, and oldest, 
way is to grow host cells via conventional cell culture methods and infect the cells with a 
virus-containing sample to confirm cell death and presence of a virus [8-11]. The second, 
and most common today, is the method of polymerase chain reaction (PCR) where 
specific nucleic acid sequences from the virus are amplified and detected [12]. The third, 
also common, method is using enzyme-linked immunosorbent assays (ELISAs) where a 
system of antibodies is used to capture and detect a specific virus [13]. Virus detection 
methods using biosensors are being developed and have promise of becoming more 
clinically relevant as they are less expensive, faster, and can be used at the point-of-care 
[14].  
2.1.1.1 Cell culture 
Cell culture for virus detection has been regarded as the gold standard method 
since the beginning of clinical diagnosis of viral diseases [15]. The earliest use of 
laboratory cell culture was used for the detection of influenza virus using various cell 
lines including Vero cells, primary epithelial cells of human adenoid, primary rhesus 
monkey kidney (PMK) cells, and Madin-Darby canine kidney (MDCK) cells [9, 10]. The 
most conventional method of virus detection is growing host cells, infecting them with 
virus-containing samples, waiting for virus propagation, and checking for any cytopathic 
effect (CPE) within the cells. This method was used to detect influenza virus from 
various specimen locations including the lungs and throats of patients [10]. This 
traditional technique was also used to detect the presence of human adenovirus in a 5-7 
day cell culture in HEp-2 cells [16]. Although the cell culture methods are well 
understood and has been used for a long time, the major drawback is the amount of time 
it takes to perform. This length of time between detection and treatment could mean the 
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difference between life and death for the patient. Another drawback to this technique is 
the variability in cell lines from lab to lab, which makes it difficult for standardization 
around the world [17]. 
2.1.1.2 Polymerase chain reaction 
PCR is a type of nucleic acid test (NAT) that is used to make millions of copies of 
a specific sequence of nucleic acid in order to increase the copy number for detection 
[12]. Once the nucleic acid of interest is replicated to a certain level, the detection is 
achieved by co-amplification of fluorescence or luminescent dyes [18]. It is widely used 
today to detect numerous infectious agents, including up to six different infectious 
diseases for blood donations in the United States [19, 20]. The PCR technique has been 
used for the rapid detection of yellow fever virus in under three hours including sample 
preparation, which is a significant improvement on the five or more days necessary for 
detection using traditional cell culture methods [21]. PCR has also been used to bring the 
detection time of influenza A virus strain H3N2 down to approximately three hours, 
which is much faster than the minimum three days necessary for traditional cell culture 
techniques [22]. Most recently, PCR has been critical for the detection of severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2); however, several hours are still 
needed to prepare and test the samples [23]. While PCR has an advantage of decreased 
detection time compared to traditional cell culture methods, PCR requires skilled 
laboratory technicians and is considerably expensive for the necessary reagents [18]. 
2.1.1.3 Enzyme-linked immunosorbent assays 
The use of ELISAs has also helped replace the time-consuming traditional virus 
detection techniques. ELISAs are plate-based assays in which immobilized antibodies are 
used to capture antigens (viruses) of interest, and secondary, enzyme- or fluorescent-
linked antibodies are used for detection. Detection is achieved when a substrate is added 
to the enzyme-linked antibody to form a measurable product, or fluorescence is measured 
from fluorescent-linked antibodies [24]. In addition to NATs, ELISAs are used for blood 
donation screening for up to seven different infectious diseases in the United States, 
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including Hepatitis B and C, human immunodeficiency virus (HIV), and Zika virus [19, 
20]. In the lab, an ELISA was used to detect H5 hemagglutinin from avian influenza 
virus in as little as 31 minutes, which is much faster than the days needed for traditional 
cell culture methods and faster than a commercially-available ELISA kit of 260 minutes 
– without loss of detection at just 0.23 ng/mL [25]. Although more rapid than traditional 
cell culture techniques, ELISAs require complex sample preparations, skilled laboratory 
personnel, and monoclonal antibodies used in the kits are expensive [18]. An ideal virus 
detection technique would be as rapid as possible, sensitive, inexpensive, and easy to 
perform. 
2.1.2 Electrochemical biosensors 
Biosensors is a broad term used to describe devices that combine a biological 
component with physicochemical detectors to detect an analyte of interest [26]. 
Biosensors are attractive alternatives to the current virus detection methods because they 
have the potential to simultaneously possess all the characteristics of an ideal detection 
system. Biosensors have three main components, a biological receptor, a transducer, and 
a detector, shown in Figure 2.1 [27, 28]. The biological receptor in the case of viral 
biosensors can be enzymes, antibodies, or nucleic acid that sense the presence of an 
analyte, and the transducer transforms the molecular interactions between the receptor 
and analyte to a quantifiable signal measured by the detector [17, 27]. Three main 
categories of biosensors exist: electrochemical, piezoelectric, and optical [17, 27]. This 
review will focus on electrochemical biosensors for virus detection applications. 
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Figure 2.1: Main components of an electrochemical biosensor [28] 
2.1.2.1 Types of electrochemical biosensors 
Electrochemical biosensors are the most common and longest-used type of 
biosensors to date [29, 30]. Three common groups of electrochemical biosensors exist, 
differing by the electrochemical property being measured: amperometric/voltammetric 
[31-34], potentiometric [35, 36], and impedimetric/conductometric [37-41]. Each of these 
have been explored for their virus detection ability using various biological receptors 
including oligonucleotides, cells, enzymes, and antibodies – discussed later in section 
2.1.2.2. 
2.1.2.1.1 Amperometric/voltammetric 
Within the amperometric category exists two subtypes of measurement strategies: 
amperometry and voltammetry. Amperometry is when the current changes are measured 
at a constant voltage, and voltammetry is when the current changes are measured with 
controlled changes in voltage [28]. The second measurement strategy is more commonly 
known as cyclic voltammetry. Amperometric biosensors work by measuring the current 
change from the oxidation or reduction (redox) of an electroactive species and sensing 
element which is linearly dependent on the analyte concentration applied [42]. Regardless 
of the measurement strategy (amperometry or voltammetry), the resulting signal from the 
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redox reaction of electroactive species in a biochemical reaction being monitored is 
correlated to the analyte concentration [29]. 
For a redox reaction occur, mediated or non-mediated pathways exist for electron 
transfer between the electroactive species and the sensing element. A mediator is an 
artificial electron transferring agent which facilitates the electron transfer between the 
analyte and electrode [30]. Commonly used mediators include ferrocene and its 
derivatives [43-45], methylene blue [46, 47], and N-methyl phenazine [48-50]. One 
graphitized mesoporous carbon-methylene blue mediated nanocomposite biosensor was 
fabricated for detecting the hepatitis C virus (HCV) core antigen using cyclic 
voltammetry measurements [47]. The methylene blue was able to effectively transfer 
electrons from the redox reaction occurring from the reduction of a horse radish 
peroxidase (HRP) antibodies immobilized on the sensor surface, shown in Figure 2.2. 
While this sensor exhibited a wide linear range of detection from 0.25 pg/mL to 300 
pg/mL with a limit of detection (LOD) of 0.01 pg/mL, multiple complex steps were 
necessary for device creation which could limit the widespread use of the sensor [47].  
 
Figure 2.2: Methylene blue (MB)-mediated electron transfer during the redox reaction 
between the gold electrode surface and HRP [47] 
 
One mediator-free sensor was created to detect the human immunodeficiency 
virus type 1 (HIV-1) p24 antigen down to 0.0064 ng/mL in the range of 0.01 to 60.00 
ng/mL [33]. As a mediator was not used in the HIV-1 biosensor, the sensitivity was in the 
ng/mL range which is higher than the HCV biosensor which had a detectable range in the 
pg/mL. While these example sensors show low limits of detection and good linear ranges, 
they are limited by their complex fabrication and testing methods requiring equipment 
capable of generating cyclic voltammograms [51]. These sensors also utilized sensor 
ligands for the biological receptor to specifically capture the analyte of interest, which 
will be further discussed in section 2.1.2.3. 
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2.1.2.1.2 Potentiometric 
Potentiometric biosensors operate by measuring the potential at a working 
electrode with respect to a reference electrode during an electrochemical reaction [30]. 
Contrary to amperometric biosensors, potentiometric biosensors operate at zero current 
and monitor the accumulation of charge at an electrode surface. The reaction produces a 
readable signal caused by a difference in ionic concentration of a target analyte that is 
reduced during an electrochemical reaction [29]. The Nernst Equation governs the 
relationship between the concentration of an analyte/its reduced species, and the 
potential, allowing the concentration to be determined by the measurement of the 
potential [28]. Equation 2.1 shows the Nernst Equation: 




�                                                (2.1) 
where E (volts) is the electrode potential at zero current, E0 (volts) is the standard 
reduction potential of the cell, R is the universal gas constant (8.314 J/(mol·K)), T (K) is 
the temperature, n is the number of electrons transferred, F is Faraday’s constant (96,485 
C/mol), CX- (mol/L) is the concentration of the reduced species at the electrode, and CX 
(mol/L) is the concentration of the non-reduced species at the electrode [28, 52]. 
One example of the potentiometric technique was used to detect poliovirus in the 
presence of a contaminating adenovirus mixture to the un-optimized concentration of 
0.644 nM (3.10 × 1011 particles/mL) [36]. The group observed significant changes in 
potential versus the reference electrode when poliovirus alone was present on the sensor 
surface compared to when a mixture of poliovirus and adenovirus was applied [36]. This 
is a significant result in the detection of poliovirus as the sensor did not require the use of 
a biological receptor to capture the virus. The group accomplished this by creating a 
poliovirus-templated alkanethiol self-assembled monolayer (SAM) onto a gold surface, 
where only poliovirus could attach during sample testing due to the specific size, shape, 
and hydrophobicity of the cavity, shown in Figure 2.3 [47].  
 
Figure 2.3: Fabrication of poliovirus-templated alkanethiol SAM on a gold surface [36] 
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Another potentiometric biosensor was used to detect the non-structural protein 1 
(NS1) from the Dengue serotype 2 virus using egg yolk immunoglobulin (IgY) as the 
biological receptor [35]. This sensor was able to quickly detect NS1 with an LOD of 0.09 
µg/mL with a linear range of 0.10-10 µg/mL in samples containing real serum [35]. 
Again, although these sensors show promise for viral detection, sensor fabrication 
contains complex steps and the necessary equipment (a potentiostat) is complex and 
requires trained personnel to operate and interpret the output. 
2.1.2.1.3 Impedimetric/conductometric 
Impedimetric biosensors detect analytes by measuring the change in impedance 
caused by a biochemical reaction or analyte binding events occurring at/on an electrode 
surface [51]. Impedance describes the opposition to the flow of electrical current, similar 
to electrical resistance [53]. However, impedance is used when alternating current (AC) 
is used to drive the flow of electrons instead of direct current (DC). Impedimetric 
biosensors utilize electrochemical impedance spectroscopy (EIS) where small amplitude 
sine wave perturbations are used over a wide frequency range to produce changes in 
impedance as a function of the change in frequency [51]. The resulting impedance versus 
frequency output is known as the electrochemical impedance spectrum. It is also 
important to note that conductance is the inverse of resistance, meaning conductance 
describes the ability of a material to allow the flow of electrical current.  
Conductometric biosensors are considered sub-sets of impedimetric sensors as 
they assume an ideal resistor system is applicable [28, 53]. Conductometric biosensors 
measure the electrical conductance across electrodes due to the presence of an analyte or 
solution [28, 54]. Typically, conductivity changes across electrodes are attributed to a 
change in ionic strength of the medium/analyte during an enzymatic reaction, but 
conductivity changes can also occur due to binding of analytes to the biosensor or 
electrode surface [40, 41]. A few advantages over amperometric and potentiometric 
sensors exist: conductometric sensors do not require a reference electrode, complex 
electrical equipment, and they can be readily downsized to reduce costs [28, 55]. These 
advantages make conductometric devices more portable and less complex to use. 
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Although conductometric sensors have many advantages, they have rarely been explored 
for their ability to detect viruses and are mostly used to detect small molecules such as 
arginine and phenol [55-57] and heavy-metal ions in water [58, 59]. 
One of the only examples of a conductometric biosensor for virus detection was 
created for the detection of bovine viral diarrhea virus (BVDV). The biosensor used anti-
BVDV antibodies as the biological receptor for specific detection of BVDV, and 
polyaniline as the sensor transducer which provided signal amplification during detection 
[41]. Signal measurement was accomplished by using a multimeter to monitor the change 
in resistance across a copper wafer surface when different concentrations of BVDV were 
applied to the sensor surface. In under ten minutes, 102 cell culture infective dose 
(CCID)/mL BVDV was detected in antigen-spiked blood serum, which is favorable when 
compared to the three or more hours of assay time using a commercially available ELISA 
kit with comparable titer detection ability [41]. 
When considering all the electrochemical techniques discussed, conductometric 
biosensors have the highest potential to be portable and rapid as they only require the use 
of a multimeter to record the resistance across electrodes or sensor surfaces. Multimeters 
can be found in handheld configurations, meaning a new sensor and multimeter can be 
brought to the point-of-care and used to detect the presence of virus when needed. 
2.1.2.2 Biological receptors 
A biological receptor (bioreceptor) is the part of a biosensor that captures a 
specific analyte of interest. The bioreceptors can be whole cells, oligonucleotides, 
enzymes, or antibodies immobilized onto the sensor surface. The two most popular 
choices for electrochemical biosensors are immobilized antibodies and complementary 
oligonucleotides, due to their superior specificity for the target analyte. 
2.1.2.2.1 Aptamers 
Aptamers are short (20-100 nucleotides) single-stranded DNA or RNA (ssDNA or 
ssRNA) oligonucleotides that are specific to the analyte of interest to be detected by a 
biosensor [28, 60]. Immobilization of aptamers onto biosensor surfaces or electrodes is 
14 
achieved via covalent attachment, physical absorption, electrostatic/hydrophobic 
interactions, or π-π stacking [60-63]. Although the immobilization of oligonucleotides 
does not specifically require complex chemistry pathways for immobilization onto the 
surface of electrodes, as is required with antibodies, groups still choose to covalently bind 
the aptamers to their sensor or electrode surfaces. The non-covalent bond pathway of 
immobilization is possible because the oligonucleotide strands have the ability to π-π 
stack with commonly-used carbon-based substrates for electrode and sensor creation [64, 
65]. This immobilization strategy can reduce sensor preparation steps, leading to faster 
sensor creation and less chance of fabrication errors. However, it is common for the 5’- 
or 3’-end of aptamers to be modified with biotin for later attachment to a streptavidin-
functionalized surface [60]. Thiolated aptamers are also commonly immobilized on gold 
nanoparticle-coated substrates and electrodes which allow them to self-assemble onto a 
gold surface [31, 66]. Regardless of how the aptamer is immobilized, when an aptamer is 
immobilized onto a sensor or electrode surface, the result is an aptasensor.  
An aptasensor can detect the interaction between the immobilized aptamer and a 
target oligonucleotide strand via any of the electrochemical strategies discusses 
previously. For example, one amperometric aptasensor was created by immobilizing 
thiolated tetrahedral-structured ssDNA probes onto a gold electrode via Au-S bonds for 
the detection of avian influenza A (H7N9) [31]. This aptasensor was able to specifically 
detect H7N9 to a LOD of 100 fM, even in the presence of other influenza viruses H1N1 
and H3N2. Aptasensors offer an attractive virus detection technique due to the highly 
specific binding events between aptamer probes and target, complementary 
oligonucleotides. However, the stability of oligonucleotides is of concern, as probe 
functionality can be reduced with changes in pH, temperature, and ionic strength of the 
sample and sensor environment [67]. 
2.1.2.2.2 Antibodies 
Antibodies are the most common bioreceptors due to their highly specific nature 
and sensitivity to target antigens [29]. When an antibody is immobilized onto a sensor or 
electrode surface, an immunosensor is created. Immobilization of antibodies is 
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accomplished by electrostatic interactions between the Fc region and sensor surface [35, 
68, 69], streptavidin-biotin binding [33], and through carbodiimide-assisted 
amidation/amine-reactive crosslinking chemistry [70-77]. Carbodiimide-assisted 
amidation and amine-reactive crosslinking chemistry are the most widely used 
immobilization technique to form a covalent bond between the biosensor surface and 
primary amine on the antibody. Carbodiimide-assisted amidation reactions are used to 
create reactive N-hydroxysuccinimide ester (NHS) groups by reacting carboxylic acid 
groups located on a biosensor surface with 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide·HCl (EDC) linkers. NHS-amine reactive crosslinking chemistry is 
performed between NHS esters and primary amines as shown in Figure 2.4. In this well 
understood chemical pathway, NHS esters react with primary amines in near-physiologic 
pH (7.2 - 9) to create stable amide bonds [78]. The immobilization chemical pathway 
from a reactive carboxylic acid group to a stable amide bond to a primary amine located 
on the antibody is used to immobilize antibodies to biosensor surfaces to create highly 
specific and sensitive devices for target antigens. 
 
Figure 2.4: NHS-amine reactive crosslinking chemical pathway to produce a stable amide 
bond between a primary amine and NHS ester [78] 
 
One amperometric immunosensor was developed using 1-pyrenebutyric acid N-
hydroxysuccinimide ester (PSE) as a linker between graphene oxide sheets and rotavirus-
specific antibodies. The PSE linker was used to non-covalently functionalize the 
graphene oxide sheets through π-π stacking of the pyrene group on PSE and the sp2 
hybridized carbon in the graphene sheets, shown in Figure 2.5 [72]. Rotavirus-specific 
antibodies were then crosslinked to the PSE by forming a stable amide bond between 
primary amines on the antibody and the NHS group on the PSE. A cyclic voltammogram 
(CV) was collected from the antibody-functionalized graphene electrode and was 
compared to a CV collected from the application of rotavirus to the antibody-
16 
functionalized graphene electrode, showing a change in current due to increased 
resistance from rotavirus-bound antibodies. The immunosensor detected rotavirus with an 
LOD of 102 plaque-forming units (pfu)/mL [72].  
 
Figure 2.5: Rotavirus immunosensor fabrication pathway [72] 
 
Another biosensor was created for the detection of the M1 protein from influenza 
virus by immobilizing polyclonal anti-M1 antibodies onto a boron-doped diamond 
electrode via the same EDC-NHS chemistry pathway [77]. Electrical impedance 
spectroscopy was used to detect the presence of decreasing concentrations of M1 protein 
to an LOD of 50 fg/mL (40 virions) in only six minutes. The immunosensor was 
compared to other detection methods for influenza including PCR, ELISA, and other 
biosensors, showing superior testing time and comparable virion detection limits [77]. 
With low limits of detection being reported, immunosensors developed by 
immobilizing antibodies to detect specific antigens show promise for being rapid, 
sensitive, and specific diagnostic tools. However, antibodies are extremely sensitive to 
their environment, as any change in pH or temperature can change their function due to 
denaturing. Additionally, immobilizing an antibody and restricting their structure to one 
conformation could lead to a loss of biological function and a loss of detection ability 
[28, 79].  
2.1.2.3 Graphene-based biosensors 
This section of the biosensors review focuses on the material used to create the 
biosensor. Since electrochemical biosensors are being reviewed, the sensor surface must 
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be conductive to allow the transport of electrons. Common materials for device and 
electrode creation include gold [31, 33, 35-37, 66, 68], graphene [39, 40, 72, 75], and 
other carbon-based materials [32, 38, 45]. Graphene is a popular material to construct 
biosensors because of its excellent electron transfer ability, high mechanical strength, and 
high surface area available for functionalization [80]. Graphene surfaces have the 
potential to replace the solid support surfaces used in conventional ELISA. Using a 
conductive surface for an ELISA can provide a faster detection method via electrical 
detection when compared to traditional methods, which were discussed in section 2.1.1.3. 
In a conventional ELISA, antibodies are immobilized onto a solid plastic support such as 
the polystyrene walls of a 96-well plate. In this type of system, the antibody that is 
immobilized on the surface has no way of producing a measurable electrical signal. 
Therefore, additional antibodies and labels are needed to produce a detectable signal, 
typically a color change from enzymatic reduction reactions. The most common way to 
develop a signal is with a sandwich ELISA, shown in Figure 2.6. To create this system, a 
primary antibody is immobilized onto a solid surface (Figure 2.6A). An antigen specific 
to the primary antibody is applied, which binds to the primary antibody (Figure 2.6B). 
After washing, a secondary antibody is attached to the other end of the antigen, which is 
bound to the primary antibody (Figure 2.6C). The last antibody attached is the detecting 
antibody labeled with a luminescent enzyme or a fluorescent tag to induce a color change 
after addition of the enzyme’s substrate (Figure 2.6D) [81, 82]. Instead of relying on a 
colorimetric readout of antigen-antibody interactions inside of a plastic well, 
electrochemical biosensors can be used to quantify the antigen presence via electrical 
signal on a conductive surface, such as graphene.  
 
Figure 2.6: Schematic of a sandwich ELISA. A) Immobilization of the primary antibody 
to the substrate, B) antigen-primary antibody binding, C) antigen-secondary antibody 
binding, and D) detecting antibody/label complex binding to the secondary antibody [82] 
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A sandwich ELISA was constructed on a graphene-sheet coated carbon electrode 
for the amperometric detection of the H5 gene from avian influenza H5N1 [83]. The 
graphene sheets were modified with PSE, functionalized with a streptavidin linker to bind 
a biotin-and fluorescein-labelled PCR H5 gene DNA strand, and finally an anti-
fluorescein HRP detecting antibody was applied, as seen in Figure 2.7. As a proof-of-
concept device, the amperometric response for the H5 gene was above the negative 
control response down to 0.2659 ng/µL, showing promise for a portable, on-site 
screening point-of-care detection device after further device optimizations [83]. Although 
this device shows promise for viral gene detection, it does not detect the influenza virus 
directly, as a PCR-amplified gene was used and diluted as the target analyte, which slows 
down detection time. 
 
Figure 2.7: Fabrication schematic of the graphene-enhanced electrochemical biosensor 
for the detection of the H5 viral gene [83] 
 
Another sandwich ELISA system was created for the detection of 
carcinoembryonic antigen (CEA). This amperometric immunosensor was fabricated in 
the same way as previously discussed on a graphene/gold nanoparticle nanocomposite 
surface [84]. The immunosensor showed two linear ranges of CEA detection between 
0.5-50 ng/mL and 250-2000 ng/mL with LODs of 0.28 ng/mL and 181.5 ng/mL, 
respectively [84]. Although this device does not detect a virus particle, it shows the 
potential application of virus detection with substitutions of the antibodies, while leaving 
the electrochemical detection technique the same. 
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In my work, a sandwich ELISA system was created to detect the presence of 
mouse immunoglobulin G (IgG) antigen and tested using the conductometric sensing 
strategy. Despite the drawbacks of using a multiple antibody-based system, the sandwich 
ELISA immunosensor system was chosen to produce the most specific sensors possible. 
To detect the analytes of choice, the conductometric sensing strategy was chosen as it 
does not require sophisticated equipment or training to obtain or analyze results, making 
the sensors easier to transition out of a laboratory setting. The sandwich ELISA system 
was developed on a graphene biosensor to allow for an electrical signal readout across 
two electrodes when the target analyte is applied. The goal of the conductometric 
sandwich ELISA biosensor was to be used for the direct detection of viral particles, 
which is currently missing from the literature. 
2.1.3 Gold nanoparticles used for analyte detection 
Although electrochemical biosensors offer an inexpensive, specific, and rapid 
method to detect analytes, other methods of detection exist that do not require additional 
fluorescent enzyme labels, electrochemical reactions, or solid sensor surfaces. For 
example, colorimetric assays based on the aggregation of metal nanoparticles have been 
developed to detect and quantify analytes [85-87]. The developed colorimetric assays 
provide rapid and sensitive detection of a variety of viruses and proteins, based on the 
aggregation or de-aggregation of nanoparticles. 
2.1.3.1 AuNP properties and aggregation 
Gold nanoparticles (AuNPs) are used for biosensing due to their unique 
physicochemical and optical properties [88, 89]. Among the most important properties of 
AuNPs are their biocompatibility, controllable size, surface modification capability, and 
their intrinsic surface plasmon resonance (SPR) [89]. SPR is a result of the cloud of free 
electrons present near the surface of AuNPs. The natural oscillations of the free electrons 
on the surface of the AuNPs are called surface plasmons, which exist at the gold metal-
dielectric interface [90]. The surface plasmons can be excited by light, and when 
coupling occurs between the incident light and the surface plasmons, electromagnetic 
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waves in the visible range are given off [88, 90]. This resonant oscillation between the 
incident light and surface plasmons is called SPR [91]. SPR is the property responsible 
for the AuNPs color in liquid solution, which is bright red, corresponding to a wavelength 
of 519 nm for 16 nm particles. A red-shift in the absorbance wavelength occurs as the 
AuNPs size increases and the liquid solution begins to show as a blue color, seen in 
Figure 2.8.  
 
Figure 2.8: 2-150 nm AuNPs color in liquid solution [92] 
 
The wavelength spectrum of the particles is measured using ultraviolet-visible 
(UV-Vis) spectrophotometry. When AuNPs of the same size aggregate, there is also a 
red-shift due to reduced inter-particle separation [93, 94]. This can be seen in Figure 2.9 
as AuNPs of diameter 16.3 nm (Figure 2.9A-C)  are aggregated in the presence of 100 
mM NaCl (Figure 2.9D-F) [93]. The aggregation of the AuNPs is quantified by the 
aggregation index (AI) shown in Equation 2.2 [95] 
𝐴𝐴𝐴𝐴 = 𝜆𝜆𝑚𝑚𝑚𝑚𝑚𝑚+60𝑛𝑛𝑚𝑚
𝜆𝜆𝑚𝑚𝑚𝑚𝑚𝑚
                                                     (2.2) 
where λmax is the absorbance at the maximum wavelength and λmax+60nm is the absorbance 
at a wavelength of 60 nm added to the maximum wavelength. This equation is used to 
determine the aggregation extent of AuNPs in two ways. First, the UV-Vis peak 
absorbance decreases as AuNPs aggregate, and second, the UV-Vis peak broadens as 
AuNPs aggregate. These two phenomena can be seen by comparing the UV-Vis spectrum 
curves in Figure 2.9A and D, where the peak absorbance is higher and sharper in Figure 
2.9A. A larger AI corresponds to a high extent of aggregation [93]. The aggregation of 
AuNPs can also be measured using dynamic light scattering (DLS), which gives the 
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hydrodynamic diameter (DH) of nanoparticles in a liquid medium. The change in DH 
(ΔDH) before and after aggregation can be calculated using Equation 2.3  
Δ𝐷𝐷𝐻𝐻 = 𝐷𝐷𝐻𝐻,𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 − 𝐷𝐷𝐻𝐻,𝑏𝑏𝑎𝑎𝑎𝑎𝑏𝑏𝑎𝑎𝑎𝑎                                        (2.3) 
where DH, after is the hydrodynamic diameter (nm) after inducing aggregation, and DH, 
before is the hydrodynamic diameter (nm) before inducing aggregation. 
The red-shift and diameter increase resulting from AuNPs aggregation can be 
used to develop a colorimetric assay by creating conditions that bring analyte-covered 
AuNPs together and then quantifies them by AI or diameter increase. For example, the 
ΔDH from Figure 2.9 is 922.2 nm – 16.3 nm = 905.9 nm. 
 
Figure 2.9: Example of AuNP aggregation resulting in a red-shift. A) UV-Vis spectrum 
of 16.3 nm AuNP, B) hydrodynamic diameter measurement of AuNP, C) TEM image of 
16.3 nm AuNP, D) UV-Vis spectrum of aggregated 16.3 nm AuNP, E) hydrodynamic 
diameter measurement of aggregated AuNP, and F) TEM image of aggregated AuNP 
[93] 
 
One AuNP assay was developed to detect clinical samples of hepatitis C virus 
(HCV) RNA based on the aggregating effects of cationic and anionic AuNP binding [94]. 
Citrate-capped AuNPs were functionalized with a thiolated-ssDNA probe specific to 
HCV RNA. When denatured, complementary HCV RNA strands were added, base-
pairing between the probe and HCV RNA strand occurred, leaving negatively charged 
RNA phosphate backbone strands un-bound. Finally, when cationic AuNPs were added, 
the particles bound to the folded HCV RNA complexes did not allow the cationic and 
anionic AuNPs to come into contact and aggregate. In contrast, when cationic AuNPs 
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were added to samples containing non-complementary HCV RNA strands, the anionic 
AuNPs were able to bind to the phosphate backbone of the RNA probe. This binding 
reduced the inter-particle distance between cationic and anionic AuNPs, leading to 
aggregation and a visible color change. The aggregation and anti-aggregation were 
characterized by UV-Vis absorption peak changes. These results were directly compared 
to PCR and ELISA techniques, which agreed favorably with both conventional tests. This 
assay allowed for the detection of unamplified HCV RNA from clinical samples in ~30 
minutes with a 94.1% specificity with a limit of detection of 4.57 IU/µL [94]. However, 
one drawback to this type of assay is the need to functionalize the AuNPs with nucleic 
acid probes, which tend to be expensive. 
2.1.3.2 Modified, functionalized AuNPs 
Modified AuNPs, commonly through antibody and nucleic acid functionalization, 
have been used extensively for the detection of analytes. These types of AuNP assays are 
specific and sensitive due to the use of specific targeting receptors for the analyte of 
interest. As discussed for bioreceptor immobilization, the modification of AuNPs is very 
similar. Thiolated probes can be readily bound to the AuNP surface, and antibody 
immobilization onto AuNPs is achieved through EDC-NHS chemistry. Additionally, 
antibodies can be passively adsorbed to the surface of citrate-capped AuNPs through 
ionic and hydrophobic interactions [96]. This was done to conjugate 13 nm AuNPs with 
anti-influenza A H3N2 HA mouse monoclonal antibodies (mAbs) for the un-amplified 
detection of influenza A virus H3N2 [96]. When the virus was in the presence of the 
AuNP-mAb complexes, aggregation lead to a red-shift in the absorbance spectrum due to 
decreased intra-particle distance. This aggregation was confirmed using DLS, where a 
ΔDH of 116 nm (21 to 137 nm) was measured. This assay had a limit of detection of 7.8 
hemagglutination units (HAU) with a detection time of only 30 minutes [96]. Another 
AuNP assay based on DLS measurements was developed to detect influenza A virus 
H1N1. The AuNPs were conjugated with mAbs specific to the influenza A virus using a 
3,3’-dithiobis(sulfosuccinimidyl propionate) bifunctional linker to covalently bind the 
mAbs to the AuNPs. AuNPs with diameters of 30, 60, and 80 nm were used to evaluate 
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the size dependence of the influenza assay, revealing that a different AuNP size did not 
affect the assay performance [97]. By optimizing the concentration of AuNPs, a limit of 
detection of <100 TCID50/mL was achieved, which is 1-2 orders of magnitude better than 
conventional ELISA kits and only requires ~30 minutes of detection time [97]. Another 
virus assay was developed using peptide-functionalized AuNPs for the detection of 
Newcastle disease virus (NDV) [98]. The AuNPs were functionalized with NDV-specific 
peptides via strong sulfur-gold bonds. Using optical density measurements with different 
virus concentrations for varying degrees of aggregation, a limit of detection of 0.125 
HAU was found in 20 minutes [98]. These virus detection assays show the aggregation of 
AuNPs as the detection pathway, but anti-aggregation of AuNPs can also be used.  
The anti-aggregation method was highlighted in a gold nanostar (AuNS) assay for 
the detection of enterovirus 71 (EV71) that causes hand, foot, and mouth disease 
(HFMD) [99]. In this assay, 105 nm AuNS were conjugated with a receptor protein with 
a known affinity to EV71 through passive adsorption. Aggregation was prevented in 
samples that contained EV71 because the receptor protein binding sites were filled, 
which prevented nonspecific interactions with contaminant proteins present in the sample 
media [99]. Raman spectroscopy peak intensities after the addition of decreasing 
concentrations of EV71 were measured, leading to a limit of detection of 107 pfu/mL in 
only 15 minutes [99]. 
Functionalized AuNPs lead to the rapid detection of various viruses with low 
limits of detection. However, preparation steps to functionalize and wash the AuNPs 
increase overall testing time. Increased testing time can cause stability issues because 
ligand-functionalized AuNPs are temperature and the external-environment dependent. 
2.1.3.3 Unmodified AuNPs 
To overcome the potential stability issues of functionalized AuNPs, unmodified 
AuNPs can be used for analyte detection assays. Using unmodified AuNPs reduces the 
complexity of analyte detection assays, as there are no AuNP pre-treatment 
functionalization steps. The detection strategy of analytes with unmodified AuNPs is the 
same as functionalized AuNPs, which is achieved through observing absorbance peak 
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shifts after aggregation or quantifying the aggregation with DLS. There are also 
opportunities to develop assays for naked-eye detection of aggregation through a color 
change of the testing liquid. Most of the developed unmodified AuNP assays are all 
centered around keeping the AuNPs dispersed in solution to keep the solution color red. 
This is achieved by adding complementary ssRNA/ssDNA primers to the sample tube, 
which contains the target virus’ RNA/DNA, leading to stable dsRNA/DNA formation 
that keeps the testing solution red. 
This technique was used to detect unamplified BVDV-RNA by naked-eye [100]. 
In this assay, BVDV probes were added to testing tubes that contained unmodified 
AuNPs and either non-complementary BVDV-RNA or complementary BVDV-RNA. 
When NaCl was added to samples containing non-complementary BVDV-RNA, no 
aggregation was observed because the BVDV probes stabilized the unmodified AuNPs 
through electrostatic interactions between the negatively charged backbone of the probe 
and citrate shell around the AuNPs [100]. When NaCl was added to samples containing 
complementary BVDV-RNA, salt-induced AuNP aggregation occurred because the 
probes hybridized to the BVDV-RNA, and NaCl was free to aggregate the un-stabilized 
AuNPs. By using a fixed concentration of AuNPs and probes, BVDV concentration was 
varied to show a LOD of 80 TCID50/mL by UV-Vis, and 200 TCID50/mL by naked-eye 
[100]. Despite these promising results, a purified RNA sample was used for detection 
because unmodified AuNPs can also passively bind to other contaminants in clinical 
samples, including other DNA fragments and proteins. 
Another assay using unmodified AuNPs was developed for the detection of 
Dengue virus using a similar detection pathway [101]. Instead of inducing aggregation of 
unmodified AuNPs with NaCl, this assay found that the addition of a neutral-charge 
peptide nucleic acid (PNA) caused aggregation because PNA removed the charge-
repulsion between AuNPs thus reducing the interparticle distance [101]. The PNA was 
the probe for the target Dengue DNA. In the presence of the Dengue DNA, hybridization 
occurred, which left the AuNPs un-aggregated in solution. This assay showed a LOD of 
Dengue DNA at 0.12 µM [101]. However, this study used a purified ideal Dengue DNA 
sample that did not originate from the full Dengue virus. This limits the actual application 
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of these types of assays because the target nucleic acids are located inside the capsid of 
the virus, which must be extracted prior to detection. While the extraction of the target 
nucleic acids is possible prior to an AuNP assay, this could result in assay complications 
because AuNPs non-specifically bind to other biomolecule fragments. One possible 
solution to avoid this pre-treatment extraction step is to develop an AuNP assay to detect 
whole viral particles. 
Only a limited number of unmodified AuNP assays exist for the detection of 
whole viral particles. One assay utilized sialic acid-stabilized AuNPs (SA-AuNPs) for the 
detection of influenza B Victoria and Yamagata [102]. Influenza viral proteins 
(hemagglutinin) are known to bind to sialic acid, which is present on the surface of lung 
epithelial cells [103]. By using SA-AuNPs, influenza virus was detected as 
hemagglutinin-sialic acid binding occurred, aggregating the nanoparticles. The 
aggregation caused peak broadening of the absorption spectrum at 610 nm, and a change 
in absorbance at this wavelength was calculated with a decreasing volume of the 
influenza virus added. A LOD of only 0.09 volume % of influenza virus was achieved 
[102]. Another viral particle detection assay was developed for human papillomavirus 
type 16 virus-like particles (HPV16 VLPs) using unmodified citrate-capped AuNPs to 
explore the interaction between VLPs and AuNPs [104]. In this study, AuNP-VLP 
complexes formed mainly through hydrophobic interactions, which hindered the salt-
induced aggregation of un-complexed AuNPs. To test that hydrophobic interactions were 
the dominant driving force for complex formation, a higher and higher concentration of 
ethanol was added to the VLP-AuNP mixture showing that aggregation was increased 
with higher ethanol concentration. VLP solubility increased at higher ethanol 
concentrations, resulting in less VLPs complexing with AuNPs, leaving more AuNPs to 
be aggregated by 70 mM NaCl [104]. 
As shown in these whole viral particle detection assays with AuNPs, there is some 
mechanism for the viral particles to aggregate and decrease the interparticle distance 




Osmolytes are water-soluble, naturally-occurring molecules that are produced by 
cells to enhance protein stability by combating osmotic stress and other environmental 
stresses [105, 106]. Osmolytes are classified into three groups, carbohydrates/polyols 
(sucrose, mannitol), amino acids (glycine), and methylamines (TMAO). Additionally, 
osmolytes can be classified as protecting or denaturing osmolytes. Protecting osmolytes 
do not affect the native protein structures and promote protein folding and denaturing 
osmolytes denature proteins into unfolded states [105, 107]. Although the exact 
mechanism of osmolyte action on protein folding/unfolding is not fully understood, it has 
been shown that protecting osmolytes are preferentially excluded from the protein surface 
and do not directly interact with the protein’s amide backbone, whereas denaturing 
osmolytes interact with the protein backbone directly, causing protein unfolding [107, 
108]. The theory of protecting osmolytes causing protein stabilization is called the 
osmophobic effect, which states that there is an unfavorable interaction between 
osmolytes and the protein peptide backbone [109]. In the unfolded state, the peptide 
backbone is more readily exposed to osmolyte resulting in a high free energy that is 
reduced by protein folding back to its native state [109]. Another important action of 
osmolytes is their ability to alter the water structure around biomolecules. Protecting 
osmolytes are excluded from the surface of proteins, and they interact with water 
molecules near the surface, increasing protein stability due to increased intra-protein side 
chain interactions [105, 110]. This is the solvation effect of osmolytes. Since the 
osmolytes pull water molecules away from the surface of proteins, the protein surface 
becomes slightly more hydrophobic, which is stabilized by intra-protein side chain 
interactions [105, 110]. 
2.1.4.1 Preferential virus aggregation 
Protecting osmolytes have been used for the preferential aggregation of both 
enveloped and non-enveloped viral particles [111, 112]. To test the aggregation ability of 
protecting osmolytes, 18-26 nm non-enveloped porcine parvovirus (PPV) was filtered 
through a 0.2 µm filter that would not normally retain the PPV in water or PBS. Over 
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80% of PPV was removed by the filter using 1.0 M glycine, mannitol, alanine, and 
trehalose, which aggregated the PPV and allowed for removal by the filter [111]. Even in 
the presence of model contaminating proteins, BSA and lysozyme, 1.0 M mannitol and 
alanine were able to remove 85.1% and 80.2% of the PPV, respectively, with less than 
5% protein removal [111]. The theory for this preferential virus aggregation versus 
protein aggregation with osmolytes is based on the relative hydrophobicity between 
viruses and proteins and the physical structure of the two macromolecules [6, 111]. When 
osmolytes are introduced into the solutions containing PPV or proteins, there is a partial 
dehydration layer around the biomolecules resulting in free energy that must be 
minimized. For proteins, their relatively more hydrophilic and flexible nature allows the 
excess free energy to be minimized by increased protein side chain interactions resulting 
in protein structure compaction and stabilization [6, 111, 113]. Since viruses are 
relatively more hydrophobic and rigid than proteins, the dehydrated and hydrophobic 
exposed patches are minimized by virus-virus aggregation [111]. This same preferential 
aggregation phenomenon was confirmed using an enveloped, 60-80 nm Sindbis virus 
heat resistant strain (SVHR) [112]. In this work, 0.3 M proline and mannitol were able to 
remove over 80% of SVHR using a 0.2 µm filter while leaving BSA and lysozyme 
proteins in solution with less than 23% removed [112]. These studies highlight the ability 
of protecting osmolytes to preferentially aggregate viral particles and not proteins. 
2.1.4.2 Osmolyte-induced AuNP aggregation virus assay 
The ideas of preferential virus aggregation, AuNP complexation with viral 
particles, and decreased intra-AuNP distance leading to a color change and measurable 
change in complex diameter have been combined to develop a general viral particle 
detection assay, shown in Figure 2.10 [6]. When an osmolyte solution was added to 
virus/AuNP complexes, aggregation occurred if a high enough concentration of virus was 
present (Figure 2.10, top left side pathway). When osmolyte was added to 
protein/AuNP complexes, aggregation did not occur because the osmolyte preferentially 
aggregated viruses, not proteins (Figure 2.10, bottom left side pathway). To test salt’s 
ability to aggregate virus/AuNP complexes, NaCl was added to AuNP/virus complexes 
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where aggregation occurred at low enough virus concentration because the virus could 
not protect the AuNPs from salt-induced aggregation (Figure 2.10, top right pathway). 
 
Figure 2.10: Scheme of virus detection using osmolyte-induced aggregation of virus-
AuNP complexes [6] 
 
In this assay, AuNPs and viral particles were complexed, aggregated using 
protecting osmolytes, and the aggregation was quantified by DLS for decreasing titers of 
PPV and BVDV before and after osmolyte addition. As a control, model proteins BSA 
and thyroglobulin were complexed with AuNPs, and their aggregation extent due to 
osmolyte addition was compared to the aggregation of virus-AuNP complexes. As 
expected, the virus-AuNP complexes aggregated with the addition of 1 M mannitol, and 
protein-AuNP complexes did not aggregate. PPV was detected in the range of 105 to 108 
MTT50/mL with a LOD of 106 MTT50/mL [6]. BVDV was detected in the range of 103 to 
107 MTT50/mL with a LOD of 104 MTT50/mL [6]. 
To expand upon this AuNP virus detection assay, I synthesized different sizes of 




2.2 Purification of viral particles 
2.2.1 Vaccine manufacturing process 
Vaccination is one of the most effective methods of preventing and eradicating 
deadly viral diseases. Millions of lives are saved every year due to vaccination, but 
producing vaccines is a difficult undertaking. Vaccine manufacturing is challenging 
because a high concentration (titer) of viral particles must be produced and purified while 
ensuring the safety and efficacy throughout the manufacturing process to meet regulatory 
guidelines. Viruses are complex biomolecules that are susceptible to their environment 
and the processes they are put through in the vaccine manufacturing process [114]. These 
manufacturing processes are separated into two broad sections: upstream production 
where the viral particles are generated in flasks and bioreactors (Figure 2.11, Upstream), 
and downstream purification where the viral particles are separated from contaminants 
using various unit operations (Figure 2.11, Downstream). Common unit operations for 
upstream production of viral products are batch-mode and perfusion (continuous) 
bioreactors. Common unit operations for the downstream purification of products are 
centrifuges, filtration units, and chromatography columns. 
 
Figure 2.11: Vaccine biomanufacturing train from upstream production through 
downstream purification [115, 116] 
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2.2.1.1 Conventional upstream vaccine production 
Perhaps the most well-known and recognizable vaccine is the seasonal influenza 
vaccine. This vaccine has been historically produced in embryonated hens’ eggs, which 
act as mini bioreactors after being inoculated with the seasonal influenza strain. Many 
issues exist with this egg-based influenza vaccine platform, such as the need for over 400 
million eggs every year for enough doses, the fact that some influenza strains are highly 
pathogenic and could kill the embryos, and if a downstream purification run fails a large 
batch of doses must be discarded [117]. To address these issues, the shift to animal cell-
culture techniques has been successfully implemented. However, a large majority of 
influenza vaccine doses are still created in eggs today [117, 118]. The slow transition 
from producing influenza vaccines in eggs to cell-culture bioreactors is due to the large 
infrastructure already in place to support the egg-based system, including collaborations 
between academic and industrial laboratories to ensure the next batch of vaccine will 
contain appropriate antigenic variants [119]. The current role of large-scale animal cell 
culture bioreactors is to augment and support the growing demand of the influenza 
vaccine, not to fully replace the well-established egg-based vaccine production network. 
However, with further developments and implementation, the reliance on egg-based 
platforms for the flu vaccine could be fully realized. Numerous cell lines have been 
considered and researched to produce influenza vaccines. These cell lines include human 
embryonic kidney (HEK) cells [120], Madin-Darby canine kidney (MDCK) cells [118, 
120], Vero cells [120], and Spodoptera frugiperda (Sf9) insect cells [120], summarized in 
Table 2.1 [121]. Most of the approved vaccines are produced using MDCK and Vero cell 
lines because they have been extensively characterized and their growth kinetics are well-
understood from numerous studies [117].  
One study directly compared MDCK and Vero cells for the production of the 
influenza virus for vaccines in a lab-scale bioreactor [122]. The adherent MDCK and 
Vero cells were grown on microcarriers inside of a 5 L stirred tank bioreactor (STR) and 
infected with influenza A Wisconsin strain at ~1.8×106 cells/mL with a MOI of 0.001. 
The cells were also grown on microcarriers in a 2 L wave bioreactor and infected at 
~1.1×106 cells/mL with a MOI of 0.018. To compare the ability of MDCK and Vero cells 
31 
to produce influenza virus, a virus productivity value was calculated from quantifying the 
HA produced during infection per cell. In the STR, MDCK and Vero cells produced 
10,000 virions/cell and 4,976 virions/cell, respectively. In the wave reactor, MDCK and 
Vero cells produced 33,255 virions/cell and 3,990 virions/cell, respectively [122]. This 
study demonstrated that MDCK cells can produce higher titer of influenza virus 
compared to Vero cells, which shows why current cell-based influenza vaccines are 
produced from MDCK cell lines. However, there is still a need to increase the 
productivity of cell lines to produce even more viral particles to meet the demand and 
replace egg-based methods. 
 












(H1N1, H3N2, B) 2007/2012 
Celtura Germany MDCK Monovalent  (H1N1) 2009 
Celvapan EU Vero Monovalent (H1N1 or H5N1) 2009 
Preflucel EU Vero Trivalent inactivated (H1N1, H3N2, B) 2010 
Flublok USA Sf9 Quadrivalent subunit (updated annually) 2013 
Flucelvax 
Quadrivalent EU/USA MDCK 
Tetravalent subunit (H1N1, 
H3N2, Victoria, Yamagata) 2016 
 
As mentioned, upstream production of viral particles is achieved in a bioreactor. 
A bioreactor is used to grow host cells which are inoculated with a virus to allow for 
virus propagation as the cells grow. The classical and commonly used mode for 
bioreactor operation is batch cultivation where cells and media are introduced into the 
bioreactor and left to grow and collected after many days of virus replication, shown in 
Figure 2.12A [123]. Bioreactors are equipped with various sensors and probes to monitor 
the temperature, dissolved oxygen level, pH, and other properties to maintain cell health 
over time. The six phases of cell concentration occur over time within a batch-mode 
operated bioreactor, as shown on the growth curve in Figure 2.12B [124]. The lag phase 
32 
is the short amount of time where cells adapt to their new environment and do not grow. 
The acceleration phase is when cell growth begins as cells uptake nutrients from the 
surrounding media and continues at a constant rate through the growth phase. The decline 
phase starts when the cells utilize all available nutrients, and growth stops through the 
stationary phase. The death phase begins when cells lose viability and lyse, or break apart 
[124]. The most critical phase to consider is the growth phase where cells are growing, 
producing virus particles, and all other biomolecules during normal cell growth. 
 
Figure 2.12: A) Schematic of a bioreactor [123] and B) growth curve of cells within a 
batch-mode bioreactor [124] 
 
While upstream studies focus on increasing the productivity of cell lines for the 
desired viral product, additional biomolecules are generated during cell growth. These 
biomolecules are considered impurities that must be separated from the viral product 
during downstream purification, so knowing the composition of what exits the bioreactor 
after growth is important for designing downstream purification methods. These 
biomolecules include both process- and product-related impurities. Process-related 
impurities include proteins from serum-based media and compounds added for cell lysis. 
Product-related impurities include host cell proteins (HCP), host cell DNA (hcDNA), and 
cell debris after cell lysis.  
The amount and type of impurities vary based on the type of expression system 
used to produce the viral product. For example, in the case of the egg-based vaccines, the 
allantoic fluid from the eggs is collected, which contains high concentrations of 
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ovalbumin protein, tissue compounds, and other solids from chicken growth [125]. In 
contrast, the flu vaccine produced using serum-free media with MDCK or Vero cells 
have considerably less solids and protein content [125]. Regardless of the expression 
system or compounds added upstream, the downstream purification train is responsible 
for removing all impurities to below regulatory-approved concentrations prior to the final 
formulation of the drug product. 
2.2.1.2 Conventional downstream purification processes 
The downstream purification train starts directly after the bioreactor harvest step 
and is called clarification. Clarification aims to remove cells, cell debris, and aggregates. 
The clarification step varies for each viral product, and different unit operations are used 
to achieve this removal [125]. The clarification step is a very important step in the 
purification train as a low solid content stream to other downstream unit operations 
allows them to operate more efficiently. Numerous unit operations are available for the 
clarification step, such as low-speed and high-speed centrifuges and various filtration 
units. The unit operation used for clarification depends on the viral product’s 
physicochemical properties, including size, shape, isoelectric point, and stability. A very 
common clarification step is using a low-speed centrifuge to pellet cells and cell debris 
from the reactor harvest and collecting the supernatant which contains the virus and other 
soluble impurities. This process was used to clarify a rotavirus vaccine produced in Vero 
cell culture by centrifuging the harvest at 2,831 × g for 30 minutes and 4,424 × g for 10 
minutes at 4°C [126]. Another centrifuge-based clarification step (1,000 × g for 10 min at 
4°C) was applied to rotavirus VLPs after a freeze-thaw cycle to lyse the cells [127]. 
Although neither study directly reported the virus recovery after the primary clarification 
step, centrifugation was adequate to remove cell debris, which allowed for additional 
purification steps with filtration and chromatography units. The major drawbacks to a 
centrifuge-based clarification step are the difficulty of scale-up and continuous operation 
[125, 128]. At the production level scale, the only way to process more harvest is to use 
additional centrifuges, which leads to increased capital costs and labor costs [125]. These 
challenges lead to the development of different clarification steps using filtration units. 
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Tangential flow filtration (TFF) and dead-end filtration (DEF) are attractive 
options for the clarification of viral products. Although DEF units are easy to implement 
at any scale, disadvantages include virus adsorption on the filter surfaces, potential 
leachables in the product stream, and rapid fouling from cake formation [125]. TFF units 
have numerous advantages, including simple design and operation, variable flow rate 
options, and can be operated continuously. As opposed to the conventional perpendicular 
feed flow of DEF, TFF utilizes a feed flow parallel to the membrane surface, which 
allows constant cake formation on the filter surfaces, leading to steady-state filtrate flux, 
shown in Figure 2.13 [129]. 
 
Figure 2.13: A) Feed and product streams in TFF and B) filtrate flux rate profile through 
filtration time using TFF [129] 
 
The TFF technique has been used extensively at the pilot and production scales 
[126, 130-132]. This size-based separation technique has received attention because viral 
particles are in the size range of nanometers, whereas cells and aggregates are in the 
micrometer range [131]. In one study, a 0.65 µm TFF membrane was used for the 
primary clarification of 5 L of influenza VLPs produced in a stirred-tank bioreactor with 
High Five (Hi5) insect cells [133]. The primary harvest clarification was successful based 
on maintaining 100% HA content before and after clarification, as well as high turbidity 
reduction [133]. Although the study did not pursue the 0.65 µm filter further for scale-up, 
the potential exists to use the membrane for similar viruses on a large scale. Another 
study demonstrated the large-scale recovery of tetanus toxin and toxoid for the 
diphtheria-tetanus-pertussis (DTP) vaccine using the TFF technique in a cGMP setting 
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[132]. The conventional primary clarification technique utilizes centrifugation, which 
shows losses greater than 25%. At a pilot-scale working volume of 400 L, the tetanus 
toxin broth was clarified by a microfiltration TFF membrane with a pore size of 0.22 µm 
at >96% recovery. The study also showed that 60,000 L of broth could be processed by 
the same filter before irreversible fouling occurred [132]. These studies highlight the 
potential and direct application of TFF for use in the primary clarification of viral 
products for use in vaccines, which is important in the downstream purification train. 
The step after clarification in the downstream purification train is the main 
purification section, which aims to separate the target viral product from other soluble 
impurities. In the main purification section, the physicochemical properties of the virus 
are of great importance in designing purification techniques. These physicochemical 
properties include the isoelectric point (pI), size, envelope presence, and hydrophobicity 
which are extensively exploited for use in chromatographic separations [5]. The 
purification strategies used include ultracentrifugation, ultrafiltration, biphasic extraction 
systems, and chromatography [5]. 
Historically, and especially in monoclonal antibody (mAb) production, 
chromatography has been used as the main unit operation in downstream purification. 
Chromatography has many different techniques, including size-exclusion, ion exchange, 
hydrophobic interaction, and affinity. For example, Protein A affinity chromatography 
has been used for the primary capture step in many production-scale mAb processes 
[134]. While these chromatography techniques have been used for efficient purification 
of mAbs, the relatively large size of viral particles limits their adsorption to the column 
resins leading to decreased purification efficiency and flow rates [135]. To address these 
issues in viral particle purification, new chromatography resins are being developed and 
tested including monoliths and larger-pore resins. The main advantage of using a 
monolith-based resin is the ability to flow at 10-20 times higher than conventional resin 
columns because mass transfer within porous resin beads is dominated by convection, 
rather than diffusion [136].  
One monolithic column chromatography technique was used for the purification 
of HIV-1 gag virus-like particles from host cell impurities, including extracellular 
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vesicles [137]. With a 1 mL monolith column, 41.9 ± 9.6% of the VLPs were recovered 
with a 90.6% total protein and 98.2% total dsDNA depletion, comparable to the 48.1% 
VLP recovery using a standard method of density gradient ultracentrifugation [137]. This 
process only took 47 minutes and resulted in 2000 doses of the purified VLP. Although 
not tested during the study, 8 L and 40 L monolith columns are commercially available, 
leading to possible scale-up opportunities for full-scale production [137]. Another study 
evaluated the ability of an 8 mL convective interaction media (CIM) quaternary amine 
(QA) monolith column to purify Vero cell-derived influenza A and B viruses. At 
physiological pH, the influenza viruses are negatively charged and bind to the QA 
monolith, which were eluted with 0.5 M NaCl. The four different influenza strains had 
recoveries between 70.8 ± 32.3% and 87 ± 30.8% [138]. Protein removal was between 
93.3 ± 0.4% and 98.6 ± 0.2% and hcDNA removal was between 76.4% and 99.9% [138]. 
2.2.1.3 Continuous-mode downstream purification 
While there have been advances in the downstream purification of viral particles 
using conventional techniques like filtration and chromatography, another optimization is 
necessary to boost the productivity of these unit operations. Switching to the continuous 
operation for these unit operations would increase throughput and productivity while 
simultaneously reducing the size of equipment [139, 140]. A reduction in the size of 
equipment would reduce the facility size of a manufacturing suite, leading to increased 
capital cost savings [139]. The first attempts of making the downstream purification train 
continuous was using chromatography for mAbs and a limited number of viruses. In one 
process for the continuous purification of influenza virus, simulated moving bed (SMB) 
chromatography was used and compared directly to conventional batch chromatography 
[141]. SMB chromatography utilizes countercurrent flow between target analytes (solids) 
and the mobile phases through an arrangement of many columns and valves, shown in 
Figure 2.14 [141, 142]. The size-exclusion SMB process continuously moves the inlet 
and outlet ports along a bed, which allows for increased resolution between solids with 
similar retention times [143]. Using this size-exclusion SMB technique, 70% of influenza 
H1N1 produced in adherent MDCK cells was recovered, compared to 80% recovery 
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using a conventional batch process [141]. Total protein reduction was 60% for the 
continuous SMB process compared to an 80% reduction in the batch process. The 
productivity was calculated to be 3.8 times higher for the continuous SMB process, 
which ultimately leads to the ability to use smaller columns compared to a batch process 
[141]. 
 
Figure 2.14: Four-zone (column) open loop SMB chromatography process [141] 
 
Another SMB process, an open-loop, two-column SMB process, was used for the 
quasi-continuous purification of adenovirus serotype 5 (Ad5) [144]. This open-loop, two-
column SMB process recovered 86% of Ad5 compared to 57% from a single column 
batch process. Host cell protein removal was 89%, and host cell DNA removal was 90% 
for the continuous process, which was comparable to the 94% removal of HCP and 94% 
removal of host cell DNA in the batch process [144]. This study calculated a productivity 
increase of 6-fold and a 51% increase in Ad5 recovery, which gives strong evidence that 
quasi-continuous chromatography has the potential to be in a novel downstream 
processing train. 
In addition to SMB, periodic countercurrent chromatography (PCC) has been 
explored as a continuous purification process. Although no study could be found for the 
purification of viral particles, PCC has been applied to the purification of therapeutic 
proteins [140]. The PCC technique utilizes several columns equal to the number of 
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chromatographic steps necessary for the separation: loading, washing, eluting, and 
regeneration. A common number of columns is three to allow for loading, eluting, and 
regeneration, shown in Figure 2.15 [140]. There are six steps in a full cycle: 
1. The first column is loaded until breakthrough  
2. The first, loaded column is connected to the second column to begin loading  
3. The first column is eluted, and the second column is loaded until breakthrough  
4. The first column is regenerated, and the second column is connected to the third 
column to begin loading  
5. The second column is eluted, and the third column is loaded until breakthrough  
6. The second column is regenerated, and the third column is connected to the first 
column 
 
Figure 2.15: Schematic of three-column PCC cycle [140] 
 
This three-column PCC process was used to purify a mAb from a proprietary 
CHO cell line [140]. The PCC process ran uninterrupted for 30 days, with the continuous 
recovery of mAb between 70-110%. Compared to a batch chromatography process, the 
39 
three-column PCC had a resin capacity of 120%, buffer usage of 75%, and column 
volume of 3.9% [140]. These comparisons to the batch process highlight the ability of a 
PCC process to greatly reduce facility size with smaller columns and buffer tanks. 
Although these continuous chromatography processes show promise for use in a 
continuous downstream processing train, several drawbacks exist. First, these processes 
are not truly continuous, as they require either discontinuous loading onto different 
columns, or interrupted outlets from valve switches. These issues could lead to the 
necessity of holding tanks, which increases facility size. Additionally, many 
chromatographic processes were not designed or optimized for use in viral particle 
purification, as shown with the limited studies. Lastly, chromatography steps account for 
up to 60% of downstream processing costs in mAb manufacturing, as Protein A resin can 
cost over $1,000,000 for a 1-meter diameter column [145]. For these reasons, 
chromatography-free downstream processing trains may be an attractive option. 
2.2.2 Aqueous two-phase systems 
The use of aqueous two-phase systems (ATPSs) could be one solution to 
replacing chromatography-intensive downstream processing trains. An ATPS is a liquid-
liquid extraction technique that can partition biomolecules of different properties to 
different liquid phases for separation. ATPSs are scalable, do not require labels, are 
biocompatible, and can be easily operated continuously [146, 147]. 
2.2.2.1 Formation and characterization 
ATPSs are formed by mixing two phase-forming components that are rich in 
water above certain critical concentrations. The phase-forming components can be water-
soluble polymers, salts, sugars, or alcohols [147]. When two of these components are 
mixed above certain critical concentrations, they separate into two phases – like how oil 
and water separate when mixed. Phase separation is dominated by three main forces: 
gravitational, buoyant, and frictional, which act on the phase droplets formed as they 
coalesce [148]. The density of each phase-forming component affects the gravitational 
force, and rheological properties such as dynamic viscosity affect the buoyant and 
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frictional forces [148]. The interfacial tension also plays an important role in the 
separation of the phases. In the case of a polymer-salt system, the large difference in 
viscosity plays a major role in phase separation as the salt phase coalesces in the 
polymer-rich phase and must travel downward through the viscous polymer. For this 
reason, polymer-salt systems tend to have higher separation times than salt-salt and other 
less viscous systems. This phenomenon is important when an ATPS is designed for 
biomolecule separation where a rapid separation is desired; different systems can have 
vastly different biomolecule separation efficiency. 
A phase diagram is used to show the different regions of an ATPS. A phase 
diagram is specific for each biphasic system of two phase-forming components and can 
change with temperature, pH, ionic strength, and molecular weight of components. A 
phase diagram for a polymer-salt system is shown in Figure 2.16 [7]. The binodal curve 
on the phase diagram separates the one-phase and two-phase region and is found by 
titrating the two phases until a turbid mixture, indicative of a two-phase mixture, is 
formed [7]. Any system formed on a unique tie line within the two-phase region will 
separate into phases with the same concentration of polymer and salt. For example, the 
ATPS formed on system point (S) will separate with a polymer-rich top phase at point 
(T), and a salt-rich bottom phase at point (B). This is true for any system formed on the 
same tie line connecting points T and B. Tie lines are described by their length (TLL), 
which is calculated by the length between points T and B [147].  
A particular system point can be uniquely identified by the tie line ratio (TLR) 
calculated as the ratio of lengths between the system point (S) and the top point (T) to the 
system  point (S) and the bottom point (B). Although each system point along a tie line 
eventually separates into the same top and bottom phase composition, there are 
differences in mixture properties, especially dynamic viscosity in a polymer-salt system. 
At low TLR, a higher volume of polymer is present, which makes the total mixture more 
viscous than a high TLR system on the same tie line. This consideration is important 
when designing an ATPS where easy fluid processability is necessary, such as in a 
continuous system. Another important consideration for different systems along tie lines 
is the differences in biomolecule partitioning. 
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Figure 2.16: Phase diagram of a polymer-salt ATPS [7] 
2.2.2.2 Theories of biomolecule partitioning 
When biomolecules are introduced into an ATPS, their partitioning is governed 
by numerous factors. Phase forming component concentrations, ionic strength, system 
temperature and pH, and biomolecule properties all affect partitioning to different phases. 
These factors are all combined into an overall partitioning coefficient, K, which is the 
concentration ratio between biomolecules in the top phase over the bottom phase at 
equilibrium (K=CT/CB), shown in Equation 2.4: 
ln𝐾𝐾 = ln𝐾𝐾𝑎𝑎 + ln𝐾𝐾ℎ + ln𝐾𝐾𝑎𝑎 + ln𝐾𝐾𝑠𝑠 + ln𝐾𝐾𝑐𝑐 + ln𝐾𝐾𝑏𝑏                    (2.4) 
where Ke is the contribution of partitioning due to electrochemical factors, Kh is the 
hydrophobic factor, Ka is the affinity factor, Ks is the biomolecule size factor, Kc is the 
biomolecule conformation factor, and Ko is all other factors such as external 
environmental factors [149]. Although it is most accurate to consider all of these factors 
for partitioning behavior [150], the Ke and Kh factors are the ruling factors for 
partitioning in polymer-salt systems [148, 149]. 
Two leading and debated theories for biomolecule partitioning exist. The first is 
based on the excluded volume theory of polymers, which states that the presence of a first 
molecule (polymer) disallows the presence of a second molecule (biomolecule) [151]. 
This mechanism suggests the presence of large-chain polymer molecules geometrically 
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block biomolecules’ partition to the polymer-rich phase, making them partition to the 
opposite, less sterically-hindered phase [152, 153]. This effect was demonstrated by 
comparing the PEG-rich recovery trends as PEG MW increased using protein from E. 
coli cell lysate during the production of plasmid DNA [153]. As PEG MW was increased 
from 600 to 4000 Da, protein recovery in the PEG-rich phase always decreased, 
independent of system pH and lysate load, suggesting the cause of the partitioning was 
due to an increased steric hindrance of higher MW PEG [153]. However, this effect was 
directly the opposite in a partitioning study using porcine parvovirus (PPV) with PEG 
MW from 3000 to 12000 [154]. In this study with PPV particles, an increase in the PEG 
MW lead to a higher recovery of PPV in the PEG-rich phase [154]. The second 
biomolecule partitioning theory is based on electrostatic and hydrophobic interactions 
between the biomolecules and phase-forming components. This theory suggests that 
biomolecules are salted-out from the salt-rich phase to the interface and then hydrophobic 
interactions pull the biomolecules from the interface to the PEG-rich phase [7, 154, 155].  
2.2.2.3 Purification of proteins, enzymes, nucleic acids 
ATPSs have been studied extensively for the purification of proteins [156-164], 
enzymes [165, 166], and nucleic acids [153, 167-169]. These systems have been run in 




Table 2.2: Summary of selected batch-mode (B) and continuous-mode (C) ATPSs for the 
purification of proteins, enzymes, and nucleic acids 
ATPS Type Biomolecule Recovery (%) 
Purity 
(%) Ref 
PEG 3350/citrate B Human IgG from CHO cells 99 76 [156] 
PEG 3350/citrate B Human IgG from CHO cells 97 72 [157] 
PEG 600/citrate/sulfate B Plasmid DNA from E. coli 91 17 [167] 
PEG 1000/citrate C Α-lactalbumin from whey 86 86 [158] 
PEG 1450/phosphate 















PEG 550/phosphate C Ascorbic oxidoreductase from curcubita maxima 236
a 34b [165] 






PEG 1000/phosphate C C-phycocyanin from spirulina maxima 50 5.8
c [161] 
PEG 6000/dextran 
500000 B mAb anti-CD34 from hybridoma cells 84 99.9 [164] 





PEG 1000/phosphate C Invertase from spent yeast 31 - [166] 
arecovery of enzyme activity  
bpurification factor (ratio of enzyme activity after purification to activity in crude extract) 
cpurity index (A620/A280) 
 
A commonly studied application of batch-mode ATPSs is for the harvest and 
primary recovery steps of monoclonal antibody (mAb) manufacturing. This was 
demonstrated in a study where an ATPS of PEG 3350/6000 Da and dextran 500,000 was 
used to purify anti-CD34 mAbs produced in hybridoma cells [164]. In this study, a PEG-
rich mAb recovery of 84 ± 7% with 0.1 ± 0.2% of total cells was achieved in an ATPS of 
PEG 6000/dextran 500,000 with 150 mM NaCl at pH 3 [164]. This study showed that the 
conventional clarification step of centrifugation or microfiltration can be skipped by 
using a one-step ATPS for the primary recovery of mAbs directly from the bioreactor 
harvest. However, one consideration not addressed in the study is the subsequent 
downstream purification steps since the purified mAbs are left in a viscous PEG-rich 
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phase that could pose processing issues. This issue was addressed by introducing a back-
extraction step after the first stage of ATPS to partition an IgG product from a PEG-rich 
phase to a citrate-rich phase for easier processing [156]. The first stage was a system of 
PEG 3350-citrate with 15% NaCl to recover 99% of the human IgG in the PEG-rich. The 
second stage introduced fresh citrate to decrease the NaCl concentration to 5%, which 
back-extracted the IgG product to the citrate-rich phase with 99% recovery and an overall 
HPLC purity of 76% [156]. 
Another option to avoid the desired product from being left in a viscous PEG-rich 
phase was demonstrated by combining an ATPS with hydrophobic interaction 
chromatography (HIC). A bottom phase from ATPS that was compatible with the loading 
step of hydrophobic interaction chromatography (HIC) was designed to eliminate any 
buffer-exchange steps between ATPS and HIC [157]. The bottom phase was 10 w/w% 
PEG 3350 and 12 w/w% citrate at pH 6, which recovered 97% IgG and 28% overall 
protein [157]. The citrate-rich bottom phase was directly loaded onto the HIC column and 
resulted in 99% IgG recovery and 91% purity. While this study shows promise for 
developing an integrated downstream purification train, these unit operations were all 
performed in batch-mode. To boost the productivity of purification processes, they could 
be run in continuous-mode. 
The design of continuous ATPSs for biomolecule purification has resulted in the 
implementation of various devices, such as column contactors and mixer-settler units, to 
achieve phase mixing and separation [170]. Coming from the chemical industry and 
traditional liquid-liquid extraction processes, column contactors, such as spray columns, 
perforated rotating disk contactors (PRDCs), and pulsed cap columns, have been 
implemented in various continuous ATPSs. A PRDC is constructed by enclosing 
perforated disks attached to a central rotating shaft, shown in Figure 2.17. PRDCs have 
advantages of high throughput, enhanced mass transfer, and ease of continuous operation. 
The disadvantages of PRDCs are column flooding and poor separation efficiency at high 
flow rates [170].  
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Figure 2.17: Perforated rotating disk contactor for PEG-citrate continuous ATPS 
 
One PRDC was used for an attempted purification of α-toxin (a zinc-
metalloenzyme, which can cause hemolysis and necrosis) from Clostridium perfringens 
broth [171]. In this system, PEG 8000 and phosphate were used as the polymer-salt phase 
forming components inside a 170 mm column with a 32 mm diameter and six perforated 
disks. A phosphate salt solution containing the α-toxin flowed into the top of the PRDC, 
and the PEG solution flowed in through the bottom of the column. Optimum conditions 
for continuous extraction of α-toxin were not found, due to column flooding, highlighting 
the possible issue of using PRDCs in continuous ATPS processes [171]. 
Another option for continuous ATPS operation is using mixer-settler units. These 
types of units achieve proper ATPS formation and separation with a mixing stage (either 
static or dynamic) and a settling stage (settling tank). This type of continuous ATPS setup 
has the advantage of being easily constructed and tested compared to column contactors. 
However, the optimization of mixing and settling in a continuous fashion may be difficult 
to achieve [170]. One mixer-settler based ATPS process was designed and tested for the 
partitioning of whey protein isolate (WPI). This simple design utilized a static glass-bead 
filled mixer followed by separation tubing and, lastly, by a separation tank for phase 
separation, shown in Figure 2.18. In this continuous ATPS prototype, up to 90% 
recovery of WPI was achieved, which showed the great potential of ATPS to be run in 
continuous-mode with a mixer-settler unit for recovery of biomolecules [163]. Another 
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mixer-settler setup for continuous ATPS was used to partition Cerrena unicolor laccase 
in a PEG 6000/phosphate system. Over 5 hours of continuous operation, with 1 hour to 
reach steady-state, 60% of laccase was recovered in the bottom phosphate-rich phase 
[172]. These studies show the potential use of mixer settler units to recover proteins and 
enzymes, but few studies have been developed for continuous virus recovery. 
 
Figure 2.18: Continuous ATPS utilizing static mixer and continuous separator for whey 
protein isolate partitioning [163] 
2.2.2.4 Purification of virus and virus-like particles 
Viruses and virus-like particles (VLPs) have seldomly been used in ATPSs, due 
to complex partitioning behavior. Additionally, viruses and VLPs used in continuous 
ATPSs have not been studied like proteins and enzymes. However, ATPSs have the 
potential to be used as a viral particle purification technique, as evidenced by the studies 
of ATPSs with other biomolecules. The vaccine and gene therapy manufacturing 
industries would benefit greatly by implementing an optimized ATPS for high recovery 
and purification of viral particles produced upstream. However, the partitioning behavior 
of viral particles in various ATPSs must be explored and understood prior to industrial 
implementation. Batch-mode ATPSs used for the purification of viral particles are 
summarized in Table 2.3. 
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Table 2.3: Summary of batch mode ATPSs for the purification of viral particles 
ATPS Biomolecule Recovery (%) 
Purity 
(%) Ref 
PEG 400/phosphate Rotavirus VLPs from High Five insect cells 85 89-94 [173] 
PEG 6000/citrate FMDV from BHK-21 cells 73 90 [174] 










PEG 8000/phosphate Bacteriophage T4 from E. coli 38 - [175] 





PEG 400/phosphate Human B19 parvo VLPs from Sf9 cells 64 91 [176] 
PEG 300/phosphate Adenoviral vectors from HEK-293 cells 90 - [177] 





PEG 400/phosphate Bacteriophage M13 from E. coli 80 - [179] 
 
To address the challenges of complex partitioning behavior of viral particles in 
ATPS, one study aimed to assess the partitioning behavior of PPV and human rhinovirus 
(HRV) at various tie lines in a PEG 12000/citrate ATPS [7]. By using two non-enveloped 
viruses with different pI but similar size within the same system, partitioning behavior 
was compared at a constant system pH of 7. When PPV was used in the ATPS, 79% 
recovery was obtained at high purity (by SDS), but only 36% of HRV was recovered [7]. 
The explanation for this was that, at a system pH of 7, PPV is negatively charged (pI 5), 
which is readily salted-out of the citrate-rich phase to the interface where it is then pulled 
to the PEG-rich phase via hydrophobic interactions [7]. However, HRV with a pI of 6.9 
has a net zero charge at the system pH, which is not readily salted-out by the citrate-rich 
phase, lowering the PEG-rich phase recovery. The main outcome from this study was that 
virus physicochemical properties, such as surface charge and hydrophobicity, play a key 
role in partitioning behavior in ATPSs and must be considered when designing a new 
process for a different virus. 
One potential issue with using ATPSs for the purification of complex viral 
particles is inactivation by high concentrations of phase forming components. This was 
demonstrated in one study for the attempted purification of bacteriophage T4 in a PEG 
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8000/phosphate system. In this system, high concentrations of PEG and phosphate 
negatively impacted the infectivity of bacteriophage T4, making quantification via an 
infectivity assay (plaque assay) unreliable [175]. To solve this challenge, different ATPS 
components would need to be screened with bacteriophage T4 alone prior to using them 
in a full ATPS. 
One of the best examples of an ATPS with viral particles was the purification of 
foot-and-mouth disease virus (FMDV) from clarified HEK-293 cell lysate [174]. This 
1000-g ATPS utilized a three-stage extraction process to use the first two stages for 
contaminant protein removal, and the third stage for back-extraction to a citrate-rich 
phase. Overall, the PEG was removed, 72% of FMDV was recovered, and 90% of the 
total protein content was removed [174]. This recovery greatly exceeds the currently 
acceptable industrial viral particle recovery of <30% [180]. To further improve this 
process, it could be transformed into a continuous three-stage ATPS, possibly using a 
mixer-settler unit for each stage. 
Another ATPS process was used for the purification of rotavirus VLPs as a 
potential vaccine candidate [173]. Rotavirus VLPs were produced in High Five insect 
cells using the baculovirus expression system, extracted from cells via disruption, and 
purified using a PEG 400/phosphate ATPS. The ATPS purification strategy was directly 
compared to a standard CsCl gradient strategy, showing that 85% of VLPs could be 
recovered using ATPS, which compared favorably to the CsCl gradient technique with 
only 2% VLP recovery [173]. The purity of recovered VLPs was 89-94%, which was 
similar to a purity of 91% by the CsCl gradient. Additionally, the ATPS technique only 
required two hours of processing time, whereas CsCl gradient purification required more 
than 24 hours [173]. However, this two-hour processing time could be lowered by 
removing the centrifuge step in the phase separation process by possibly converting it to a 
continuous ATPS. 
Since the literature on viral particles used in ATPSs is limited, my work focused 
on developing and testing a continuous ATPS for the purification of viral particles, 
discussed in Chapter 5. The numerous benefits that continuous unit operations bring to 
industry are driving the biomanufacturing industry to implement continuous operations. 
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Since ATPSs can be easily scaled up and run in continuous-mode, the future of 
downstream processing trains may be ATPS-based. 
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3 Flexographic-printed graphene biosensors for 
electrochemical analyte detection 
3.1 Introduction 
In this chapter, results from testing graphene ink printed biosensors are 
summarized. The graphene biosensor project first started by fabricating sensors using 
pre-made graphene/cellulose paper sheets from XG Sciences. The XG Science paper-
based sensors lead to the rapid and specific detection of four different proteins applied to 
the sensor surface via the conductometric detection technique [40]. With this first 
publication, the graphene biosensors were on track for being applied to detect other 
analytes, specifically a malaria biomarker. After 2012, XG Sciences changed their 
production method for the graphene/cellulose blended paper. This change in production 
method lead to the failure of biosensors constructed from it. Due to this, we began 
printing our own graphene biosensors onto various paper and non-paper substrates using 
XG Sciences’ graphene-based ink. By starting with a graphene ink that could be applied 
to any surface desired, there was an opportunity to fully customize the graphene 
biosensors for analyte detection. These optimizations included different printing 
substrates, anilox ink roll size, number of printing coats, and different ink properties. The 
goal of printing custom graphene ink devices was to restore the electrochemical protein 
detection ability lost from XG Sciences’ graphene/cellulose paper, and to use the sensors 
as point-of-care (POC) devices for other analytes of interest. 
Paper-based POC biosensors have been developed to provide inexpensive, 
disposable, and rapid detection of various diseases. Not only do these devices benefit 
developing countries, they can also benefit rural parts of developed countries, as they do 
not require extensive lab equipment or long periods of time. The major advantages of 
such devices is the simple testing and results read-out, and the ability of wicking aqueous 
samples through the paper to transport necessary reactants/sample buffers to different 
areas of the device without the use of pumps [181, 182]. For example, one 
immunochromatographic strip on nitrocellulose was used to detect foot-and-mouth 
51 
disease virus (FMDV) by creating a visible test line using gold nanoparticles in five 
minutes, similar to an at-home pregnancy test [183]. With rapid POC devices, results can 
be obtained for diagnosis without a patient ever leaving the test site, reducing follow-up 
exams [28, 184]. 
These POC devices need a way to quantify the biomolecule they are designed to 
detect. The most common technique for quantification of the analyte is through 
electrochemical detection, discussed in section 2.1.2. Using electrochemical detection, it 
is possible for the biological information to be processed to an electric signal [28]. 
However, for these electrochemical techniques to be implemented, a conductive species 
must be used in the construction of the sensors to carry the electric signal. Our graphene-
based sensors avoid this issue by being intrinsically conductive. When an analyte is 
applied to the graphene sensor surface, a change in the electrical properties of the device 
can be directly measured. 
In this chapter, each sub-section of results will be in order of logical optimizations 
tested to restore the sensors’ ability to detect the presence of protein on the surface. 
3.2 Biosensor testing and theory 
A circuit board with permanent copper leads was used for rapid testing of up to 
five graphene biosensor sheets, with the full sensor testing arrangement shown in Figure 
3.1. To test a graphene biosensor sheet, the amperage was recorded at constant volts 
(typically between 5-10 mV) for the dry sheet and buffer-only application as starting 
baselines. Using a micropipet, 10 µL of the lowest concentration of protein (0.01 mg/mL) 
was applied to the surface. The amperage was recorded after 30 seconds, 40 seconds, and 
50 seconds and averaged for the amperage change resulting from that protein 
concentration. The solution was wicked from the surface and increasing concentration of 
protein (0.1 – 5 mg/mL) was applied to measure the resulting change in amperage. 
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Figure 3.1: Graphene biosensor testing lab set-up 
 
To quantify the presence of varying protein concentration on the surface of the 
graphene biosensor, sheet resistivity (SR) was calculated from measured amperage 
changes at constant voltage across a 1-cm wide graphene sheet, shown in Figure 3.2. The 
SR (Ω/sq) was calculated using Equation 3.1 
𝑆𝑆𝑆𝑆 = 𝑉𝑉∙𝑊𝑊
𝐼𝐼∙𝐿𝐿
                                                        (3.1) 
where V (volts) is the constant potential difference applied across the copper leads, W 
(cm) is the width of the graphene sheet, I (amps) is the resulting current through the 
graphene sheet, and L (cm) is the distance between electrodes where the potential is 
applied (constant, 1 cm). 
 
Figure 3.2: Five sheets of two-terminal graphene/cellulose biosensors applied to reusable 
circuit board  
 
The Langmuir Isotherm was used to explain and model the change in SR with an 
increase in the concentration of protein adsorbed to the sensor surface. The Langmuir 
Isotherm has a few basic assumptions: 1) the surface for adsorbing is perfectly flat and 
homogeneous, 2) the adsorbing material (protein) adsorbs into an immobile state, 3) all 
binding sites on the surface are energetically equivalent and require the same binding 
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energy, 4) each binding site binds exactly one species of adsorbing material, and 5) there 
are no intra-site interactions between adjacent sites [185]. A simple graphical 
representation of the Langmuir Isotherm where a solid surface (grey box) with binding 
sites (black curves) is adsorbing an analyte of interest (red circles) can be seen in Figure 
3.3. As seen in Figure 3.3, the adsorption rate slows as the concentration of adsorbate 
increasing due to the limited number of binding sites become filled. In the case of the 
biosensors, the red circles are proteins and the binding sites are individual graphene 
nanoplatelet sheets. By measuring the SR change as protein concentration increases, we 
can obtain a Langmuir Isotherm curve like Figure 3.3. 
 
Figure 3.3: Langmuir Isotherm representation with solid surface binding sites adsorbing 
an analyte of interest 
 
The Langmuir Isotherm used to relate the SR change to protein concentration can 







                                            (3.2) 
where ΔSR (Ω/sq) is the change in SR at the protein concentration point compared to the 
buffer-only application, ΔSRmax (Ω/sq) is the maximum change in SR between a protein 
application step (typically the highest concentration) and buffer-only application step 
during sample testing, C (mg/mL) is the protein concentration applied, and Kd (mg/mL) 
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is the equilibrium dissociation constant. The data collected from a tested graphene sheet 
can be normalized by ΔSRmax to compare with other sheets by Equation 3.3 
𝐶𝐶
Θ
= 𝐶𝐶 + 𝐾𝐾𝑑𝑑                                                    (3.3) 
where Θ = ΔSR/ΔSRmax. Using Equation 3.3, Kd is determined for an analyte applied to 
the surface during testing. The dissociation constant is a measure of the sensitivity of the 
sensor, which is dependent on the analyte size. A lower Kd value corresponds to a higher 
amount of protein bound to the sensor surface, increasing the sensitivity of the sensor, 
shown in Figure 3.4 [186]. The Kd represents the equilibrium adsorption between the 
ligand graphene surface (L) and protein (P). When a protein adsorbs to the graphene 
surface, a complex between the ligand and protein (P∙L) is formed. 
 
Figure 3.4: Dissociation constant (Kd) definition and chemical equilibrium between 
graphene surface ligand (L) and protein (P) absorbate [186] 
3.3 Results and discussion 
3.3.1 Results from 2013 graphene biosensor publication 
Graphene biosensors constructed and tested prior to 2012 lead to the stacked 
graphene nanoplatelet paper sensor publication in 2013 by Heldt et al [40]. These 
biosensors were two-terminal sensors constructed on standard glass slides, seen in Figure 
3.5. The graphene/cellulose biosensors were able to detect and distinguish between 
various proteins present on the sensor surface including bovine serum albumin (BSA), 
chicken egg white lysozyme (LYS), bovine hemoglobin (HEM), and bovine fibrinogen 
(FIB). These proteins had a range of isoelectric points, hydrophobicity, and molecular 
weights. Increasing concentrations of each protein was applied to the graphene sensor 




Figure 3.5: Two-terminal graphene/cellulose biosensor constructed on glass slide [40] 
 
By fitting the SR versus protein concentration data to the Langmuir Isotherm, the 
equilibrium dissociation constant (Kd) was determined for each protein. The main finding 
was that the Kd was a function of the protein molecular weight due to protein adsorption 
to the graphene surface, seen in Figure 3.6. One of the major issues with the 
graphene/cellulose sensors is the swelling effect when liquid is applied to the sensor 
surface. Due to the swelling, SR increased by more than three times, likely due to the 
stacked graphene nanoplatelets separation during liquid application, which reduced the 
graphene-to-graphene contacts. 
 
Figure 3.6: Equilibrium dissociation constant as a function of molecular weight for LYS, 
HEM, BSA, and FIB [40] 
3.3.2 XG Sciences’ graphene paper manufacturing change 
In 2013, XG Sciences changed their graphene/cellulose paper manufacturing 
process. Due to this change, the lab began to see inconsistencies in protein detection 
compared to the results obtained from the stacked graphene sensor publication. 
Biosensors created with paper after 2013 resulted in limited increase in SR with 
increasing protein concentration. As a control, the buffer used to dissolve the BSA, 
phosphate buffered saline (PBS), was applied to the sensor surface to compare increases 
in SR between the protein and buffer, seen in Figure 3.7. Without the ability to 
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distinguish between PBS and BSA applications on the sensor surface, the sensors do not 
work. 
 
Figure 3.7: Graphene (November 2014 batch) sensor ability to distinguish between PBS 
and BSA applications 
 
Between 2014 and 2016, work was done by previous graduate student, Soontorn 
Tuntithavornwat, to chemically alter the graphene paper with treatment of 2 w/w% 
glutaraldehyde (GA), 1 w/w% zinc nitrate (ZN), and 1 w/w% poly(vinyl alcohol) (PVA) 
to improve the wet and dry strength of the paper. This strength improvement was 
hypothesized to decrease the swelling effect of buffer application to the surface, which 
should improve sensitivity of SR measurements with protein application. Treatment with 
the GA, ZN, and PVA mixture improved the wet strength thirteen times (from 0.5 mPa to 
7.2 mPa) while maintaining protein sensing ability, seen in Figure 3.8. However, tests 
comparing protein application versus buffer-only application were not performed to 
confirm the sensing ability of the treated sensors was specific to protein. 
 
Figure 3.8: BSA sensing ability of GA/ZN/PVA-treated graphene sensors 
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3.3.3 Graphene ink printing for sensor creation and protein detection 
When I joined the Heldt lab in May 2016, we looked for an alternative method to 
creating the graphene sensors, as the paper received from XG Sciences post-2013 was not 
performing the same way as paper pre-2013. This alternative method was printing XG 
Sciences’ graphene ink onto various paper and non-paper substrates. The flexographic 
printing method was chosen because it can use water-based and non-water-based inks and 
is compatible with a variety of printing substrates. The flexographic proofer (Figure 
3.9A) used to print the graphene ink lines (Figure 3.9B) was purchased from Harper 
Scientific. Many variables affect the print quality when using the flexographic printing 
method, including anilox size, ink properties, substrate type, and number of coats. A vital 
ink property that affects flexographic printing is the ink viscosity. A suitable ink viscosity 
was determined to be 518 cS, measured with a Zahn cup number 5. The viscosity of the 
ink was measured prior to every experiment to keep the viscosity constant across 
substrates. The other printing parameters were changed to determine proper feature 
formation and sensor detecting ability. 
 
Figure 3.9: A) Flexographic proofer used to print B) graphene ink lines 
3.3.3.1 Determination of necessary printing coats 
First, the number of coats needed on a paper substrate was determined with SR 
measurements. Low SR was desired to confirm when enough ink was applied to the 
substrate surface to allow for proper electron transport across the printed graphene ink. 
One, two, and three coats of ink were printed on copy paper, and SR was recorded with 
applying PBS on the surface multiple times, seen in Figure 3.10. Three coats (or passes) 
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was necessary on copy paper to achieve a minimum SR variation across PBS 
applications, so all future sensors were made from three passes of ink. 
 
Figure 3.10: SR change with one, two, and three coats of graphene ink on a paper 
substrate 
3.3.3.2 Anilox sizing for paper and non-paper substrates 
The next optimization step was to determine the size of anilox needed to transfer 
ink to the paper substrate to print the necessary features. We received two anilox sizes: 
75/26 and 70/36. The numbers that define an anilox size have specific meanings. The first 
number is used to define the transfer volume of ink to a substrate surface. The transfer 
volume is given in units of billion cubic microns (BCM) of ink per square inch of 
substrate (BCM/in2). The second number is used to define the number of cells per inch 
(LPI) across a straight line on the anilox, also called cell finesse. A larger LPI means 
more cells per inch, resulting in a smaller cell volume. To determine which anilox 
performed the best with unmodified graphene ink, three coats of ink were printed onto 
standard copy paper and SR was measured with increasing BSA concentration on three 
individual 1 cm lengths of paper. Both anilox produced similar SR measurements, but 
anilox 70/36 had less variation across sheets tested, and produced a higher ΔSR (SR5 
mg/mL BSA - SRbuffer), seen in Figure 3.11. From this result, anilox 70/36 was chosen for all 
future printing onto paper substrates. 
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Figure 3.11: SR measurements using anilox 70/36 and 75/26 comparison with increasing 
BSA concentration 
 
A different size anilox was needed for printing onto non-paper substrates due to 
the surface roughness and porosity differences between substrates. We received anilox 
size 120/20 and 200/14 to print onto poly(ethylene terephthalate) (PET) and Tyvek type 
1079. These substrates were chosen for controls as they are non-porous, non-swelling, 
and hydrophobic. Printing with these two anilox showed that only one coat of graphene 
ink was needed on the surface of each substrate, likely due to the low surface roughness 
compared to the paper substrates. To determine which anilox roll produced the best 
graphene sensor sheets, an increasing concentration of BSA was applied to sensors 
constructed from each roll and substrate type. The criteria for “best sensors” were 
achieving low SR, low SR variance, plus low and consistent Kd values. Ten sensors were 
constructed from each anilox roll on PET and tested with increasing BSA concentration 
applications from 0 to 5 mg/mL, seen in Figure 3.12. Kd values were calculated for each 
sensor, and the average Kd/standard deviation were found for each anilox. Sensors from 
anilox 200/14 gave a Kd of 1.64 ± 0.46 μM, and sensors from anilox 120/20 gave a Kd of 
1.64 ± 0.35 μM. Both anilox rolls produced sensors that performed similarly for BSA 
detection, however, anilox 120/20 produced sensors that started at a lower SR. Tests on 
the PET substrate alone was not enough to determine which anilox was best. The same 
anilox were tested on another non-paper substrate, Tyvek. 
60 
 
Figure 3.12: SR values with increasing BSA concentration from sensors constructed 
using PET with anilox A) 200/14 and B) 120/20 
 
Five sensors constructed from printing graphene ink onto Tyvek type 1079 were 
tested for their ability to detect BSA, shown in Figure 3.13. The Kd from sensors made 
with anilox 200/14 was 1.76 ± 0.72 μM, and 1.89 ± 0.63 μM for anilox 120/20. While 
comparing Kd values between anilox rolls was inconclusive, considering dry device SR 
values between anilox for both PET and Tyvek substrates, anilox 120/20 performs the 
best. For these reasons, anilox 120/20 was chosen for printing on non-paper substrates. 
 
Figure 3.13: SR values for increasing BSA concentration from sensors constructed using 
Tyvek with anilox A) 200/14 and B) 120/20 
 
With the number of coats and anilox roll necessary for printing on each substrate, 
sensors were created and tested for their ability to detect BSA versus PBS-only 
applications. Two paper substrates were tested first: conventional copy paper and 
chromatography-grade paper. Copy paper was chosen because it is inexpensive and 
readily available. Chromatography paper was chosen for its controlled purity by the 
manufacturer, ensuring we could receive the same quality of paper in the future. 
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3.3.3.3 Protein detection with paper and non-paper sensors 
The first graphene ink biosensors tested with BSA and compared to PBS 
applications were printed on 11”x17” copy paper. The average ΔSR for the five devices 
tested with BSA was 18 Ω/sq, and the average ΔSR for the five devices tested with just 
PBS was 2.3 Ω/sq, seen in Figure 3.14. Due to the large error, no statistically significant 
difference was found, meaning there was no reliable way to determine if BSA or PBS 
was present on the surface of the sensor. The reason for this is hypothesized to be the 
swelling effect of the graphene/cellulose devices. As any liquid is placed on the sensor 
surface, the liquid swells the paper and causes sheets of graphene to become separated, 
regardless of protein presence. 
 
Figure 3.14: Average SR increase with increasing BSA concentration applications and 
PBS applications on three-coat, copy paper devices printed with anilox 70/36 
 
Next, graphene ink biosensors were printed onto chromatography filter paper. The 
same BSA versus PBS application test was used for sensors printed on chromatography 
paper. The average ΔSR for the five devices tested with BSA was 15 Ω/sq, and the 
average ΔSR for the five devices tested with PBS was 6 Ω/sq, seen in Figure 3.15. The 
average SR difference between BSA-tested and PBS-tested devices was not significantly 
different. This was additional evidence that any liquid on the sensor surface would 
produce an SR change, regardless of protein presence. To limit the swelling effect of the 




Figure 3.15: SR curves for A) BSA and B) PBS tested three-coat, graphene ink devices 
on chromatography filter paper 
 
Sensors were printed onto PET film and tested for BSA detection versus PBS-
only application. The PET film is extremely hydrophobic, which should reduce the 
swelling effect of the paper substrates and allow for the detection of protein presence 
based on an increase in the sheet resistivity. The devices with BSA application had an 
average ΔSR of 22 Ω/sq, and the devices with PBS-only application had an average ΔSR 
of 28 Ω/sq, seen in Figure 3.16. Again, with similar average change in SR between BSA 
and PBS-only applications, the devices were not able to detect protein on the surface of 
the sensor. This result indicates that the swelling of the porous substrates was not the only 
effect causing similar SR changes in the tests. This result shows that any liquid present on 
the sensor surface causes the SR to change. 
 




As another control for a non-paper substrate, Tyvek grade 1079 was used for 
sensor printing and tested for its detection ability. Devices tested with BSA had an 
average ΔSR of 27 Ω/sq, and the devices tested with PBS-only had an average ΔSR of 23 
Ω/sq, seen in Figure 3.17. Again, the same result as PET film was obtained with Tyvek 
grade 1079. These results combined show that liquid present on the sensor surface is 
causing the change in SR, not purely the presence of protein on the surface. One possible 
reason for this could be the fact that liquid has the ability to contact the electrical leads 
during resistivity measurements, which could alter the electrical performance of the 
sensors. To test this theory, hydrophobic wax was printed onto the paper substrates to 
create a barrier between the testing region and the electrical leads on the sensor surface, 
discussed in Section 3.3.4. 
 
Figure 3.17: SR curves for A) BSA and B) PBS tested one-coat, graphene ink devices on 
Tyvek grade 1079 
3.3.3.4 Custom graphene ink testing 
Custom graphene inks were formulated during a month-long internship at XG 
Sciences to increase the compatibility of ink with protein application. Specifically, 
poly(acrylic acid) (PAA) was added to the ink formulation solvent to make the resulting 
ink more hydrophilic compared to the normal ethyl cellulose used in the ink. 
Additionally, a different size of graphene nanoplatelets was used to formulate the ink to 
increase the available binding surface area from ~50 m2/g to over 500 m2/g. Three 
devices created using the PAA-custom ink were tested with BSA applications (Figure 
3.18, solid lines), and two devices created using the same ink were tested with PB only 
applications (Figure 3.18, dashed lines). The ΔSR for BSA-tested devices was 1080 
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Ω/sq, and PB-tested devices had a ΔSR of 1800 Ω/sq. Although this ink was slightly 
more hydrophilic than the standard ink tested, it did not result in acceptable protein 
detection. 
 
Figure 3.18: SR curves for PAA-custom graphene ink devices on GP copy paper 
 
Three devices created using the size-custom ink were tested with BSA 
applications (Figure 3.19, solid lines), and two devices created using the same ink were 
tested with PB only applications (Figure 3.19, dashed lines). The ΔSR for BSA-tested 
devices was -7090 Ω/sq, and PB-tested devices had a ΔSR of 13000 Ω/sq. This custom 
ink had large variance from device to device, immediately making this ink unsuitable for 
repeatable device sensing ability. 
 
Figure 3.19: SR curves for custom-size graphene ink devices on GP copy paper 
3.3.4 Wax printing hydrophobic barriers 
Printing barriers onto the paper substrates requires the optimization of 3D printing 
wax onto the surface of the sensor, and the subsequent heating of the wax to penetrate 
through the paper to form a complete barrier. 3D printing was achieved using a 
replication rapid prototyper (RepRap) with a heated syringe extruder for printable wax. 
The RepRap and the printed wax features to create a liquid flow channel can be seen in 
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Figure 3.20. The RepRap is only capable of printing the heated wax onto the top surface 
of the substrate, so additional heating of the wax was necessary to penetrate the wax 
through the thickness of the substrate to form the complete hydrophobic barrier. 
 
Figure 3.20: RepRap 3D printer with printed wax lines 
 
After graphene ink lines were printed onto copy paper and chromatography paper 
by the flexographic proofer, wax was 3D printed across the graphene ink lines to create 
the hydrophobic barriers. To fully penetrate the wax through the graphene ink lines and 
paper substrates, the wax was melted at 90°C for five minutes. The fully melted wax 
barriers on the graphene lines can be seen in Figure 3.21. With the hydrophobic barriers 
in place, the liquid application region is the ~2 mm gap between wax lines. 
 
Figure 3.21: Hydrophobic wax barriers printed onto graphene ink lines 
3.3.4.1 Wicking tests 
A wicking test was designed to confirm proper wax barrier formation through the 
paper substrate and to show the hydrophobicity of both the wax and graphene ink line. A 
drop of red-dyed water was applied to one side of the paper substrate, and the time to 
cross to the other side of the paper was recorded (Figure 3.22). The wicking test was 
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performed on copy paper with and without the graphene line, chromatography paper with 
and without the graphene line, and on the cellulose/graphene paper blend from XG 
Sciences. As expected, the copy paper without the graphene line had the shortest time to 
cross at 10 seconds, and chromatography paper with the graphene line had the longest 
time to cross at 30 seconds. The long time to cross is because chromatography paper is 
thicker than the copy paper and cellulose/graphene paper blend. Interestingly, the 
application of the graphene line caused the time to cross to increase by 10 seconds in the 
case of copy paper and chromatography paper, shown in Figure 3.23. During the tests, no 
wicking to the outside of the wax lines was observed, confirming that the hydrophobic 
barriers were fully formed and retained the liquid between the wax lines. From this test, 
the graphene lines with wax barriers were used to electrochemically detect the presence 
of protein on the surface without liquid interference on the conductive leads. 
 
Figure 3.22: Wicking test schematic for the wax barriers on various paper substrates 
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Figure 3.23: Wicking test results on paper substrates with and without graphene lines 
3.3.4.2 Paper substrate device testing with wax barriers 
Biosensors were fabricated by three-pass printing graphene ink onto copy paper 
and wax barriers were 3D printed onto the surface. Four sensors were tested for their 
ability to detect BSA from 0.01 to 5 mg/mL and compared to a control PB-only 
application sensor, shown in Figure 3.24. Sensors tested with BSA had an average ΔSR 
of 3.3 Ω/sq, and the sensor tested with PB-only had an average ΔSR of 4.3 Ω/sq. As seen 
in Figure 3.24, the PB-only sensor fell directly in the same range of SR changes as the 
BSA-tested sensors meaning there is no different protein application compared to buffer-
only application. 
 
Figure 3.24: SR curves for BSA-tested sensors (1-4) and PB-tested sensor (%) with 3D-
printed wax barriers on copy paper 
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Additional biosensors were fabricated by three-pass printing graphene ink onto 
chromatography paper and wax barriers were 3D printed onto the surface. Four sensors 
were tested for their ability to detect BSA from 0.01 to 5 mg/mL and compared to a 
control PB-only application sensor, shown in Figure 3.25. Sensors tested with BSA had 
an average ΔSR of 33000 Ω/sq, and the sensor tested with PB-only had an average ΔSR 
of 760 Ω/sq. Although the comparison of ΔSR between BSA and PB sensors seems to 
suggest there is a significantly large increase in SR for BSA and not PB, the large 
variablility between sensors 1-4 is unacceptable for reliable analyte detection. 
 
Figure 3.25: SR curves for BSA-tested sensors (1-4) and PB-tested sensor (%) with 3D-
printed wax barriers on chromatography paper 
 
These results from paper-based sensors with wax barriers indicate that the liquid 
contact to the electrical leads is not the dominating effect of SR increase. Regardless of 
protein presence on the sensor surface with wax barriers, SR increases. This means the 
sensors are not specific enough to what was applied on the surface and the specificity 
must be increased for proper analyte detection. One attempt to increase the specificity of 
the sensors was by functionalization with primary antibodies. 
3.3.5 Functionalization of graphene sensors 
Before a complete sandwich ELISA system was constructed on the graphene 
biosensor surface, proper immobilization of antibodies on the graphene surface was 
tested. As discussed in section 2.1.2.2.2, the immobilization of antibodies onto graphene 
is accomplished by π-π stacking an amine-reactive probe onto the graphene surface and 
applying antibodies onto the probe for immobilization via EDC-NHS chemistry between 
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the NHS probe and primary amine on the FC region of antibodies. The amine-reactive 
linker applied to the graphene surface was 1-pyrenebutanoic acid succinimidyl ester 
(PBA-NHS) (Figure 3.26A). After linker attachment, donkey anti-goat IgG antibodies 
labelled with HRP were applied and immobilized on the surface by EDC-NHS chemistry 
(Figure 3.26B). Ethanolamine was used to cap unreacted PBA-NHS linkers (Figure 
3.26C). This functionalization procedure was performed in non-stick test tubes by adding 
the appropriate liquid component and rocking. After numerous washing steps, a 3,3’,5,5’-
tetramethylbenzidine (TMB) substrate and hydrogen peroxide was added. TMB is a 
colorless chromogenic substrate for HRP which acts as a hydrogen donor during the 
redox reaction of H2O2 to water by the enzyme HRP. When HRP is in the presence of 
TMB and H2O2, the enzymatic reaction produces a blue colored 3,3’,5,5’-
tetramethylbenzidine diimine. The reaction is stopped using sulfuric acid which turns the 
solution color to yellow and can be read at 450 nm for quantification.  
 
Figure 3.26: Primary antibody immobilization onto graphene sheet 
 
To test the immobilization procedure, sheets of graphene were fully 
functionalized and the absorbance at 450 nm was compared to non-functionalized 
graphene sheets, sheets with PBA manually pipetted onto the surface, and sheets without 
the PBA-NHS linker added. Additionally, plain copy paper was used as a negative 
control for functionalization. Functionalized graphene sheets had an average absorbance 
of 1.4 ± 0.4 and manually applied PBA functionalized graphene sheets had an average 
absorbance of 1.7 ± 0.5, suggesting that the PBA application process does not affect the 
immobilization of antibodies, seen in Figure 3.27. Non-functionalized graphene sheets 
had an average absorbance of 0.04 ± 0.001, confirming that if no antibodies are added to 
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the sheets, no color change is observed. Functionalized plain paper, no PBA on graphene 
sheets, and no PBA on plain paper had average absorbances of 1.2 ± 0.6, 0.8 ± 0.3, and 
1.4 ± 0.2 respectively. Although these values do lie within the error of fully 
functionalized graphene sheets, plain paper would lack the conductivity provided by the 
graphene to be viable in electrochemically detecting the antigen. This high absorbance 
from functionalized plain paper is likely due to antibodies passively absorbed into the 
porous paper. From this functionalization test, it was confirmed that our procedure 
immobilizes antibodies onto the graphene sheets. 
 
Figure 3.27: Absorbance measurements of HRP-labelled antibody functionalized 
graphene sheets and plain copy paper sheets 
3.3.5.1 Sandwich ELISA system design and testing 
Once proper immobilization of antibodies onto the graphene sheet was confirmed, 
a full sandwich ELISA system was designed and tested for the specific detection of our 
analyte of interest, mouse IgG. To functionalize the graphene biosensors, goat anti-mouse 
IgG antibodies were immobilized on the surface of the graphene shown in Figure 3.28. 
The PBA-NHS linker was applied to the surface of the graphene sensor (Figure 3.28A). 
Next, anti-mouse IgG antibodies were applied to the surface to be immobilized by the 
NHS on the PBA and primary amines on the FC regions of the antibodies (Figure 3.28B). 
BSA was added to the sensor surface to block non-specific binding of the antigen to the 
sensor surface itself, and ethanolamine was used to cap unreacted PBA-NHS linkers 
(Figure 3.28C). The antigen of interest, mouse IgG, was applied to the surface and 
captured by the immobilized antibodies by specific antibody-antigen interactions (Figure 
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3.28D). Finally, detecting goat anti-mouse antibodies labelled with a AuNP were applied 
to the antigen (Figure 3.28E). The detecting antibodies act as signal-enhancing 
molecules as the immobilization of a AuNP-labelled antibody should drastically change 
the electrical properties of the sensor surface. 
 
Figure 3.28: Sandwich ELISA system on graphene sheet 
 
To test the functionalized graphene sheets using a sandwich ELISA system, a 
constant concentration for the detecting antibody was used at 0.1 mg/mL and an 
increasing concentration of mouse IgG was applied to the primary antibody-
functionalized graphene sheets from 10-5 to 10-1 mg/mL. With an increased amount of 
mouse IgG bound to the sensor, which would result in an increase amount of AuNP-
labelled detecting antibody, a decrease in the resistivity was expected. The AuNP should 
act as an electron-mediator to increase the conductivity of the bound complex when 
electrochemically tested. Five sensors were tested, and the SR curves before (black 
curve) and after (red curve) detecting antibody application for individual sensors is 
shown in Figure 3.29A-E. This data is shown as individual functionalized devices to 
show the inconsistent results obtained for changes in the SR as mouse IgG and dAbs 
were applied to the surface. Sensors A, C, and D have the expected drop in SR with 
increasing mouse IgG concentration, and sensors B and E have an increase in the SR with 
increasing mouse IgG concentration. Another issue is that there should be an observable 
difference in SR curves before and after dAb application, and there is no such result. This 
suggests that the application of a AuNP-labelled species onto the graphene sheets did not 
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significantly change the electrical properties. Without a change in the SR during testing, 
there is no reliable method to detect the presence of the target analyte.  
 
Figure 3.29: SR curves for 5 functionalized graphene sheets tested using a sandwich 
ELISA system for mouse IgG detection 
3.4 Conclusions 
The results discussed here for the graphene biosensors project show limited 
success in the detection of target analytes. Throughout biosensor creation, various 
conditions were explored to obtain positive results. Paper and non-paper substrates were 
used for biosensor creation with no change in SR when comparing BSA-applications to 
buffer-only applications. The number of ink coats, ink conductivity, and graphene sheet 
hydrophobicity/size were varied in attempts to change the electrical and chemical 
properties of the biosensors without success. Wax barriers were used to reduce swelling 
effects of the biosensors also without successful protein detection. Additionally, 
functionalization of the graphene sheets with a sandwich ELISA system was performed 
which also lead to insufficient data to support the detection of target analytes. Overall, 
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with a wide variety of parameters tested for the biosensors project, no positive and 
publishable results were obtained. The results discussed in this dissertation should act as 
a review of optimization attempts for creating graphene-based biosensors for rapid 
analyte detection. 
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4 Virus particle detection using various sizes of gold 
nanoparticles aggregated by osmolytes 
4.1 Introduction 
Up to nine different infectious diseases are tested for in blood donations in the 
United States [19]. These infectious diseases are detected by confirming the presence of 
antibodies to the disease with immunoassays or amplifying the nucleic acid from the 
virus itself using a nucleic acid test (commonly polymerase chain reaction). Although 
effective, these tests are specific to only one virus at a time, are time consuming, and 
expensive. A faster, non-specific test would increase throughput of samples and reduce 
costs by being able to confirm the presence of any viral particle in each sample. One 
potential way to accomplish this is utilizing gold nanoparticles (AuNPs) in a virus 
detection assay. 
AuNPs have unique optical properties that can aid in detection and is called 
surface plasmon resonance (SPR). SPR dictates the AuNP’s color in solution and changes 
with different sizes of AuNPs and their inter-particle distance [187]. SPR is a result of 
exciting the cloud of free electrons present near the surface of metals, including AuNPs. 
The natural oscillations of the free electrons on the surface of the AuNPs are called 
surface plasmons, which exist at the gold metal-dielectric interface [90]. When excited by 
light, the surface plasmon oscillations can couple with the incident light, which emits 
electromagnetic waves in the visible range [88, 90]. This resonant oscillation between the 
incident light and surface plasmons is called SPR [91]. AuNPs with a certain size have a 
characteristic ultraviolet-visible (UV-Vis) absorption spectrum and absorbance peak. For 
example, 15 nm diameter AuNPs have an absorbance peak at a wavelength of 519 nm, 
corresponding to a deep red solution [6].  
AuNPs and other metallic nanoparticles are capable of Rayleigh scattering, which 
is the phenomenon of elastic scattering of light by particles smaller than the wavelength 
of the incident light [188]. Within the Rayleigh scattering range, which is appropriate for 
sub-100 nm nanoparticles, the scattering light intensity is proportional to the sixth power 
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of the particle diameter [189]. AuNPs light scattering ability can be used to determine 
their size using dynamic light scattering (DLS). It has been shown that assays developed 
using a light scattering detection system have a lower limit of detection up to four orders 
of magnitude compared to absorbance based systems [187]. For this reason, light 
scattering-based assays are more appropriate for detecting low concentrations of virus 
present in samples, which has been used to detect whole virus particles [97], viral nucleic 
acids [94], and viral antibody markers [190].  
The detection pathway of these virus detection tests typically occurs in two steps. 
First, AuNPs are functionalized with virus-specific nucleic acid probes or capture 
antibodies (Figure 4.1A). Then, the functionalized AuNPs aggregate in the presence of 
the target viral oligonucleotides or virus particles (Figure 4.1B). This aggregation occurs 
when target virus is added because viral particles are symmetrical. The symmetrical 
nature of viruses allows multiple antibodies to bind to the same virus, causing a cross-
linking like pattern to occur, shown in Figure 4.1B. The same would not occur in the 
presence of proteins because proteins cannot bind to multiple antibodies. The aggregation 
results in a measurable change in size directly measured using DLS.  
 
Figure 4.1: A) AuNP functionalization with virus-specific antibodies and B) induced 
aggregation of AuNPs after the addition of target viral particles 
 
One example of a functionalized AuNPs aggregation assay was detection of 
influenza virus with influenza-specific antibody functionalized AuNPs [97]. When 
influenza virus was added to a solution of antibody-functionalized AuNPs, aggregation 
occurred and was measured by DLS with a limit of detection (LOD) of <100 TCID50/mL, 
which was 1-2 orders of magnitude lower than conventional diagnostic kits [97]. These 
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tests have shown improved detection ability compared to ELISA-based and PCR-based 
tests. However, like these conventional tests, they also depend on the use of nucleic acids 
and antibodies that must be immobilized onto the AuNPs, which increases preparation 
complexity and cost. Stability issues are also a concern when nucleic acids and antibodies 
are used. Thus, an unmodified AuNP, whole viral particle test is desired to reduce the 
cost and increase simplicity. 
The goal is to create a viral particle assay using unmodified AuNPs. Without 
functionalizing the AuNPs, a different aggregation technique must be used. It has been 
well studied that NaCl has the ability to aggregate citrate-capped AuNP by neutralizing 
the negative charge distribution with Na+ cations in as little as 100 mM NaCl [93, 94]. 
One assay was developed that utilizes NaCl to aggregate unmodified, non-stabilized 
AuNP. In this assay, hepatitis C virus (HCV) RNA was detected based on NaCl-induced 
AuNP shown in Figure 4.2 [191]. First, extracted HCV RNA from clinical samples was 
added to a tube containing a hybridization buffer with the targeting RNA primer. The 
mixture was then denatured and annealed to allow the primer to bind to the HCV RNA. 
NaCl and AuNPs were then added to the tube and the color was observed after 1 minute 
of incubation (Figure 4.2, Complementary Target). In this case, the primer hybridized 
with the target, which left the AuNPs unprotected and thus aggregated by NaCl. In the 
case where a non-complementary target RNA was added in the sample tube, the RNA 
primers were adsorbed to the surface of the AuNPs through electrostatic interactions 
between the nitrogenous backbone of RNA and the AuNPs, which protected the AuNPs 
from NaCl-induced aggregation (Figure 4.2, Non-complementary Target). This assay 
had a LOD of 50 copies/reaction, which was 1,200 times lower than a conventional 
ELISA for the HCV core antigen [191]. Although this assay significantly improved upon 
the conventional method, it still utilized oligonucleotide probes that have stability issues. 
Additionally, the sample preparation steps to extract HCV RNA are complex. 
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Figure 4.2: Colorimetric detection pathway for HCV RNA using unmodified AuNPs via 
NaCl-induced aggregation [191] 
 
One different method of causing AuNP aggregation is using osmolytes, which are 
known to aggregate viral particles [111, 112]. Osmolytes are water-soluble, naturally-
occurring molecules that are produced by cells to enhance protein stability. Osmolytes 
work by combating osmotic stress and other environmental stresses to help cells maintain 
their structure by regulating water content within the cell [105, 106]. Osmolytes have 
been used for the preferential aggregation of both enveloped (Sindbis virus) and non-
enveloped (PPV) viral particles [111, 112]. The theory for this preferential virus 
aggregation versus protein aggregation with osmolytes is based on the relative 
hydrophobicity between viruses and proteins and the physical structure of the two 
macromolecules [6, 111]. When osmolytes are introduced into solutions containing PPV 
or proteins, there is a partial dehydration around the biomolecules. This is because 
osmolytes have a higher affinity for water molecules than does the protein backbone 
[108]. Excess free energy is generated that must be minimized when water molecules are 
pulled away from the biomolecule surface. For proteins, their relatively more hydrophilic 
and flexible nature allows the excess free energy to be minimized by increased protein 
side chain interactions, resulting in protein structure compaction and stabilization [6, 111, 
113]. The mechanism of free energy reduction due to osmolyte-induced dehydration in 
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the case of viruses is different. It has been shown that viruses are relatively more 
hydrophobic and rigid than proteins [113]. Due to the relatively high hydrophobicity of 
viruses, they are dehydrated to a greater extent than proteins when exposed to osmolytes. 
Since viruses cannot reduce the excess free energy by structure compaction like proteins, 
the hydrophobic exposed residues are minimized by virus-virus aggregation [111]. This 
difference in free energy reduction mechanism between proteins and viruses gives the 
virus detection assay its specificity because AuNP/protein complexes should not 
aggregate to the same extent as AuNP/virus complexes when exposed to osmolytes. 
This osmolyte-induced, preferential aggregation of viral particles action was used 
to develop a PPV and BVDV detection assay [6]. The viral particles were capable of non-
specifically binding to AuNPs through a combination of electrostatic [192] and 
hydrophobic interactions [104]. The hypothesized mechanism of this interaction is that 
viral particles have surface-exposed, positively charged patches on the capsid which can 
electrostatically bind with the citrate-capped AuNPs. After complexing viral particles 
with 15 nm AuNPs via these electrostatic interactions, mannitol was used to aggregate 
the AuNP/virus complexes. The addition of 1M mannitol dehydrated the viral particles 
and caused the complexes to aggregate. This aggregation was detected using DLS. The 
AuNP/virus complex size before and after aggregation was measured by DLS and 
compared to AuNP/protein complex size before and after aggregation. This resulted in a 
LOD of 6 log MTT50/mL for PPV and 4 log MTT50/mL for BVDV [6].  
The previous virus detection study using 15 nm AuNPs served as the baseline to 
be improved using different sizes of AuNPs in the same aggregation assay. To improve 
the virus detection assay, different sizes of AuNPs were synthesized and used to 
potentially lower the LOD for the same viruses. To explore how different sizes of AuNPs 
interact with viruses and effect the assay, AuNPs with a diameter of 50 nm were used 
with BVDV particles (Figure 4.3E), and AuNPs with diameters of 5, 15, and 40 nm were 
used with PPV particles (Figure 4.3A-C). These sizes were chosen to have the size ratio 
between the AuNP and virus diameters to be <1, ~1, and >1, shown in Figure 4.3. The 
diameter ratios between viral particles and AuNPs were expected to change the detection 
ability two different ways. First, a diameter ratio >1 should lead to both a larger surface 
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for viruses to bind to (Figure 4.3C and F), and an enhanced DLS signal with larger 
AuNPs should be observed. This enhanced signal is expected because the intensity of the 
scattered signal in DLS to changes in the radius of the AuNPs has the relation of (DLS 
intensity ∝ AuNP radius6) [193]. Second, a diameter ratio <1 should cause smaller 
AuNPs to electrostatically bind to the viral particles more readily since the positively 
charged patches on the virus surface may be hard for larger AuNPs to access. This would 
result in the virus surface being more covered by the smaller AuNPs, shown in Figure 
4.3A and D. At a diameter ratio of ~1, there are less AuNPs covering the virus surface as 
the AuNPs would be electrostatically hindered from completely covering the surface, 
shown in Figure 4.3B and E. 
 




However, from this work, the use of the osmolytes mannitol and glycine as 
aggregating agents for the various sizes of AuNP/virus complexes did not result in an 
improved virus detection assay, as the LODs for both viruses were unchanged compared 
to the original assay using 15 nm AuNPs. 
4.2 Materials and methods 
4.2.1 AuNP and cell culture materials 
Gold (III) chloride trihydrate (≥99.9%), trisodium citrate (ACS grade, ≥99.0%), 
bovine serum albumin (≥98%), D-mannitol (≥98%), and sodium phosphate dibasic 
heptahydrate (ACS grade, 98.0-102.0%) were purchased from Sigma-Aldrich (St. Louis, 
MO). Sodium phosphate monobasic monohydrate (ACS grade, 98.0-102.0%) and sodium 
chloride (ACS grade, ≥99.0%) were a gift from MilliporeSigma (Burlington, MA). 
Barnstead™ nanopure water (Thermo Scientific, Waltham, MA) with an electrical 
resistance of ≥18 MΩ was used to create the aqueous solutions. AuNPs with a diameter 
of 5 nm (typical diameter 5.3-5.8 nm) were purchased from Ted Pella (Redding, CA) and 
were used without any modification. The 5 nm AuNPs had a particle concentration of 
8.3×10-8 M.  
Minimum essential medium, Dulbecco’s modified eagle’s medium, fetal bovine 
serum (Mexico origin), horse serum (New Zealand origin), 10,000 U/mL penicillin 
streptomycin, 0.25% trypsin-EDTA (1X), phosphate buffered saline pH 7.2 (1X), and 
sodium bicarbonate (7.5%) for cell culture and virus propagation were from Gibco™ 
(Grand Island, NY). All solutions were filtered through a 0.2 μm Nalgene™ Rapid-
Flow™ sterile disposable bottle-top filter with PES membrane from Thermo Scientific 
into an autoclaved vessel for storage before use. 
4.2.2 Virus production and purification 
Porcine kidney cells (PK-13) were purchased from the American Type Culture 
Collection (ATCC®) (cat# CRL-6489™) and cultured in minimum essential medium 
(MEM) supplemented with 10 vol% fetal bovine serum (FBS) and 1 vol% 
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penicillin/streptomycin (pen/strep). The cells were incubated at 37°C, 5% CO2, and 100% 
humidity. PPV strain NADL-2 was a gracious gift from Dr. Ruben Carbonell at North 
Carolina State University (Raleigh, NC). PPV strain NADL-2 was propagated in PK-13 
cells as described previously [194]. After PPV propagation in PK-13 cells, the cell lysate 
was clarified by centrifugation at 5,000 rpm at 4°C for 15 minutes in a ST16R centrifuge 
with a TX-400 swing-bucket rotor (Thermo Scientific). The collected supernatant was 
dialyzed using Biotech cellulose ester 1000 kDa dialysis tubing at 4°C with two 4 mM 
phosphate buffer (pH 7.2) exchanges over two days. The dialyzed PPV was further 
purified using an Econo-Pac 10DG size-exclusion desalting column and used within one 
week of purification. 
Bovine turbinate cells (BT) were purchased from ATCC (cat# CRL-1390™) and 
cultured in Dulbecco’s modified essential medium (DMEM) supplemented with 10 vol% 
horse serum and 1 vol% pen/strep [195]. The cells were incubated at 37°C, 5% CO2, and 
100% humidity. BVDV strain NADL was purchased from USDA APHIS. BVDV was 
propagated in BT cells [6, 196]. After BVDV propagation, the cell lysate was clarified 
and stored the same as PPV. 
4.2.3 Synthesis and characterization of AuNPs with various sizes 
Various sizes of AuNPs were synthesized and characterized. AuNPs ranging from 
~27 to 106 nm in diameter were synthesized by the seed-mediated, room temperature 
growth method with trisodium citrate (Na3Ctr) and chloroauric acid (HAuCl4) [193]. The 
synthesis of larger AuNPs started with monodisperse 15 nm diameter AuNP seeds that 
were synthesized by the conventional Turkevich method of adding Na3Ctr to reduce 
boiling HAuCl4 [6]. By changing the volume of water and AuNP seed additions to 
constant volumes of HAuCl4 and Na3Ctr, different diameters of AuNPs were synthesized 
over time at room temperature, shown in Table 4.1 [193]. The concentration of HAuCl4 
was 44.7 mM, the concentration of the seed AuNPs was 6.54×1012 particles/mL, and the 
concentration of Na3Ctr was 38.8 mM [193]. 
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22.7 36.220 0.227 3.377 0.176 
34.2 38.786 0.227 0.811 0.176 
45.7 39.270 0.227 0.327 0.176 
57.1 39.432 0.227 0.165 0.176 
68.6 39.502 0.227 0.095 0.176 
80.0 39.537 0.227 0.060 0.176 
91.4 39.557 0.227 0.040 0.176 
102.9 39.569 0.227 0.028 0.176 
114.3 39.577 0.227 0.020 0.176 
4.2.4 Concentration determination of different AuNP sizes 
The concentration of AuNPs was determined by the molar extinction coefficient 
method after collecting the UV-Vis spectra and size via DLS, which has been shown to 
be accurate for AuNPs between 5 and 100 nm [197]. The concentration of AuNPs 
calculated from the UV-Vis spectra method was adjusted so that all reactions would have 
the same binding surface area across all sizes. The concentration of 3.5 nM was used for 
15 nm AuNPs for the detection of PPV and BVDV [6]. Using Equation 4.1, the surface 











2�                                                (4.1) 
where C1 is the concentration of the 15 nm AuNPs (3.5 nM), C2 is the desired 
concentration of any other sized AuNPs, D1 is the diameter of 15 nm AuNPs (15 nm), 
and D2 is the diameter of any other sized AuNPs. This equation shows a higher 
concentration of larger diameter AuNPs are necessary for the virus detection assay.  
4.2.5 AuNP/virus and protein complex formation 
Different concentrations of PPV, BVDV, and BSA were added to the AuNPs of 
different sizes to form complexes to be aggregated by osmolyte or salt. PPV from 8 log 
MTT50/mL to 4 log MTT50/mL was added in a 1:1 volume ratio (total volume of 1 mL) 
with AuNPs and mixed overnight on a Roto-shake Genie rocker (Bohemia, NY) with end 
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over end rotation. The same overnight mixing was performed for BVDV from 6 log 
MTT50/mL to 2 log MTT50/mL, and BSA at 0, 1 nM, and 1 µM to form AuNP 
complexes. For AuNPs with diameter 40 and 50 nm, the complexes were centrifuged at 
6000×g for 20 minutes in a ST16R centrifuge with a microliter 30 x 2 mL fixed angle 
rotor (Thermo Scientific) to remove un-complexed material in the supernatant, and 
resuspended in 1 M mannitol, glycine, or NaCl.  
For AuNPs with a 5 nm diameter, the manufacturer did not recommend 
centrifugation of the complexes as they are readily aggregated by centrifugation. Instead, 
250 µL of 7.0 nM AuNPs and 250 µL of PPV were combined and mixed overnight the 
same way as above. The concentration of aggregating agent was doubled to 2 M to allow 
for a 500 µL addition to achieve the same final concentration of components with a final 
volume of 1 mL after aggregation. 
4.2.6 Quantification of aggregated AuNP/virus complexes by DLS 
A Malvern Nano ZS Zetasizer (Malvern, UK) was used to collect DLS curves of 
intensity versus hydrodynamic diameter (DH) for samples before and after aggregation. 
The software-generated Z-average for the size distribution was used as the DH for each 
sample. The AuNP material properties were set at a refractive index of 0.20 and an 
absorption of 3.32 [198]. The water dispersant properties were set to a temperature of 
20°C, a viscosity of 1 cP, and a refractive index of 1.333. Samples were placed in 
disposable acrylate cuvettes at a volume of 1 mL. 
The quantification of AuNP/virus complexes was achieved using DLS to 
determine the DH before and after aggregation by osmolyte or salt. The change in 
hydrodynamic diameter (ΔDH) was used to quantify the extent of aggregation, which was 
inferred by measuring the change in size of the aggregates using Equation 4.2, 
Δ𝐷𝐷𝐻𝐻 = 𝐷𝐷𝐻𝐻,𝑐𝑐𝑏𝑏𝑐𝑐𝑐𝑐𝑐𝑐𝑎𝑎𝑐𝑐𝑎𝑎𝑠𝑠 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑐𝑐𝑎𝑎𝑛𝑛𝑎𝑎 − 𝐷𝐷𝐻𝐻,𝑐𝑐𝑏𝑏𝑐𝑐𝑐𝑐𝑐𝑐𝑎𝑎𝑐𝑐𝑎𝑎𝑠𝑠 𝑏𝑏𝑎𝑎𝑎𝑎𝑏𝑏𝑎𝑎𝑎𝑎 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑐𝑐𝑎𝑎𝑛𝑛𝑎𝑎          (4.2) 
where DH, complexes after treatment is the hydrodynamic diameter of AuNP/virus complexes 
after aggregation by osmolyte or salt (nm), and DH, complexes before treatment is the 
hydrodynamic diameter of AuNP/virus complexes before aggregation by osmolyte or salt 
(nm). 
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4.3 Results and discussion 
4.3.1 Virus interaction with various AuNP sizes 
The interaction between different sizes of AuNPs and virus particles was 
explored. The two model viruses to be detected in the AuNP assay, PPV and BVDV, 
have diameters of ~20 nm [199] and ~50 nm [200]. To explore how different sizes of 
AuNPs interact with the two viruses, AuNPs with diameters of 5, 15, and 40 nm were 
chosen for PPV (Figure 4.3A-C), and AuNPs with a 50 nm diameter were chosen for 
BVDV (Figure 4.3D-E). These sizes were chosen to have the size ratio of AuNP to virus 
diameters be <1, ~1, and ~2. For AuNPs that are smaller in diameter than the virus 
particles, it is believed that the AuNPs surround the virus particles (Figure 4.3A and D). 
The size ratio of ~1 for PPV has already been performed and serves as the base line 
control to compare the other size ratios (Figure 4.3C) [6]. When sufficiently large 
AuNPs are used, the opposite should occur, where many virus particles surround a single 
AuNPs (Figure 4.3C and F). 
It was hypothesized that the configuration where virus particles surround the 
larger AuNPs (ratio ~2) would result in a higher DLS signal, and hence a lower LOD if 
enough virus is present to be aggregated by the osmolytes. This is because the inter-
particle distance decrease of larger AuNPs results in more scattered light than decreasing 
the inter-particle distance between smaller AuNPs. Additionally, the larger AuNPs have a 
higher accessibility of the virus to bind due to the increased surface area. This should 
help ensure the virus particles are complexed with AuNPs prior to aggregation so the 
virus can be detected. This hypothesis was tested by measuring the size of AuNP/virus 
complexes before and after osmolyte-induced aggregation with DLS. The results 
indicated that neither larger AuNPs nor smaller AuNPs resulted in an improved virus 
detection assay because the LOD was not reduced.   
4.3.2 Synthesis and characterization 
After synthesis, the particles were characterized by UV-Vis, DLS, and TEM. The 
UV-Vis absorption spectrums for 27, 68, 96, 100, and 106 nm diameter AuNPs are 
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shown in Figure 4.4A. A red-shift in absorbance peak is clearly visible due to the 
increased size of AuNPs, and the absorbance peaks are very close to the expected 
literature values [193]. To determine the size of the different diameter AuNPs, DLS 
curves collected shown in Figure 4.4B. The Z-average hydrodynamic diameter collected 
during DLS measurements were used as the reported sizes of AuNPs, which is the 
diameter at peak intensity. The synthesized AuNPs of different diameter are 
monodisperse based on the presence of only one peak on the DLS curves, except for 68 
nm particles, possibly due to a small amount of contamination. To confirm the correct 
size and shape of AuNPs, TEM images were collected and can be seen in Figure 4.4C 
for 68 nm and 100 nm AuNPs. The TEM image confirmed the size of the 100 nm 
AuNPs. The peak-broadening of the larger AuNPs (>100 nm) seen in UV-Vis (Figure 
4.4A) is caused by dephasing of the surface plasmons from an enhanced mean free path 
of electrons, which causes new plasmon modes to appear at higher wavelengths [201-
203]. The measured sizes of the AuNPs from the TEM images were similar to the sizes 
determined by DLS, with a slight over-estimation of the size by DLS. This result has 
been observed by others characterizing AuNPs and is due to DLS measuring the 
hydrodynamic diameter of the particles, which includes the solvation layer, whereas 
TEM measures the absolute size [188].  
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Figure 4.4: Characterization of various sizes of AuNPs showing the A) UV-Vis 
absorption spectrums, B) DLS curves, and C) TEM images of 68 nm and 100 nm AuNPs 
4.3.3 Aggregation of 40 nm AuNP/PPV complexes 
AuNPs with a diameter of 40 nm (AuNP40) were complexed with PPV in the 
range of 8 log MTT50/mL to 4 log MTT50/mL and aggregated using 1 M mannitol, 1 M 
glycine, and 1 M NaCl. 1 nM and 1 µM BSA were used as controls to show the specific 
nature of osmolytes to aggregate AuNP40/virus complexes, but not AuNP40/BSA 
complexes. Aggregation of the AuNP40/virus and BSA complexes by mannitol, glycine, 
and NaCl are shown in Figure 4.5. At 7 log MTT50/mL, there began to be a difference 
between AuNP40/PPV complexes before and after treatment with mannitol (Figure 4.5A) 
and glycine (Figure 4.5B). Below that concentration, not enough virus was present to be 
aggregated and measured. A concentration of 8 log MTT50/mL was necessary to halt salt-
induced aggregation of the AuNPs (Figure 4.5C). From the previous assay with AuNP15, 
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6 log MTT50/mL was needed to halt salt-induced aggregation [6]. This difference is likely 
because of the larger AuNP surface exposed to the salt environment when compared to 
using smaller AuNPs. Diameters of ~75 nm (Figure 4.5D) and ~55 nm (Figure 4.5E) 
were achieved by aggregating AuNP40/BSA control complexes with mannitol and 
glycine, respectively. Using Equation 4.2, ΔDH values of ~25 nm and ~7 nm were 
calculated for mannitol-treated AuNP40/BSA complexes and glycine-treated 
AuNP40/BSA complexes, respectively. The ΔDH values for BSA complexes represent the 
limit of the DLS to distinguish between AuNP/virus and AuNP/BSA complexes 
aggregated by mannitol and glycine. ΔDH was calculated for mannitol and glycine 
aggregated AuNP40/PPV complexes and compared to ΔDH calculated for aggregated 
AuNP40/BSA complexes, showing that the LOD for mannitol-treated complexes was 7 
log MTT50/mL (Figure 4.5G, red line). The LOD for glycine-treated complexes was also 
7 log MTT50/mL (Figure 4.5H, red line). 
The baseline LOD results from the AuNP15/PPV assay was 6 log MTT50/mL for 
PPV [6]. Neither mannitol-treated nor glycine-treated AuNP40/PPV complexes led to an 
improved LOD. This result did not support the hypothesis that larger diameter AuNPs 
would increase the DLS intensity signal at lower concentration of virus. 
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Figure 4.5: AuNP40/PPV complexes aggregated by A) 1 M mannitol, B) 1 M glycine, and 
C) 1 M NaCl. AuNP40/BSA complexes aggregated by D) 1 M mannitol, E) 1 M glycine, 
and F) 1 M NaCl. G) ΔDH as a function of AuNP40/PPV complexes aggregated by 
mannitol with the red line representing the LOD. H) ΔDH as a function of AuNP40/PPV 
complexes aggregated by glycine with the red line representing the LOD. 
4.3.4 Aggregation of 50 nm AuNP/BVDV complexes 
AuNPs with a diameter of 50 nm (AuNP50) were complexed with BVDV in the 
range of 6 log MTT50/mL to 2 log MTT50/mL and aggregated using 1 M mannitol, 1 M 
glycine, and 1 M NaCl. BSA was used as a control. Aggregation of the AuNP50/virus or 
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protein complexes by mannitol, glycine, and NaCl are shown in Figure 4.6. At 5 log 
MTT50/mL, there began to be a difference between AuNP50/BVDV complexes before and 
after treatment with mannitol (Figure 4.6A). At 6 log MTT50/mL, there began a 
difference between AuNP50/mL complexes before and after treatment with glycine 
(Figure 4.6B). Below these concentrations, not enough virus was present on the AuNP 
surface to be aggregated and measured. A concentration of 5 log MTT50/mL was 
necessary to halt salt-induced aggregation of the AuNPs (Figure 4.6C), which is lower 
than AuNP40 used with PPV likely because of the larger size of BVDV compared to PPV 
capable of shielding the NaCl from aggregating the AuNPs. Diameters of ~80 nm 
(Figure 4.6D) and ~60 nm (Figure 4.6E) were achieved by aggregating AuNP50/BSA 
control complexes with mannitol and glycine, respectively, leading to ΔDH values of ~30 
nm and ~6 nm. ΔDH values of ~30 nm and ~6 nm were calculated for mannitol-treated 
AuNP50/BSA complexes and glycine-treated AuNP50/BSA complexes, respectively. The 
ΔDH values for BSA complexes represent the limit of the DLS to distinguish between 
AuNP/virus and AuNP/BSA complexes aggregated by mannitol and glycine. ΔDH was 
calculated for mannitol and glycine aggregated AuNP50/BVDV complexes and compared 
to ΔDH calculated for aggregated AuNP50/BSA complexes, showing that the LOD for 
mannitol-treated complexes was 4 log MTT50/mL (Figure 4.6G, red line). The LOD for 
glycine-treated complexes was 6 log MTT50/mL (Figure 4.6H, red line).  
The baseline LOD results from the AuNP15/BVDV assay was 4 log MTT50/mL 
for BVDV [6]. These results did not improve the LOD compared to when 15 nm AuNPs 
were used, which did not support the hypothesis that larger diameter AuNPs would 
increase the DLS intensity signal at lower concentration of virus. 
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Figure 4.6: AuNP50/BVDV complexes aggregated by A) 1 M mannitol, B) 1 M glycine, 
and C) 1 M NaCl. AuNP50 /BSA complexes aggregated by D) 1 M mannitol, E) 1 M 
glycine, and F) 1 M NaCl. G) ΔDH as a function of AuNP50 /BVDV complexes 
aggregated by mannitol with the red line representing the LOD. H) ΔDH as a function of 
AuNP50 /BVDV complexes aggregated by glycine with the red line representing the 
LOD. 
4.3.5 Aggregation of 5 nm AuNP/PPV complexes 
Since larger AuNPs complexed with the virus did not result in a lower LOD, it 
was decided to try AuNPs that were smaller than the virus. AuNP5 (5 nm particles) were 
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complexed with PPV in the range of 4 to 8 log MTT50/mL with the same osmolytes and 
salt. BSA was used as the control. Aggregation of the AuNP5/PPV or BSA complexes are 
shown in Figure 4.7. Regardless of the concentration of PPV used to complex with the 
AuNP5, the same level of aggregation was observed when mannitol and glycine were 
added, shown in Figure 4.7A and B. However, as expected, salt-induced aggregation 
was stopped at higher concentration of PPV (6 log MTT50/mL), meaning PPV shields the 
AuNPs from being aggregated, as shown in Figure 4.7C. Regardless of the BSA 
concentration used, the same degree of aggregation was observed when compared to PPV 
samples (Figure 4.7D and E). The ΔDH values calculated for AuNP5/BSA complexes 
were ~130 nm for mannitol treated complexes and ~30 nm for glycine treated complexes. 
Using these ΔDH values for AuNP5/BSA complexes as the LOD for AuNP5/PPV 
complexes, there is no detection ability when aggregated by mannitol or glycine (Figure 
4.7G and H, respectively). These results indicated that the AuNP5 were aggregating due 
to osmolyte addition regardless of the biomolecule or biomolecule concentration. 
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Figure 4.7: AuNP5/PPV complexes aggregated by A) 1 M mannitol, B) 1 M glycine, and 
C) 1 M NaCl. AuNP5/BSA complexes aggregated by D) 1 M mannitol, E) 1 M glycine, 
and F) 1 M NaCl. G) ΔDH as a function of AuNP5 /PPV complexes aggregated by 
mannitol with the red line representing the LOD. H) ΔDH as a function of AuNP5 /PPV 
complexes aggregated by glycine with the red line representing the LOD. 
 
To test this theory, AuNP5 were mixed with an equal volume of nanopure water, 1 
M mannitol, 1 M glycine, and 1 M NaCl, and DLS curves were collected for each 
condition to test if the size increased just with osmolyte treatment without biomolecule 
presence. The results are shown in Figure 4.8. The AuNP5 straight from the manufacturer 
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and in water showed a DH of ~11 nm, see Figures 4.8A and B. Although the size is larger 
than the expected 5 nm, it is common for DLS to over-estimate the true size of the 
particles as it is measuring the hydrodynamic diameter, and not true diameter of the 
particles [188]. The size of the particles was confirmed with TEM imaging, showing a 
size between 6-7 nm, shown in Figure 4.9. AuNP5 mixed with glycine showed only a 
slight increase in hydrodynamic diameter to 16 nm, (Figure 4.8C). AuNP5 mixed with 
mannitol and NaCl showed an increase in diameter to 113 nm and 950 nm, respectively. 
Although the salt-induced aggregation is expected for bare AuNPs, the high degree of 
aggregation due to mannitol treatment was unexpected and undesired. One possible 
reason for this aggregation by mannitol could be that the high number of hydroxyl groups 
present on mannitol can substitute citrate ions on the surface leading to a destabilization 
of the AuNPs. This increased hydroxyl group affinity to smaller AuNPs was noticed 
when a reducing agent with a high number of hydroxyl groups was more efficient at 
synthesizing smaller diameter AuNPs, compared to reducing agents with a lower amount 
of hydroxyl groups [204]. Due to the challenge of osmolytes aggregating the plain 
AuNP5, they were not investigated for further use in virus detection. 
94 
 
Figure 4.8: DLS curves showing the size of A) AuNP5 straight from the manufacturer’s 
bottle and B) AuNP5 in nanopure water. DLS curves of AuNP5 aggregated by C) 1 M 
glycine, D) 1 M mannitol, and E) 1 M NaCl. 
 
 
Figure 4.9: TEM images of 5 nm AuNPs at two different magnification levels 
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Overall, by utilizing AuNP40 with PPV, AuNP50 with BVDV, and AuNP5 with 
PPV, there was no improvement to the virus detection assay previously published using 
AuNP15 for PPV and BVDV. The LODs remained at 6 log MTT50/mL for PPV and 4 log 
MTT50/mL for BVDV. 
4.4 Conclusions and future work 
Synthesis of various sizes of AuNPs was performed and characterized for use in a 
PPV and BVDV detection assay. AuNP40 were complexed with PPV, resulting in a LOD 
of 7 log MTT50/mL when aggregated by 1 M mannitol. AuNP50 were complexed with 
BVDV, resulting in a LOD of 5 log MTT50/mL when aggregated by 1 M mannitol. 
AuNP5 were used in an attempt to detect PPV, but the high concentrations of osmolytes 
used in the aggregation step led to AuNP aggregation regardless of the presence of virus 
or control protein. Neither an increase nor decrease in the size of AuNPs lead to an 
improved LOD compared to the published work of using 15 nm AuNPs in the same 
detection assay. These results indicate that the size of AuNPs used in the virus detection 
assay do not play a critical role in detection. 
Future work for the AuNP project includes using 100 nm AuNPs (AuNP100) to 
test if a size ratio between AuNP and BVDV of 2 would improve the detection ability. 
The size ratio of 2 between PPV and AuNPs40 did not lead to an improved LOD, but 
BVDV is a larger virus that could complex with a few number of AuNP100. By 
complexing with fewer, larger AuNPs BVDV could be detected due to the increase in 
scattered light intensity with larger AuNPs. 
The system pH could be varied to improve the virus detection assay. Since the 
virus pI dictates the surface charge on a virus particle, the system pH could be lowered to 
cause more electropositive patches to be present. With more electropositive patches 
present, the electrostatic interaction may become stronger between citrate-capped AuNPs 
and virus particles. The stronger electrostatic interaction may lead to the ability to use a 
lower concentration of virus particles to bind to AuNPs, and thus a lower amount of virus 
would be needed for osmolyte-induced aggregation. 
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Additionally, other osmolytes such as alanine and trehalose have been shown to 
aggregate enveloped and non-enveloped viruses, which could be used to aggregate the 
AuNP/virus complexes [111, 112]. Alanine is an amino acid with a hydrophobic side 
chain that may be able to aggregate viral particles more effectively. Alanine residues in 
protein molecules are normally buried within the protein structure to protect it from 
solvent exposure [205]. This effect could be exploited for the aggregation assay because 
the hydrophobic residues from alanine could aid in stabilization and enhanced 
aggregation of the dehydrated hydrophobic patches of virus particles. Trehalose is a sugar 
with two molecules of glucose linked by an α, α-1,1-glucosidic bond [206]. Trehalose has 
a high affinity for water due to multiple hydrogen bonding events between its two 
glucose rings and water molecules [207]. The high affinity for water would rapidly 
dehydrate the virus surface, potentially causing more virus aggregates to form as more 
and more water is pulled away from the virus surface. This could improve the AuNP 
assay by allowing a lower concentration of osmolyte to be used in the aggregation step, 
or to dehydrate a smaller concentration of virus particles due to the strong dehydration 
ability of trehalose. 
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5 Continuous downstream purification of viral products 
using an aqueous two-phase system 
5.1 Introduction 
Vaccination remains the best method to prevent the transmission of 
communicable human diseases. According to the World Health Organization (WHO), in 
2018, 86% of infants worldwide (116.3 million) received three doses of the diphtheria-
tetanus-pertussis vaccine. But that left 14% of children under the age of 1 (19.4 million) 
unvaccinated [208]. One reason for this is due to vaccine supply shortages. Over the past 
15 years, significant manufacturing problems have led to numerous vaccine shortages. 
These shortages have led to the inability for even the United States to meet past demands 
of vaccines for hepatitis A/B, rabies, and influenza [209, 210]. The ever-expanding world 
population will continue to increase the demand for vaccines. The biomanufacturing 
industry must develop and implement novel production methods to supply the market 
quickly and reliably with vital virus-containing biotherapeutics. One such solution is to 
switch to continuous operation. 
The switch to continuous operation would increase profits by increasing 
productivity and flexibility, while decreasing capital and operating costs [211-213]. This 
switch requires a fully integrated, end-to-end, continuous biomanufacturing process. 
Upstream unit operations that operate continuously are currently in operation [214, 215], 
but truly continuous downstream processes are still being developed. Truly continuous 
downstream processes must also handle the increasing titers produced in the bioreactor to 
purify viral products safely and quickly. 
Current semi-continuous downstream processes are focused on simulated moving 
bed (SMB) chromatography. There are only a limited number of SMB virus purification 
processes due to the complex nature of designing an SMB process [139, 141, 216]. One 
SMB chromatography process purified human influenza virus from a serum-free MDCK 
cell culture supernatant. The process resulted in 89% virus recovery, 52% protein 
removal, and 99.7% DNA removal using a quaternary amine anion exchange monolith 
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[139]. However, to achieve the FDA-required DNA maximum amount of 10 ng/dose, a 
Benzonase®-treatment was necessary and adds an addition step of Benzonase® removal 
later in the process. In addition, a 10% column load was required to keep contaminant 
protein and DNA levels low [139]. This low of a column load leads to higher processing 
time and cost due to under-utilized column resin. Another SMB chromatography process 
used size-exclusion chromatography (SEC) to purify adenovirus from a filtered harvest of 
Triton X-100 and Benzonase®-treated HEK-293 cell media. Use of the two-column SEC 
technique resulted in 86.3% virus yield, 90% DNA removal, and 89% host cell protein 
(HCP) removal [144]. These two SMB chromatography processes show promise for 
operating a semi-continuous downstream purification, since most SMB processes are 
continuous loading and semi-continuous elution. Since SMB processes are not fully 
continuous and resin costs remain high, other unit operations need to be explored. 
Aqueous two-phase systems (ATPSs) can be run as fully continuous processes. 
An ATPS is a liquid-liquid extraction technique that is used to partition molecules 
between two semi-miscible liquid phases and is typically comprised of a polymer and salt 
for biomolecule separations [147, 149]. Water is the major component in ATPS, making 
the materials inexpensive and environmentally-friendly compared to common 
chromatography resins [217]. ATPSs have been tested extensively in batch-mode to 
separate and purify proteins [161, 163], phages [175], and viruses [7, 154, 173]. ATPS 
was used for the separation and purification of porcine parvovirus (PPV) with an 
infectious titer recovery of 79%, DNA removal of 78%, and high protein removal using a 
mixture of poly(ethylene glycol) (PEG) and citrate [7]. 
There have been several continuous ATPS designs used for the recovery of 
proteins [158, 161, 163] and enzymes [165, 166, 218]. Two vital considerations for 
continuous ATPS operation are effective mixing and phase separation. The most common 
designs for continuous ATPSs include the use of column contactors, such as rotating disk 
contactors (RDC) and mixer-settlers [170]. The key difference between these types of 
designs are how mixing is achieved. RDC uses mechanically spun plates to form mixing 
vortices between plates and in-line turbulence generators mix the ATPS in mixer-settles. 
One continuous ATPS used an RDC to extract α-lactalbumin from a mixture of α- and β-
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lactalbumin [158]. This was performed by spiking α- and β-lactalbumin into the citrate-
rich phase, then a PEG-rich phase was flowed through the bottom of the citrate-rich 
phase inside the RDC. Adequate contact between phases was provided and 86% of the α-
lactalbumin was recovered in the PEG-rich phase with an 86% purity. Although high 
recovery and purity of the product was achieved using the RDC, two hours was required 
to achieve steady-state operation while flowing at 3 mL/min [158]. Another draw-back to 
column contactors is the issue of column flooding, which decreases separation 
performance [170]. 
Mixer-settlers avoid issues of flooding and mechanical failures by employing 
various in-line static mixer designs, such as a tube filled with glass-bead or baffles. These 
types of mixers use in-line obstacles to disrupt the streamlines of the flowing phases, 
creating droplets of each phase. Continuous ATPSs with a polymer as one of the phase 
forming components will typically operate in the laminar flow regime due to the high 
viscosity of the polymer. For this reason, in-line mixers are appropriate because they can 
blend the two phases by disrupting the flow pattern and creating convective radial 
mixing. Separation of mixed phases is achieved using long lengths of tubing and 
decanters. Continuous ATPS using a mixer-settler was used to study the partitioning of 
bovine whey protein isolate (WPI) proteins (α- and β-lactalbumin) between PEG-rich and 
phosphate-rich phases [163]. After 12 minutes of continuous operation, 72% of the initial 
total protein was partitioned to the phosphate-rich phase, while 30% of the total protein 
was collected in the PEG-rich phase [163]. Although the purity of the collected phases 
was not quantified, SDS-PAGE gels showed the phosphate-rich phase contained only 
bands corresponding to β-lactalbumin, demonstrating that a high purity was achieved 
[163]. This study demonstrated the ease of scale-up from batch mode experiments to a 
fully continuous separation process. 
In this work, we developed a fully continuous ATPS for the purification of PPV 
and human immunodeficiency virus type-1 group antigen virus-like particles (HIV VLPs) 
from crude cell supernatant without pre-treatment. Optimizations of mixer types was 
performed to achieve proper mixing of phases and partitioning of viral particles to the 
PEG-rich phase while partitioning most contaminant proteins and DNA to the citrate-rich 
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phase. Recovery and purity of each viral product was determined over approximately 40 
minutes. 
5.2 Materials and methods 
5.2.1 Materials 
Poly(ethylene glycol) 12,000 (MWavg 11,000-15,000) , citric acid monohydrate 
(ACS grade ≥98%), sodium dodecyl sulfate (BioReagent, ≥98.5%), sodium citrate 
tribasic dihydrate (ACS reagent, ≥99%), and 2-mercaptoethanol were from Sigma-
Aldrich (St. Louis, MO). Minimum essential medium, fetal bovine serum (Mexico 
origin), 10,000 U/mL penicillin streptomycin (pen-strep), 0.25% trypsin-EDTA (1X), 
phosphate buffered saline pH 7.2 (1X), and sodium bicarbonate (7.5%) for cell culture 
and virus propagation were from Gibco™ (Grand Island, NY). Thiazolyl blue tetrazolium 
bromide (98%) was from Alfa Aesar (Ward Hill, MA). SeeBlue™ Plus2 prestained 
standard, NuPAGE™ 3-(N-morpholino)propanesulfonic acid (MOPS) sodium dodecyl 
sulfate (SDS) running buffer (20X), SimplyBlue™ SafeStain, and NuPAGE™ 4-12% 
Bis-Tris gels were from Invitrogen (Carlsbad, CA). Pierce™ lithium dodecyl sulfate 
(LDS) sample buffer non-reducing (4X) was from Thermo Scientific (Waltham, MA). 
Barnstead™ nanopure water (Thermo Scientific) with an electrical resistance of ≥18 MΩ 
was used to create all solutions. All solutions were filtered through a 0.2 μm Nalgene™ 
Rapid-Flow™ sterile disposable bottle-top filter with PES membrane from into an 
autoclaved vessel for storage before use. 
5.2.2 Methods 
5.2.2.1 Cell maintenance 
Porcine kidney cells (PK-13) were purchased from the American Type Culture 
Collection (ATCC®) (cat# CRL-6489™) and cultured in minimum essential medium 
(MEM) supplemented with 10 vol% fetal bovine serum (FBS) and 1 vol% pen/strep. The 
cells were incubated at 37°C, 5% CO2, and 100% humidity. PPV strain NADL-2 was a 
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gracious gift from Dr. Ruben Carbonell at North Carolina State University (Raleigh, NC). 
PPV strain NADL-2 was propagated in PK-13 cells as described previously [194]. After 
three freeze-thaw cycles, the cell lysate was clarified by centrifugation at 5,000 rpm at 
4°C for 15 minutes in a ST16R centrifuge with a TX-400 swing-bucket rotor (Thermo 
Scientific). The PPV-containing supernatant was stored at -80°C until use. 
5.2.2.2 MTT assay for PPV titer 
The titer of PPV was found by the MTT colorimetric cell viability assay [219]. 
PK-13 cells at a seeding density of 8×104 cells/mL were placed in 96-well plates and 
incubated overnight. The next day, the cells were infected with PPV by serially diluting 
across the plate at a ratio of 1:5 and placed back in the incubator for 6 days. 6 days after 
infection, 5 mg/mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) salt in 1X pH 7.2 PBS was added to each well to allow living cell’s mitochondrial 
reductase to reduce the MTT to (E,Z)-5-(4,5-dimethylthiazol-2-yl)-1,3-diphenylformazan 
(formazan). The solubilizing solution, consisting of 10 w/v% sodium dodecyl sulfate 
(SDS) with 0.01 M hydrochloric acid (HCl), was added to dissolve the formazan. The 
absorbance at 550 nm was measured with a Synergy™ Mx microplate reader from 
BioTek (Winoski, VT), and the 50% viral infectious dose was determined in units of 
MTT50/mL. 
5.2.2.3 Fluorescence measurements for HIV VLP detection 
The HIV VLPs were expressed in proprietary Hansenula polymorpha cells 
donated by Esperovax (Plymouth, MI). The fluorescence from the GFP was recorded 
with a Synergy™ Mx microplate reader in a black, flat-bottom 96-well plate at an 
excitation wavelength of 485 nm and emission of 509 nm. 
5.2.2.4 ATPS formation 
Unpublished work in our lab from an ATPS tie line study using a 12 kDa 
PEG/citrate ATPS determined the highest recovery of PPV in the PEG-rich phase at a tie 
line length (TLL) of 32 w/w% and tie line ratio (TLR) of 0.5. For this reason, this system 
of PEG and citrate was chosen as the ATPS to be run continuously. To form the TLL 
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32%/TLR 0.5 system, stock solutions of 45 w/w% PEG (ρ = 1.065 g/mL), 30 w/w% 
citrate (ρ = 1.158 g/mL), and nanopure water were mixed to achieve starting system 
concentrations of 18 w/w% PEG, 12 w/w% citrate, and 70 w/w% water. To achieve these 
starting system concentrations, 41% of the total volume was 45 w/w% PEG, 38% of the 
total volume was 30 w/w% citrate, 11% of the total volume was viral product, and 11% 
of the total volume was water. 
5.2.2.5 Mixer-settler construction 
An air-powered mixer operating at 1,500 rpm with a 5 cm diameter Cowles blade 
was used to mix ATPS components. This mixer was used as the positive control of 
mixing for the in-line mixers. Two in-line mixer designs were tested for their ability to 
sufficiently mix the PEG, citrate, and water prior to testing the separation ability and 
ATPS formation of the full system. The first mixer was constructed by filling a 15 cm 
length of Tygon S3 E-LFL (Saint Gobain, Malvern, PA) polyvinyl chloride (PVC) tubing 
(6.35 mm inner diameter) with approximately 150, 3 mm outer diameter glass beads from 
Fisher Scientific (Waltham, MA) until fully packed. This was designated the “glass bead 
mixer”. The second mixer was assembled by inserting 2, 12-element helical blades (4.76 
mm outer diameter) from Cole-Parmer (Vernon Hills, IL) into a 15 cm length of 4.76 mm 
ID Tygon S3 E-LFL PVC tubing, which was designated the “helical mixer”.   
After each in-line mixer, 45.7 cm of 2 mm ID Tygon tubing was shaped into a 
spiral by winding around a 100 mL graduated cylinder (9.5 cm outer diameter) to begin 
phase separation before the settler. The settler was a 15 mL centrifuge tube with 2 mm 
OD holes drilled into the top of the cap, direct bottom of the tube, and half-way up the 
vertical wall of the tube for PEG-rich phase collection, citrate-rich phase collection, and 
feed inlet lines, respectively. Each hole was sealed with DAP® RapidFuse® Fast Curing 
All Purpose Adhesive with Plastic Primer glue to prevent leaking. The full system 
process flow diagram and in-lab set-up are shown in Figure 5.1A and B, respectively. 
Close-up images of the helical mixer and the separator section of the continuous ATPS 
set-up are shown in Figure 5.1C and D, respectively. 
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Figure 5.1: A) Process flow diagram of continuous ATPS and B) in-lab bench scale set-
up. C) Close-up picture of the in-line helical mixer and D) separator section. 
5.2.2.6 COMSOL Multiphysics simulation of helical mixer 
COMSOL Multiphysics was used to further evaluate the helical mixer 
performance. The program simulated the two-phase laminar flow through the helical 
mixer (Figure 5.1C). A schematic of the numerical model and the associated 
computational grid are shown in Figures 5.2A and B, respectively. A finite-element 
approach was employed as implemented in COMSOL Multiphysics to solve the 
incompressible Navier-Stokes equations for the two-phase flow of the PEG-rich (stream 
1) and the citrate-rich (stream 2) mixture [220, 221]. A phase-field approach was adopted 
to model the interaction between the two immiscible components [222]. The governing 
equations were solved iteratively, where within each iteration first velocity and pressure 
fields were calculated together directly, and then the phase-field variable was computed 
in the same manner. The fluid flow and phase-field equations were discretized via P2+P1 
scheme and quadratic elements, respectively. Tetrahedral elements were used to mesh the 
computational domains (see Figure 5.2B), and the grid was chosen such that the changes 
in the results due to the mesh refinement were marginal. 
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Figure 5.2 : COMSOL Multiphysics modelling of in-line helical mixer showing the A) 
mixer geometry and B) mesh pattern used in the simulation 
 
The flow within the helical mixer was driven in the simulation by applying inlet 
and outlet boundary conditions upstream and downstream of the mixer. Consistent with 
stream 1 and steam 2 in the experiments, the fluid velocity (measured in m/s ) and the 
phase-field variable are specified as 
𝒖𝒖𝑖𝑖𝑛𝑛 = �
4.0404 × 10−3 𝒆𝒆𝑧𝑧 𝑓𝑓𝑓𝑓𝑓𝑓 𝑥𝑥 > 𝑆𝑆
2.869 × 10−3 𝒆𝒆𝑧𝑧 𝑓𝑓𝑓𝑓𝑓𝑓 𝑥𝑥 ≤ 𝑆𝑆
 and Φ = �
1 𝑓𝑓𝑓𝑓𝑓𝑓 𝑥𝑥 > 𝑆𝑆
−1 𝑓𝑓𝑓𝑓𝑓𝑓 𝑥𝑥 ≤ 𝑆𝑆 
at the inlet (see Figures 5.4A and B) and the outlet pressure is fixed to zero. 
Additionally, no-slip and 90° contact angle conditions were imposed on wetted walls. 
Furthermore, the properties of PEG-rich and citrate-rich phases, and the surface tension 
between them were set to µPEG = 0.0912 Pa∙s, ρPEG = 1015 kg/m3, µcitrate = 0.001 Pa∙s, 
ρcitrate = 1068 kg/m3, and γ = 0.000463 N/m, respectively. 
5.2.2.7 Continuous ATPS operational procedure 
A mass balance was performed around the mixer to determine proper flow rates 
of the stock PEG, citrate, and water into the mixer to achieve the desired TLL 32% TLR 
0.5 ATPS (Appendix Figure A.1). To confirm the proper ATPS was formed by the 
mixer, physical property measurements of the PEG-rich and citrate-rich phase after 
separation were performed on the density, dynamic viscosity, and refractive index, as 
described previously [7]. Density measurements were performed by weighing a 1 mL 
sample on a Mettler-Toledo analytical balance (Columbus, OH). Dynamic viscosity 
measurements were performed with an SV-10 sine-wave vibro viscometer from A&D 
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(Tokyo, Japan). Refractive index measurements were performed using a Digital Brix/RI-
Chek refractometer from Reichert Technologies (Depew, NY). These measurements were 
used to compare batch-mode and continuous-mode phase samples to confirm proper 
ATPS formation. 
To equilibrate the continuous ATPS, 45% PEG, 30% citrate, and water were 
pumped through a mixer at 1.45 g/min (ρ=1.065 g/mL), 1.45 g/min (ρ=1.158 g/mL), and 
0.73 g/min (ρ=1.0 g/mL), respectively, for a total mixture flow rate of 3.63 g/min 
(ρ=1.209 g/mL). The PEG, citrate, and water flowed through the entire system for 15 
minutes to allow for steady-state operation prior to introducing any viral product. After 
system equilibration, the water line was switched to a crude viral product tube for 
purification for continuous operation. PEG-rich and citrate-rich fractions were collected 
by two individual peristaltic pumps set at different flow rates (typically between 1.0-1.5 
mL/min) to keep the interface of the phases within the separator at the same level. 
Fractions were collected every 2 minutes for 10 seconds. After fraction collection, PPV 
was quantified by MTT assay to assess recovery in both phases. Recovery of PPV in the 
PEG-rich and citrate-rich phases was calculated using Equation 5.1: 
𝑃𝑃𝑃𝑃𝑃𝑃 𝑆𝑆𝑅𝑅𝑅𝑅𝑓𝑓𝑅𝑅𝑅𝑅𝑓𝑓𝑅𝑅 (%) = �10
𝑅𝑅𝑃𝑃,𝐶𝐶 ∙ 𝑃𝑃𝑃𝑃,𝐶𝐶
10𝑅𝑅𝑀𝑀 ∙ 𝑃𝑃𝑀𝑀
� � ∙ 100                    (5.1) 
where T is the titer of PPV (log10 MTT50/mL) in the PEG-rich phase (P), citrate-rich 
phase (C), or PPV starting material (M), VP,C is the volume of the fraction collected for 
10 seconds (mL), and VM is the volume of starting material flowed into the system for the 
total testing time (mL). 
Recovery of the HIV VLPs in the PEG-rich and citrate-rich phases was calculated 
from fluorescence measurements using Equation 5.2: 
𝐻𝐻𝐴𝐴𝑃𝑃 𝑃𝑃𝑉𝑉𝑃𝑃 𝑆𝑆𝑅𝑅𝑅𝑅𝑓𝑓𝑅𝑅𝑅𝑅𝑓𝑓𝑅𝑅 (%) = 𝑅𝑅𝑛𝑛𝑈𝑈𝑃𝑃,𝐶𝐶 ∙ 𝑉𝑉𝑃𝑃,𝐶𝐶
𝑅𝑅𝑛𝑛𝑈𝑈𝑀𝑀 ∙ 𝑉𝑉𝑀𝑀
∙ 100                        (5.2) 
where RFU is the constant-volume relative fluorescence units per 100 μL of the PEG-rich 
phase (P), citrate-rich phase (C), or starting HIV VLP material (M), and V is the phase 
volume measured (μL). 
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5.2.2.8 SDS-PAGE, Bradford assay, PicoGreen DNA assay 
Contaminant protein partitioning was visualized using sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). The gels were run using 4-12% Bis-
Tris 1.0 mm 12-well NuPAGE™ gels with NuPAGE™ MOPS running buffer in an 
XCell SureLock Mini-Cell from Life Technologies (Carlsbad, CA). Samples were 
prepared and denatured by mixing 25 μL of sample in 25 μL 4X sample buffer with 
addition of 4 μL of 2-mercaptoethanol. Samples were placed in a dry block heater at 
95°C for 5 minutes prior to loading. The SeeBlue Plus2 pre-stained protein ladder (191-
14 kDa) was used as the protein band standard. 10 μL of protein standard and sample was 
loaded into the gel and ran at a constant 200 V for 50 minutes. Gels were stained with 
SimplyBlue™ SafeStain as per the manufacturer’s microwave protocol for a 5-ng 
detection limit. 
Contaminant proteins present in each ATPS phase were quantified using the 
Pierce™ Bradford Coomassie assay from Thermo Scientific according to the 
manufacturer’s microplate protocol. The concentration of virus present in samples is 
much lower than the limit of detection for the Bradford assay and therefore did not 
interfere with contaminant protein quantification. To eliminate interference from high 
concentrations of PEG and citrate present in samples, PEG-containing samples were 
diluted 1:33 in nanopure water and citrate-containing samples were diluted 1:22 in 
nanopure water prior to addition of assay reagents. Contaminant protein recovery was 
calculated using Equation 5.3: 
𝑃𝑃𝑓𝑓𝑓𝑓𝑃𝑃𝑅𝑅𝑃𝑃𝑃𝑃 𝑓𝑓𝑅𝑅𝑅𝑅𝑓𝑓𝑅𝑅𝑅𝑅𝑓𝑓𝑅𝑅 (%) = 𝐶𝐶𝑃𝑃,𝐶𝐶 ∙ 𝑉𝑉𝑃𝑃,𝐶𝐶 ∙ 𝐷𝐷𝑛𝑛
𝐶𝐶𝑀𝑀 ∙ 𝑉𝑉𝑀𝑀 ∙ 𝐷𝐷𝑛𝑛
∙ 100                         (5.3) 
where C is the protein concentration (μg/mL) in the PEG-rich phase (P), citrate-rich 
phase (C), or PPV starting material (M). DF is the dilution factor for each sample. 
DNA content in the PEG-rich and citrate-rich samples was quantified using the 
Quant-iT PicoGreen dsDNA kit from Thermo Scientific. Standard curves were created by 
diluting the stock λ DNA standard in a range of 1-10 ng/mL in 2 w/w% PEG and 0.24 
w/w% citrate diluted in 1X TE buffer for quantitating dsDNA in PEG-rich and citrate-
rich samples. A standard curve from 10-200 ng/mL in 1X TE buffer was created to 
quantitate starting viral product dsDNA content. The PEG-rich samples were diluted in 
107 
1X TE buffer to 2 w/w% PEG according to the manufacturer’s recommendation, and 
citrate-rich samples were diluted in 1X TE buffer to 0.24 w/w% citrate to reduce assay 
interference. Samples were compared to the total amount of dsDNA present in the crude 
starting PPV to quantify DNA removal. DNA recovery was calculated using Equation 
5.4: 
𝐷𝐷𝐷𝐷𝐴𝐴 𝑓𝑓𝑅𝑅𝑅𝑅𝑓𝑓𝑅𝑅𝑅𝑅𝑓𝑓𝑅𝑅 (%) = 𝐶𝐶𝑃𝑃,𝐶𝐶 ∙ 𝑉𝑉𝑃𝑃,𝐶𝐶 ∙ 𝐷𝐷𝑛𝑛
𝐶𝐶𝑀𝑀 ∙ 𝑉𝑉𝑀𝑀 ∙ 𝐷𝐷𝑛𝑛
∙ 100                            (5.4) 
where C is the DNA concentration (ng/mL) in the PEG-rich phase (P), citrate-rich phase 
(C), or PPV starting material (M). 
5.3 Results and discussion 
5.3.1 Model virus and virus-like particles 
PPV and HIV VLPs were used as viral products to test the ability of continuous 
ATPS to partition viral products to the PEG-rich phase while leaving contaminant 
proteins and host-cell DNA in the citrate-rich phase. PPV was chosen as a model non-
enveloped virus for purification due to its small size and physicochemical properties 
making it difficult to recover from traditional filtration or chromatographic techniques. 
The physicochemical properties of PPV are summarized in Table 5.1. 
HIV VLPs were expressed by genetically modified Hansenula polymorpha cells 
donated by Esperovax. These VLPs are created for their potential use as an oral vaccine 
candidate. The VLPs self-assemble after the core HIV-1 structural polyprotein gag is 
made by the cells and bud through the cell membrane (Appendix Figure A.2). The 
physicochemical properties of the HIV VLPs are summarized in Table 5.1. The pI of the 
VLPs is unknown but is likely less than 7 for two reasons: first, the pI of the proteins 
present in the gag polyprotein are less than 7 [223, 224], and second, glycoproteins 
comprising the Hansenula polymorpha cell membrane have high-mannose type N-
glycans. The envelope proteins terminate with mannose residues that have excess 
hydroxyl groups, likely resulting in a pI well below 7 [225]. The enveloped HIV VLP 
was chosen to demonstrate the flexibility of the continuous ATPS to purify a potential 
vaccine candidate. 
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Table 5.1: Virus and VLP physicochemical properties 
Virus Model For Genome Shape Envelope Size (nm) pI 







18 – 26 
[227] 
4.8 – 5.1 
[229] 
HIV VLP HIV oral vaccine None Pleomorphic spherical [230] 
Yes 
[230] 




5.3.2 Selection of in-line mixer 
The first unit operation to be designed was the in-line mixer. The chosen mixer 
needed to produce a homogeneous mixture of the PEG, citrate, water, and viral particles 
to allow for proper mass transport of viral particles to each phase. The in-line mixer 
performance was evaluated by comparing each one to the mixing ability of an air-
powered Cowles blade mixer. The air-powered mixer (Figure 5.3A) was used as the gold 
standard for mixing the components, as it produces turbulent mixing with a spinning 
blade for high shear rates. A straight length of tubing the same length as the in-line 
mixers was used as the negative control to demonstrate no mixing, as the system was run 
in laminar flow (Figure 5.3B). Both in-line mixers (Figure 5.3C and D) were compared 
to the air-powered mixer’s ability to create a homogeneous mixture. Due to the high 
viscosity of PEG and low flow rate of the system, the helical mixer and glass bead mixer 
were tested, which are both capable of dispersing high viscosity fluids in the laminar flow 
regime [231, 232]. A helical static mixer redistributes fluid in the radial and tangential 
directions using only the process stream’s energy, which achieves mixing by disrupting 
the streamlines in laminar flow [233]. 
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Figure 5.3: Collage of different mixing modes for continuous ATPS. Mixing ATPS with 
an A) air-powered mixer, B) straight length of tubing, C) glass bead mixer, D) and helical 
mixer. 
 
The two in-line mixers, the glass bead mixer and the helical mixer, were tested for 
their ability to produce a homogeneous mixture at their outlet, and for proper phase 
separation after mixing. Mixing and settling was visualized with the addition of neutral 
red. Neutral red was added to the citrate phase and then partitioned to the PEG-rich 
phase. Mixing the ATPS components with the air-powered mixer for 5 minutes resulted 
in a completely homogeneous mixture shown in Figure 5.3A at 0 minutes of settling 
time. After 20 minutes of settling time, the neutral-red dye partitioned to the PEG-rich 
top phase, leaving the citrate-rich bottom phase clear seen in Figure 5.3A. The mixing 
and partitioning shown in Figure 5.3A was used as the benchmark for the in-line mixers 
to determine if proper mixing was achieved.  
A flow rate of 3 mL/min (3.63 g/mL) was chosen as a starting basis to flow 
through the glass bead mixer and the helical mixer. The glass bead mixer was expected to 
produce a highly homogeneous mixture due to flow distribution as the liquid components 
encountered the beads [163]. Mixing is achieved in a glass bead mixer because as the 
laminar flow streamlines encounter a bead, they are deflected around the bead causing 
crowding between phases next to the sphere. This crowding results in a change in the 
velocity of the streamlines close to and far away from the bead. The difference in 
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streamline velocity causes convective mixing [234]. However, the glass bead mixer did 
not produce a fully homogeneous mixture as there is a clear interface between the phases, 
indicating that proper mixing was not achieved, seen in Figure 5.3C (red arrow) at 0 
minutes of settling time. Additionally, a high pressure drop was observed across the glass 
bead mixer during testing due to the high viscosity of PEG. This high pressure drop, even 
at a relatively low flow rate of 3 mL/min, excluded it for further scaled up experiments. 
The helical mixer was able to produce a more homogeneous mixture (Figure 5.3D, 0 
min) which was similar in appearance to the air-powered mixer. This successful mixing 
was achieved because the helical elements in the mixer disrupt and disperse the laminar 
flow streams radially towards the tube wall to induce convective mixing [233]. By re-
distributing laminar flow streams radially, striations, or unmixed regions, are minimized 
[232]. The mixing action of the helical mixer was greater than the glass bead mixer 
possibly because in the glass bead mixer, especially in the creeping flow regime, the 
streamlines may not have been sufficiently dispersed radially. additionally, the helical 
mixer does not have the issue of generating a high pressure drop since most of the mixer 
is an open channel compared to the glass bead mixer. 
The helical mixer was able to closely replicate the mixing ability of the air-
powered mixer, and for this reason, was chosen as the in-line mixer type for the 
continuous ATPS. A still image from a video of the helical mixer action is shown in 
Appendix Figure A.3. The video shows a neutral red dye being dispersed evenly 
throughout the mixture as it travels down the length of the mixer. 
5.3.3 Helical mixer performance simulated in COMSOL Multiphysics 
A simulation of the helical mixer was generated in COMSOL Multiphysics to 
further confirm mixing action of the PEG and citrate phases. The steady-state flow 
structure inside the mixer was visualized by plotting the magnitude of the fluid velocity 
contours at several cross-sections along the tube and by drawing streamlines originating 
from the inlet, shown in Figure 5.4A. The tortuous paths of the flow streamlines 
highlighted the critical role of advection in facilitating mixing. Additionally, the degree 
of mixing along the tube was visualized in the form of cross-sectional contours of the 
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phase-field variable, shown in Figure 5.4B. The simulation revealed that the red colored 
PEG phase and blue colored citrate phase are efficiently blended by the helical blades. By 
10th element of the helical mixer, the red and blue color are nearly completely mixed, 
represented by the green color shown in Figure 5.4B. These results illustrated how well 
the PEG and citrate phases were blended efficiently by flowing it through a properly 
designed static mixer consisting of a tube embedded with a series of twisted blades. 
Overall, numerical calculations corroborated nicely with the experimental observations, 
and provide further confirmation of the excellent performance of the helical mixer. 
This simulation will be helpful in future scale-up designs of the continuous ATPS 
to simulate increased flow rates, different phase forming concentrations, and tubing sizes 
without extensive experimental trials. 
 
 
Figure 5.4: COMSOL Multiphysics modelling of in-line helical mixer showing the A) 
mixer geometry and B) mesh pattern used in the simulation. C) Streamlines and fluid 
velocity magnitude contours and D) phase field contours 
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5.3.4 Settler design 
A settler must be used to allow the PEG-rich and citrate-rich phases to separate 
after mixing. From the experimental study of the different in-line mixers, 20 minutes of 
gravity-driven settling time was necessary to achieve phase separation in batch systems. 
This settling time was achieved in the settler section of the bench scale set-up, seen in 
Figure 5.1D. The first part of the settler section used a straight length of tubing to begin 
phase separation. The second part of the settler section was a separator column to allow 
for phase hold-up before collection. Half of the separation time was achieved with a 15 
mL tube separator, and the other half of the separation time was achieved using tubing 
between the mixer and settler. To achieve the separation time, 3 m of 2.0 mm ID tubing 
was used. 
To determine if the continuous settler section was allowing the phases to separate 
properly, refractive index (RI), dynamic viscosity, and density of the PEG-rich was 
collected and compared to the batch ATPS. For the citrate-rich phase comparison 
between batch and continuous modes, only density was measured, as viscosity and RI 
measurements are unaffected by varying citrate concentrations. The comparison between 
batch mode and continuous mode measurements, along with the percent difference 
between the measurements can be seen in Table 5.2. The physical property 
measurements confirmed that the proper PEG-rich and citrate-rich phases were obtained 
after separation evidenced by low percent difference values. 
Table 5.2: Physical property measurement comparison between batch mode and 
continuous mode ATPS TLL 32% TLR 0.5 







Batch 1.015 ± 0.009 1.068 ± 0.008 320 ± 130 1.3852 ± 0.0001 
Continuous 1.018 ± 0.005 1.070 ± 0.016 310 ± 31 1.3847 ± 0.0002 
% Difference 0.20 0.10 4.5 0.03 
5.3.5 HIV VLP recovery and purification 
The HIV VLPs were first introduced as the viral product to be purified by the 
continuous ATPS due to the simple detection of the GFP label. Purification of HIV VLPs 
was achieved using the continuous ATPS set-up shown in Figure 5.1B. After 15 minutes 
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of system equilibration without HIV VLP flow, HIV VLP was continuously injected into 
the system for 40 minutes to test HIV VLP partitioning to the PEG-rich and citrate-rich 
phase. 10 minutes after HIV VLP injection, HIV VLPs began to partition to the PEG-rich 
phase more favorably compared to the citrate-rich phase, shown in Figure 5.5A. 
Although the expected residence time through the separator section was 20 minutes, HIV 
VLPs were collected in the outlet sooner possibly because the first HIV VLPs to enter the 
filled separator column could travel quicker through the PEG-rich phase due to un-
hindered transport. After 20 minutes of operation, the partitioning between the two 
phases reached a plateau, indicating 20 minutes was the proper separation time to reach 
steady-state, which matched the batch system separation time. HIV VLP flow was 
stopped at 40 minutes to demonstrate the ability of the system to achieve equilibrium 
again after HIV VLP flow stopped (Figure 5.5A, vertical dashed line). No HIV VLP was 
collected in either phase 20 minutes after HIV VLP flow was stopped, indicating a 20-
minute residence time. For the 40 minutes of continuous operation with HIV VLP flow, 
69 ± 1% of the HIV VLP was recovered in the PEG-rich phase and 41 ± 7% of the HIV 
VLP was recovered in the citrate-rich phase. The recovery and purification of HIV VLPs 
are summarized in Table 5.3. 
This was an unoptimized system using partitioning parameters that were 
established for PPV in batch-mode. With ATPS parameters specifically determined for 
the HIV VLPs, recoveries of the VLPs would likely increase. 
114 
 
Figure 5.5: A) HIV VLP recovery in the PEG-rich and citrate-rich fractions collected 
over 60 minutes of continuous separation, B) PPV recovery in the PEG-rich and citrate-
rich fractions collected over 30 minutes of continuous separation, C) DNA recovery in 
the PEG-rich and citrate-rich fractions collected from HIV VLP purification, D) DNA 
recovery in the PEG-rich and citrate-rich fractions collected from PPV purification, E) 
SDS-PAGE gel showing contaminant protein content in the PEG-rich and citrate-rich 
phases from HIV VLP purification, and F) SDS-PAGE gel showing contaminant protein 
content in the PEG-rich and citrate-rich phases from PPV purification. 
 
Table 5.3: Recovery and purification of PPV and HIV VLPs summary 
Virus PEG-rich Recovery (%) DNA Removal (%) Protein Purity 
HIV VLP 69 ± 1 73 ± 1 Pure by SDS 
PPV 107 ± 56 96 ± 3 Pure by SDS 
 
The partitioning of host cell dsDNA was observed by quantifying the DNA in 
each PEG-rich and citrate-rich fraction using the PicoGreen assay. With the high 
concentration of PEG and citrate present in the samples, PEG-rich samples were diluted 
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to a final concentration of 2 w/w% PEG, and citrate-rich samples were diluted to a final 
concentration of 0.24 w/w% citrate. The DNA partitioning over 40 minutes of continuous 
operation of the ATPS can be seen in Figure 5.5C. The DNA recovery in the PEG-rich 
phase was 27 ± 1%, and DNA recovery in the citrate-rich phase was 78 ± 5%. This 
demonstrates cATPS can remove a majority of host cell DNA in single step. 
The purity of the collected HIV VLP product in the PEG-rich phase was 
visualized with SDS-PAGE. Protein bands from PEG-rich and citrate-rich fractions 
collected during continuous separation of VLPs can be seen in Figure 5.5E, with all 
detectable proteins partitioning to the citrate-rich phase. The figures show that the PEG-
rich phase containing the HIV VLP product is highly purified from contaminant proteins. 
5.3.6 PPV recovery and purification 
With the successful recovery and purification of HIV VLPs, PPV was introduced 
into the continuous ATPS as the viral product. However, initial trials showed low 
recovery of PPV in the PEG-rich phase using the same continuous ATPS used for HIV 
VLPs. Typical PPV recovery was 10-15% in the PEG-rich phase, and 60-80% in the 
citrate-rich phase, which was not expected. Batch experiments using the same ATPS 
concentrations had over 70% recovery in the PEG-rich phase, with rarely any PPV in the 
citrate-rich phase, as it was readily salted-out of the citrate when mixed with a vortex 
mixer [7]. It was hypothesized that PPV takes longer to partition to the PEG-rich phase 
compared to HIV VLPs due to the difference in pI (5 for PPV and likely <5 for HIV 
VLPs), and differences in the viral surface affinity to the relatively more hydrophobic 
PEG-rich phase. The pI of the viral product in ATPS directly effects the salting-out 
ability of the citrate. The net negative surface charge on PPV at a system pH of 7 is of 
less magnitude when compared to the net negative surface charge on the HIV VLPs 
because of the lower pI. This makes the HIV VLPs electrostatically repulsed out of the 
citrate-rich phase with more force than PPV. Additionally, HIV VLPs have a lipid bilayer 
which is hydrophobic due to the presence of many mannose N-glycans on the lipid 
surface [235]. This allows the HIV VLPs to have a higher affinity to the relatively more 
hydrophobic PEG-rich phase compared to PPV, which has been shown to be slightly 
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more hydrophobic than common proteins [113]. It was hypothesized that HIV VLPs were 
quickly salted-out from the citrate-rich phase to the interface and pulled into the PEG-
rich phase by hydrophobic interactions between the HIV VLP lipid bilayer and high MW 
PEG. 
A different mixing strategy was implemented for the PPV-containing ATPS to 
ensure PPV had time to partition to the PEG-rich phase after being salted-out from the 
citrate-rich phase. This was achieved by mixing a 250 g system with 10 vol% PPV in a 
glass bottle with a stir bar and flowing directly into the continuous settler. This design 
change for PPV purification can be seen in Figure 5.6 (note the change from the helical 
mixer in Figure 5.1B). 
 
Figure 5.6: Mixer set-up for ATPS TLL 32 TLR 0.5 with 10 vol% PPV for continuous 
purification 
 
After the 250 g system was mixed in the glass bottle with a stir bar for 10 
minutes, the PPV-containing ATPS was continuously flowed through the separator 
tubing and settler sections. PPV favorably partitioned to the PEG-rich phase as expected 
during the 30 minutes of continuous operation, shown in Figure 5.5B. For the 30 minutes 
of continuous operation, 107 ± 56% of the PPV was recovered in the PEG-rich phase and 
0.9 ± 0.3% of the PPV was recovered in the citrate-rich phase. The recovery and 
purification of PPV are summarized in Table 5.3. 
The DNA recovery in the PEG-rich phase was 1.1 ± 2.7%, and the DNA recovery 
in the citrate-rich phase was 85 ± 10%, shown in Figure 5.5D. The high recovery of 
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DNA in the citrate-rich phase is consistent with another study that recovered plasmid 
DNA in the salt-rich phase of ATPS [167]. Thus, this continuous ATPS is a good unit 
operation for the removal of DNA from viral products and increased mixing may assist in 
DNA removal from the PEG-rich phase. 
SDS-PAGE was performed on every other collected fraction to visualize the 
purity of the PEG-rich and citrate-rich phase, shown in Figure 5.5F. The main 
contaminant in the crude PPV injected into the system was BSA. The PPV was made 
with 10 vol% FBS added to the cell culture media, which contains 3-5 g/dL of total 
protein [236]. The citrate-rich fractions contained a majority of the contaminant proteins, 
with only minimal amounts of protein seen in the PEG-rich fractions. The protein band 
present in the PEG-rich fractions correspond to BSA present in the sample with high 
concentration of PEG. Proteins present in high concentrations of PEG are known to cause 
smearing and protein band migration [237], which was also tested by spiking known 
concentrations of BSA into water and PEG to compare the protein band locations 
(Appendix Figure A.4). 
The Bradford assay was used to attempt to quantify the protein content in the 
PEG-rich and citrate-rich phases. Due to high concentrations of PEG and citrate in the 
samples, 27 w/w% and 24 w/w% respectively, samples were diluted to 1 w/w% to 
minimize the interference. However, batch-mode experiments showed diluting the 
samples to 1 w/w% PEG caused the protein concentration to be below the lowest limit of 
detection possible by the assay at 2.5 μg/mL. This resulted in <56% protein recovery in 
the PEG-rich phase, however, the true protein content is expected to be much lower in the 
PEG-rich phase. Protein recovery in the citrate-rich phase was 15 ± 7%, with the 
remaining protein likely trapped in the interface between the PEG- and citrate-rich 
phases. While it was difficult to quantify, high levels of proteins were removed from the 
stock PPV. 
5.4 Conclusions 
This is the first demonstration of continuous ATPS for viral particle purification. 
This system was able to purify both an enveloped (PPV) and non-enveloped (HIV VLP) 
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virus from their contaminants. The continuous ATPS was able to recover 107 ± 56% of 
PPV in the PEG-rich phase with high protein and DNA removal. The system was also 
able to recover 69 ± 1% of HIV VLPs in the PEG-rich phase with similar contaminant 
removal. The scale up and continuous operation of this ATPS was achieved by ensuring 
continuous mixing and settling of the ATPS components was achieved. Mixing was the 
critical step to partition the viral product to the PEG-rich phase while leaving the 
contaminants in the citrate-rich phase. HIV VLPs were readily partitioned to the PEG-
rich phase when mixed by the helical mixer, but PPV required the use of a mechanical 
mixer to ensure adequate phase contact between ATPS components. This difference in 
partitioning ability between the two viral products was hypothesized to be due to the 
difference in physicochemical properties of the virus. The pI of the viral products dictated 
the salting-out ability of the citrate-rich phase and the presence of a lipid bilayer envelope 
of HIV VLPs allowed them to easily partition to the PEG-rich phase. With further scale-
up and optimization of the continuous ATPS for a target viral product, this purification 
process has the potential to be used in large-scale, fully continuous downstream 
processing trains in vaccine manufacturing. 
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6 Conclusions and future work 
6.1 Conclusions 
This dissertation discussed the development of two novel virus detection methods 
and one virus purification method. The first detection method used graphene biosensors 
and was discussed in Chapter 3. The second virus detection method utilized gold 
nanoparticle (AuNP) aggregation and was discussed in Chapter 4. The virus purification 
technique was a scaled up continuous aqueous two-phase system (ATPS) and was 
discussed in Chapter 5. 
Graphene ink printed biosensors were created for potential use as inexpensive 
point-of-care devices. The goal was to flexographically print electrochemical biosensors 
that were capable of distinguishing between analyte-containing samples compared to 
buffer-only samples. The sheet resistivity (SR) on the sensor surface was monitored as 
different concentrations of analyte was applied and compared to the SR changes due to 
buffer-only applications. Biosensors created with paper and non-paper substrates showed 
no ability to distinguish between either sample applied to the surface. The number of ink 
coats, ink conductivity, and graphene sheet hydrophobicity/size were varied in attempts 
to change the electrical and chemical properties of the biosensors without success. Each 
set of tested biosensors resulted in the same conclusion: SR changes were due to applying 
any liquid to the surface, independent of what biomolecule was present in the sample. 
This conclusion led to the strategy of applying hydrophobic wax barriers on the graphene 
surface to contain the liquid sample in a testing region without contacting the electrical 
leads. However, wax barriers were reduced the swelling effects of the biosensors but 
were also unsuccessful at protein detection. Additionally, functionalization of the 
graphene sheets with a sandwich enzyme linked immunosorbent assay (ELISA) was 
performed which also lead to insufficient SR differences to detect target analytes. 
Overall, with a wide variety of parameters tested for the biosensors, no positive and 
publishable results were obtained. 
The virus detection ability of the AuNP aggregation assay was studied using 
different sizes of AuNPs. The original assay utilized 15 nm AuNPs for the detection of 
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porcine parvovirus (PPV) to 6 log MTT50/mL and bovine viral diarrhea virus (BVDV) to 
4 log MTT50/mL when aggregated by 1 M mannitol. The goal was to synthesize other 
sizes of AuNPs and use them in the assay to lower the limit of detection (LOD). Seed-
mediated, room temperature synthesis of 27, 68, 96, 100, and 106 nm diameter AuNPs 
was successfully performed. The AuNPs were characterized by ultraviolet-visible 
spectroscopy (UV-Vis), dynamic light scattering (DLS), and transmission electron 
microscopy (TEM). The different sizes of AuNPs were used to explore how the LOD of 
the assay would change based on the differences in interactions between AuNPs and viral 
particles. AuNPs with a 40 nm diameter were complexed with PPV, resulting in a LOD 
of 7 log MTT50/mL when aggregated by 1 M mannitol. AuNPs with a 50 nm diameter 
were complexed with BVDV, resulting in a LOD of 5 log MTT50/mL when aggregated 
by 1 M mannitol. AuNPs with a diameter of 5 nm were used in an attempt to detect PPV, 
but the high concentrations of osmolytes used in the aggregation step led to AuNP 
aggregation regardless of the presence of virus or control protein. Neither an increase nor 
decrease in the size of AuNPs lead to an improved LOD compared to the published work 
of using 15 nm AuNPs in the same detection assay. These results indicated that the size 
of AuNPs used in the virus detection assay do not play a critical role in detection. 
A novel continuous virus purification technique using an aqueous two-phase 
systems (ATPS) was developed. The goal was to scale up a batch ATPS and confirm the 
recovery and purification of PPV and human immunodeficiency virus-like particles (HIV 
VLPs) was not lost. The continuous mixing section of the ATPS was identified as the unit 
operation that influenced proper viral particle partitioning to the poly(ethylene glycol) 
(PEG) rich phase. Different in-line mixer types were tested for their ability to properly 
mix the citrate salt and viscous PEG components. The components flowing through the 
system were in the laminar flow regime due to the low flow rate tested for the bench-
scale operation and high viscosity PEG. Testing revealed that an in-line helical mixer was 
able to disperse the phases in the laminar flow regime. HIV VLPs were readily 
partitioned to the PEG-rich phase when mixed by the helical mixer, but PPV required the 
use of a mechanical mixer to ensure adequate phase contact between ATPS components. 
This difference in partitioning ability between the two viral products was hypothesized to 
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be due to the difference in physicochemical properties of the virus. The pI of the viral 
products dictated the salting-out ability of the citrate-rich phase and the presence of a 
lipid bilayer envelope of HIV VLPs allowed them to easily partition to the PEG-rich 
phase. The continuous ATPS was able to recover 107 ± 56% of PPV in the PEG-rich 
phase with high protein and DNA removal. The system was also able to recover 69 ± 1% 
of HIV VLPs in the PEG-rich phase with similar contaminant removal. With further 
scale-up and optimization of the continuous ATPS for a target viral product, this 
purification process has the potential to be used in large-scale, fully continuous 
downstream processing trains in vaccine manufacturing. This work was the first 
demonstration of continuous ATPS for viral particle purification. 
6.2 Future work 
This dissertation contains numerous tests to develop a graphene biosensor for 
rapid analyte detection, an optimization strategy for the AuNP virus detection assay, and 
a scale up design of a continuous ATPS. However, there are other experiments that can 
be performed to further improve each method. 
To improve the graphene biosensors for analyte detection, the graphene ink 
properties could be altered. Results were discussed from biosensors created with a 
different ink binder and graphene nanoplatelet grade, but other binds and grades of 
graphene could be used. For example, a more hydrophilic ink binder could be used during 
the formulation of the ink which could provide biomolecules a more suitable graphene 
ink surface during sample application and testing. 
The LOD of the AuNP aggregation assay was not improved using different sizes 
of AuNPs. This indicated that AuNP size was not the main influencer in virus detection. 
Many other system parameters exist that could influence the detection ability. The system 
pH could be lowered closer to the virus pI, which would create more positively charged 
patches on the virus surface. With more positively charged patches, the negatively 
charged citrate-capped AuNPs could electrostatically bind to the AuNPs more readily. 
With more AuNPs complexed with the virus, the light scattering ability of the aggregated 
complexes with less viral particles could be improved, leading to a lower LOD. One 
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possible issue with this change would be the stability of the AuNPs at a lower pH, as the 
change in pH could cause the citrate-capped AuNPs to aggregate. Different shapes of 
AuNPs also exist, such as gold nanorods (AuNRs), gold nanostars (AuNSts), and gold 
nanocubes (AuNCs). The different shapes of AuNPs have different characteristic UV-Vis 
spectra and light scattering ability. For example, AuNRs have a characteristic two-peak 
UV-Vis spectra due to the longitudinal and transverse surface plasmon resonance (SPR) 
properties due to the large aspect ratio of rods compared to spheres [238]. This could be 
exploited because as AuNRs aggregate, one of their characteristics peaks could disappear 
due to losing that characteristic aspect ratio of monodisperse AuNRs. Additionally, 
different osmolytes could be used to induce aggregation in the assay. Other osmolytes 
such as alanine and trehalose have been shown to aggregate enveloped and non-
enveloped viruses, which could be used to aggregate the AuNP/virus complexes [111, 
112]. Alanine is an amino acid with a hydrophobic side chain that may be able to 
aggregate viral particles more effectively. Alanine residues in protein molecules are 
normally buried within the protein structure to protect it from solvent exposure [205]. 
This effect could be exploited for the aggregation assay because the hydrophobic residues 
from alanine could aid in stabilization and enhanced aggregation of the dehydrated 
hydrophobic patches of virus particles. Trehalose is a sugar with two molecules of 
glucose linked by an α, α-1,1-glucosidic bond [206]. Trehalose has a high affinity for 
water due to multiple hydrogen bonding events between its two glucose rings and water 
molecules [207]. The high affinity for water would rapidly dehydrate the virus surface, 
potentially causing more virus aggregates to form as more and more water is pulled away 
from the virus surface. This could improve the AuNP assay by allowing a lower 
concentration of osmolyte to be used in the aggregation step, or to dehydrate a smaller 
concentration of virus particles due to the strong dehydration ability of trehalose. 
The ATPS was the first of its kind technique for continuous viral particle 
purification, which leaves it open for numerous optimization opportunities and future 
work to make it a complete and robust process. The current system could be improved by 
implementing a true continuous mixer for PPV purification. One possible way to 
accomplish this would be to use the same glass bottle/stir bar configuration but purchase 
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another 3-channel pump to flow the stock components into the mixer. The current system 
could also benefit from additional scale-up beyond 3 mL/min. At an increased flow rate, 
the helical mixer should have increased performance as turbulence is reached in the 
mixer. If sufficient mixing is not achieved with the single 12-element helical mixer, 
additional mixers could be put in series, or a larger-diameter helical mixer could be 
constructed from larger inserts. Proper quantification of contaminant proteins in the PEG-
rich and citrate-rich phases also needs to be performed. Attempts to quantify the protein 
in both phases using the Bradford assay, microBCA, and UV adsorption were mostly 
unsuccessful due to the high concentrations of PEG and citrate interfering with the assay 
reagents. One quantification technique that may possibly work is densitometry from 
SDS-PAGE gels. This technique has been used before in a PEG 400 Da-potassium 
phosphate ATPS, and could be implemented for our PEG 12,000 Da-citrate ATPS [179]. 
Ideally, in-line biomolecule quantification techniques should be implemented because 
this is a fully continuous ATPS. With robust in-line quantification techniques, industrial 
implementation of a continuous ATPS could be realized. This is because industrial 
bioprocesses are under strict regulatory guidelines that require quantification of the 
bioproducts at each stage of the manufacturing process. One possible in-line 
quantification technique could utilize nanoparticle tracking analysis (NTA), but issues of 
resolution to detect viral particles is a concern. Additional changes to the ATPS itself 
could result in improved recovery and processability. Unpublished work in the Heldt lab 
has shown the addition of osmolytes to ATPS improves the recovery of the viral product 
on a lower TLL. A lower TLL means a lower w/w% PEG-rich phase is collected, which 
has a much lower viscosity without a loss of recovery. This change would increase the 
processability of the PEG-rich product containing phase for further downstream 
processes. One of these downstream processes is the recovery of the viral product out of 
the PEG-rich phase. Two methods for recovering the viral product out of the PEG-rich 
phase are back extraction using a second stage of ATPS or filtering the viral product out 
of the PEG-rich phase. Back extraction is the technique to partition the product from the 
PEG-rich phase into the citrate-rich phase using a different ATPS that more favorably 
partitions the virus to the citrate-rich phase. This technique has been used before to purify 
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and back extract foot-and-mouth disease virus in a batch system [174]. Lastly, to 
convince industry to implement a continuous ATPS for virus purification, an economic 
analysis should be performed. 
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Figure A.1: Mass balance and schematic of 32% TLL 0.5 TLR ATPS. The green boxes 
are boxes that should be changed for each run to ensure the density of PEG and citrate 
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Figure A.2: TEM images of HIV gag-GFP VLPs purified by ultra-centrifugation 
  
 




Figure A.4: SDS-PAGE of 0.01-4 mg/mL BSA in water and 33 w/w% PEG showing 
band migration 
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Fig. 1. Simplify scheme of continuous 
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